Toxic Effects of Kainic Acid Upon Dopaminergic and Opioid Systems in Rat Brain. by Ridd, Michael J.
TOXIC EFFECTS OF KAINIC ACID UPON 
DOPAMINERGIC AND OPIOID SYSTEMS IN RAT BRAIN
By
M ICHAEL J. RIDD, BSc (Hons)
A thesis submitted in accordance with the requirements of the University of Surrey for
the Degree of Doctor of Philosophy
Receptors and Cellular Regulation Research Group 1996
School of Biological Sciences,
University of Surrey,
GUILDFORD,
SURREY, GU2 5XH
ProQuest Number: 27726960
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 27726960
Published by ProQuest LLC (2019). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
ACKNOWLEDGEMENTS
I am very grateful to my supervisors. Dr. Ian Kitchen and Dr. Paul Fosbraey, for their 
advice and encouragement throughout my doctoral studies.
I would like to thank everybody in the Receptors Lab at Surrey and Janet Wetherell, 
Tim Townend, May Irwin and Sarah Passingham at C.B.D. Porton Down.
I would especially like to thank my parents and brother for all their help and support.
I would also like to thank the staff of the University of Surrey Experimental Biological 
Unit for their skilled help, free sandwiches and fruit and countless cups of coffee.
T h is  w ork  has been funded  by C .B .D . P o rto n  D ow n.
1
SUMMARY
1. The acute toxic effects of kainic acid (KA) (16mg/kg; intraperitoneal) upon rat brain 
dopamine Da and g-opioid receptors were investigated by homogenate receptor binding 
and receptor autoradiography 4 hrs after treatment. Distribution studies were carried 
out using [3H]-KA administered intraperitoneally with 16mg/kg KA to determine the 
percentage of KA reaching brain areas. KA was also studied for its effect on [3H]- 
dopamine release from striatal slices in vitro.
2. Homogenate receptor binding studies carried out with the Da antagonist [125I]- 
iodosulpiride indicated the presence of a single saturable binding site in all regions from 
saline-treated rats. In saline-treated rats there was good quantitative agreement between 
levels of [125I]-iodosulpiride binding determined using homogenate receptor binding 
and receptor autoradiography. KA produced a 2-fold decrease in receptor affinity for 
[125I]-iodosulpiride and a 2-fold increase in receptor density in cerebellum, cortex, 
hippocampus, medulla and pons and midbrain and hypothalamus but not striatum. 
Quantitative autoradiography showed similar increased D% labelling in these regions 
following KA treatment whilst caudate putamen, nucleus accumbens and olfactory 
tubercle displayed equivalent numbers of sites in saline and KA-treated rats.
3. Homogenate receptor binding studies carried out with the D2 antagonists [3H]- 
raclopride and [3H]-spiperone indicated the presence of single saturable binding sites in 
all regions from saline-treated rats. [3H]-raclopride binding in striatum was twice [3H]- 
spiperone binding in saline-treated rats but in the rest of the brain Bmax values for 
dopamine D% binding where approximately equivalent. KA produced a significant 
increase in receptor number for [3H]-raclopride in. striatum and whole brain minus
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striatum but no change in pH]-spiperone binding. Furthermore, KA produced a 2-fold 
increase in receptor affinity for [3H]-raclopride in striatum and a small but significant 
increase in the whole brain minus striatum but had no effect on Kd for [3H]-spiperone. 
In brains of saline-treated rats [3H]-raclopride and [125I]-iodosulpiride may bind to the 
long form of the D2 receptor and [3H]-spiperone may bind with higher affinity to the 
short form. It is postulated that KA effects on D2 receptors may be a reflection of an 
increase in gene transcription of the D2 receptor gene or a change in its mRNA stability. 
KA may also alter the affinity state or ligand binding site of D2 long form transcripts 
which differentially affects the binding affinity of radioligands because of the tricyclic 
structure and bulky phenyl ring substituents of [125I]-iodosulpiride.
4. Homogenate receptor binding studies carried out with the selective (i-agonist [3H]- 
DAGO indicated the presence of a single saturable binding site in all regions from 
saline-treated rats. In saline-treated rats there was quantitative agreement between levels 
[3H]-DAGO binding determined using homogenate receptor binding and receptor 
autoradiography. KA produced a 2-fold increase in receptor affinity for [3H]-DAGO in 
all regions except cerebellum and an increase in receptor number in cerebellum, 
hippocampus, midbrain and hypothalamus which was significant in cortex, medulla and 
pons and striatum. Quantitative autoradiography showed similar increased ^-labelling 
of structures comprising these regions which was significant throughout the cortex 
except for the temporal region. The effects of KA on [3H]-DAGO binding may reflect a 
compensatory increase in the rate of jx-receptor mRNA transcription as a result of |i- 
receptor stimulation by enkephalin produced from elevated levels of its precursor 
proenkephalin. In addition, the effects of KA on binding affinity of [3H]-DAGO may 
be a reflection of increased expression of G0 G-protein mRNA and/or increased 
functionality of Gi/0 G-proteins posdschaemia.
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5. Distribution studies showed that after 4 hrs over 60% of intraperitoneally 
administered KA enters the brain. The high percentage of KA in rat brain in this study 
may be attributable to uptake across the blood-brain barrier by the glutamate carrier and 
disruption of the blood-brain barrier caused by KA-induced seizures. Highest labelling 
of [3H]-KA was observed in the hippocampus and striatum and this correlates with 
regions where the densest population of KA receptors are found.
6 . KA (10|iM-10mM) was studied for its effect on [3H]-dopamine release from rat 
brain striatal slices in vitro. KA produced a dose-dependent increase in the release of 
[3H]-dopamine from striatal slices in vitro which was calcium-dependent at low KA 
concentrations (10p.M and 50|iM) and calcium-independent at concentrations above 
IOOjiM. It is suggested that a dual action is responsible for striatal KA-induced release 
of [3H]-dopamine in vitro, a KA receptor-mediated effect involved in calcium- 
dependent dopamine release and a calcium-independent action representing sodium- 
dependent dopamine release from cytoplasmic stores. KA (50jjM-10mM) was studied 
for its effect on potassium-stimulated [3H]-dopamine release from rat brain striatal 
slices in vitro. KA produced a dose-dependent inhibition of potassium-stimulated [3H]- 
dopamine release from rat striatal slices in vitro, possibly due to inactivation of voltage 
channels on dopaminergic terminals. The effects of intermediate doses of KA on basal 
and evoked [3H]-dopamine release from striatal slices in vitro were both blocked by the 
a-amino-3-hydroxy-5-methyl-isoxazole/KA receptor antagonist 6,7-dinitroquinoxaline- 
2,3-dione (500|iM) suggesting mediation of dopamine release by KA and a-amino-3- 
hydroxy-5-methyl-isoxazole receptors.
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CHAPTER 1 
INTRODUCTION
16
1.1 General introduction
The excitotoxins are a diverse group of compounds which cause neuronal death and are 
structurally related to the excitatory neurotransmitter, glutamate (Figure 1). Kainic acid 
(KA), isolated from the Japanese seaweed, Digenea simplex, is the most widely studied 
and was considered the most toxic. Recently, more potent excitotoxins have been 
described, notably domoic acid (Tasker et al. 1991). This newer compound appears to 
act in a similar though not identical way to KA (Strain & Tasker, 1991) but is extremely 
expensive and in short supply, so restricting its study. Considering these factors, KA 
is considered a representative excitotoxin upon which neurochemical and toxicological 
studies can be performed. There have been no reported instances of intoxication from 
exposure of KA in humans although the (3-enantiomer of KA was used clinically as an 
antiascaridiasis agent in Japan after the war. However, in December 1987, a major 
outbreak of food poisoning in Canada was traced to the ingestion of cultivated mussels 
originating in eastern Prince Edward Island. These were contaminated with domoic 
acid produced by the marine pennate diatom, Nitzchia pungens (Wright et al. 1989). 
Clinically, gastrointestinal disorders were a common occurrence, and in about one-third 
of the 145 confirmed cases, there were also marked neurological effects. These 
included confusion and disorientation, limbic seizures and status epilepticus and coma 
in extreme cases (Teitelbaum, 1990). Some of the surviving patients still suffer from 
serious short-term memory impairment (Zatorre, 1990). Post-mortem histopathology 
on brains from four patients who died, demonstrated marked bilateral neuronal 
destruction in the hippocampus (Carpenter, 1990).
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Figure 1. Structures of three excitatory amino acid agonists
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CH3
CH, CH2COOH
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c h 3 c h 3
C H  CH =  CH  CH =  C CH2COOH
NH COOH
Structures of gluamate, kainic acid and domoic acid.
1.1.1 Physical properties and potency of kainic acid
KA is a non-degradable, rigid, cyclic analogue of glutamate which circulates in the 
bloodstream in a charged hydrophilic state (Preston & Hynie, 1991). KA is 30- to 100- 
fold more potent than glutamate as a neuronal excitant. Of all neurotoxic excitatory 
amino acids, KA was believed to be the most potent, with the potency order being: 
KA> ibotentate> N-methyl-DL-aspartate> dihydrokainate> DL-homocysteate> L- 
cysteate> L-asparate> L-glutamate (Davenport et al. 1990). However, using both 
binding assays and electrophysiologically, domoic acid, an analogue of KA, has been 
shown to be approximately three times more potent and in mice an acute toxic dose of 
intraperitoneally administered domoic acid is 4mg/kg (Tasker et al. 1990) compared to 
9-15mg/kg KA in rats (Ben-Ari et al. 1980a).
1.1.2 Lethality of kainic acid
Few studies have considered the toxicity of KA itself, most have used KA as a selective 
lesioning agent of central nervous system pathways. The LD50 for intraperitoneally 
administered KA in rats weighing approximately 250g has been estimated as 20.9mg/kg 
by probit analysis (Fosbraey et al. 1992). There is a steep relationship between dose 
and percentage mortality of intraperitoneally administered KA, the complete range from 
0 to 100% mortality is covered in a doubling of the dose (Fosbraey et al. 1992) (Figure 
2).
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Figure 2. Determination of the LD50 for intraperitoneally administered kainic 
acid in rats
100-,
80 —
6 0 -
4 0 -
2 0 -
100
Dose of intraperitoneally administered kainic acid (mg/kg, log scale)
Relationship between the dose and percentage mortality for intraperitoneally 
administered kainic acid in rats weighing approximately 250g. Each point 
represents a group of six rats except 16mg/kg kainic acid which represents nine 
rats. Points were fitted with a line that represents a best fit by probit analysis 
using the GA04 programme (Calloway, 1972) and dashed lines represent 95% 
confidence limits of the line of best f it  The LD50 for kainic acid in rats is
estimated as 20.9mg/kg. Data were taken from Fosbraey et al. (1992). 16, 19,
22.6,26.9 or 32mg/kg kainic acid was administered intraperitoneally and the time 
to death was recorded. All surviving rats were killed after 7 days.
20
1.1.3 Kainic acid electrographic activity
KA induces severe convulsions when administered systemically or intracerebrally into 
rats (Ben-Ari et al. 1980a; Kleinrok & Turski, 1980; Lothman et al. 1981; Nadler, 
1981; Olney et al. 1979; Schwob et al. 1980; Sloviter & Damiano, 1981; Sperk et al. 
1981). After injection of KA into rats, electrographic activity usually starts after 5 mins 
and correlates strikingly with observed behavioural changes (Ben-An et al. 1981; 
Sloviter & Damiano, 1981). Ben-Ari and co-workers (1981) described three phases of 
electrographic changes. They suggested that after parenteral administration of KA 
epileptiform activity is initiated in the entorhinal cortex and is then immediately 
propagated to the CA3 area of the hippocampus and to the amygdaloid complex (Ben- 
Ari et al. 1981). These early changes in electrographic activity correspond to the 
development of wet-dog shakes and other early developing behaviours (Ben-Ari et al. 
1981). The epileptiform activity then progresses to other limbic structures, including 
the median thalamic complex and medial frontal cortex before diffusing to the rest of the 
cortex. At a sufficient dose of KA, these episodes rapidly follow each other and 
produce a status epilepticus. During the period of severe status epilepticus electrical 
seizures become synchronised in the entorhinal cortex, amygdala and hippocampus and 
are propagated to other non-limbic brain areas which coincides with motor events. 
After the termination of motor symptoms, rhythmic spiking progressively decreases but 
can still be observed several days (Ben-Ari et al. 1981; Lothman & Collins, 1981) and 
even three weeks later spiking can be detected in the amygdala (Ben-Ari et al. 1981; 
Tanaka et al. 1988).
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1.1.4 Behavioural changes induced by kainic acid
Systemic, intraventricular or intra-amygdaloid administration of KA to the rat elicits 
marked behavioural alterations that are fast in their onset and last 3-5 hrs (Ben-Ari et al. 
1981; Sperk et al. 1983). They can be divided into several distinct changes. As early 
as 5 mins after injection of KA, rats often assume a marked catatonic posture with 
staring. This behaviour persists for about 1 hr, but may be masked by other 
neurological symptoms later on. After 15-30 mins rats display masticatory movements, 
head nodding and myclonic twitches of the head, face and fore-limbs and intermittent 
wet-dog shakes. This behaviour lasts for approximately 30 mins to 1 hr and is later 
obscured by generalised seizures. These signs of poisoning seen with KA are 
reminiscent of a 5-hydroxytryptamine (5-HT)-dependent syndrome. 5-HTi receptor 
agonists produce head twitches and wet-dog shakes (Heaton et al. 1988) and 5 -HT2 
agonists produced fore-paw treading and hind-limb abduction (Dickinson & Curzon, 
1983). Further, wet-dog shakes can be completely prevented by inhibition of 5-HT 
synthesis with p-chlorophenylalanine (Lenicque et al. 1981). There is also some 
evidence for the involvement of dopamine in KA-induced wet-dog shakes since lesions 
of nigrostriatal neurones produced by 6-hydroxydopamine enhance and L-Dopa, a 
precursor of dopamine, block wet-dog shakes (Kleinrok &Turski, 1980), although this 
has been disputed since pretreatment with high doses of dl-oc-methyl-p-tyrosine, an 
inhibitor of tyrosine hydroxylase, has no effect (Lenicque et al. 1981). There is 
evidence for increased neurotoxicity to KA following alterations to dopaminergic 
neurotransmission: FLA-63, an inhibitor of dopamine-p-hydroxylase, enhances the 
incidence of fatal convulsions (Lenicque et al. 1981). The data is therefore suggestive 
of a major role of 5-HT in KA neurotoxicity and a possible role of dopamine.
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At the next phase, starting about 1 hr after KA administration, individual recurrent 
motor seizures become prominent and spread throughout the brain. Between 90 and 
120 mins repeated severe limbic motor seizures involving the whole body occur 
accompanied by pronounced salivation and production of foam at the mouth. 
Depending on the route of application and dose of KA, limbic motor seizures may 
proceed to different stages of severity. Mild limbic seizure signs are seen after 
intahippocampal injection of low doses of KA (French et al. 1982). Similar doses may 
induced full-blown limbic motor seizures in the deep piriform cortex, amygdala or 
substantia nigra (Berger et al. 1986). Eventually, such limbic seizure attacks may 
culminate in status epilepticus lasting for several hrs, with histopathological 
consequences for susceptible brain regions. In some rats intense agitation, cycling and 
jumping can be seen during the period of general convulsions and also after termination 
of the status epilepticus. Two to three hrs after KA administration the seizures decline 
and the rats appear exhausted. This is followed by aphagia and aggression in rats that 
survive (Lenicque et al. 1981). The effects of KA on food intake may involve y- 
aminobutyric acid neurotransmission (Lenique et al. 1979) and aggression may be 
related to central mechanisms involving 5-HT (Lenicque etal. 1981) since KA-induced 
aggression is potentiated by p-chlorophenylalanine (Koe & Weissman, 1966).
Sperk and co-workers (1985) have suggested that the severity of seizures and number 
of wet-dog shakes induced by KA are dependent on the dose of KA administered. 
However, others have reported that most signs of KA poisoning are directly related to 
dose of KA, with the exception of wet-dog shakes, the severity of which appears to be 
inversely related (Fosbraey et al. 1992). The most likely explanation for this 
discrepancy is that wet-dog shakes become obscured by the development concurrently 
or subsequently of other signs of poisoning.
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1.1.5 Neurochemical changes induced by kainic acid
After the systemic injection of convulsive doses of KA to rats, two distinct phases of 
neurochemical changes have been observed in the brain:
(i) a partially reversible increase in the turnover of the monoamine neurotransmitters,
noradrenaline, dopamine and 5-HT during convulsions, seen from 2 hrs up to 24 hrs
(Giorguieff et al. 1977; 
following KA injection and affecting all major brain areas (Kleinrok & Turski, 1980;
Sperk et al. 1983). Additionally, using in vivo microdialysis it has been shown that
striatal dopamine levels are the most markedly increased 4 hrs after the intraperitoneal
injection of 16mg/kg KA in rats (Figure 3). These effects have been suggested to be
caused by a strong increase in the firing rate of monoaminergic neurones shortly after
injection of KA. This is unlikely to be merely a consequence of generalised seizure
activity as the effects also occur in rats that show no overt convulsions (Sperk et al.
1983).
(ii) an irreversible decrease of glutamate decarboxylase and choline acetyltransferase 
activities, developing after 3-30 days and restricted to only certain structures such as the 
hippocampus, amygdala and piriform cortex (Heggli & Malthe-S orenssen, 1982; Sperk 
et al. 1983). At later time periods the degree of these enzyme changes may be directly 
related to the excitotoxic and convulsive properties of KA. It has been hypothesised 
that anoxic-ischaemic brain damage and brain oedema resulting in damage of the basal 
portions of the brain in addition to disturbances of microcirculation may be additional 
factors important in the pathogenesis of late irreversible changes because irreversible 
brain damage and late neurochemical changes correlate with the severity of behavioural 
changes rather than with the dose of KA injected (Sperk et al. 1985). The 
neurochemical changes induced by KA are summarised in Table 1.
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1.1.6 Acute neuropathological changes induced by kainic acid
Macroscopic inspection of brains obtained from animals killed during or shortly after 
KA-induced seizures, 90 mins after systemic KA administration or later, reveals an 
increase in the volume of the hemispheres. Notably, the temporal lobes appear to be 
swollen and show incisures while other brain regions such as frontal cortex, 
cerebellum, caudal parts of the brain stem are macroscopically normal. 
Histopathological changes at the time of acute seizures are characterised by dendritic 
swelling and by shrinkage and pycnosis of perikarya (Sperk et al. 1983). Additionally, 
signs of general brain oedema with swelling of astrocytes can be observed throughout 
the brain which disappear in some brain areas, including parts of neocortex, the 
striatum and the cerebellum after 12-24 hrs.
1.1.7 Brain damage induced by kainic acid
Despite some variations between individual animals, a mostly consistent pattern of 
damaged brain regions is found after either systemic, intraventricular, 
intrahippocamapal or intra-amygdaloid application of KA, once status epilepticus has 
been reached and maintained beyond a critical time period (Ben-Ari, 1985; Tremblay et 
al. 1983). The areas that exhibit the most severe epileptic discharges during 
convulsions undergo neuronal death (Lothman et al. 1981; Schwob et al. 1980; Zaczek 
et al. 1980) which is associated with ladder-like DNA fragmentation in rat brain 
(Filipkowski et al. 1994). Slight DNA degradation, confirmed using in situ nick- 
translation, has been observed as early as 12 hrs following the intraperitoneal 
administration of lOmg/kg KA (Filipkowski et al. 1994). Uniquely, KA not only
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produces axon-sparing lesions when injected locally into any brain area (Coyle et al. 
1978) but causes secondary distant lesions remote from the site of injection. The area 
most severely affected is the entire amygdaloid complex including the bed nucleus of 
the stria terminalis of which the posterior cortical amygdaloid nucleus appears to be the 
most sensitive (Schwob et al. 1980). Massive neuronal degeneration occurs 
predominantly in piriform and entorhinal cortices where initially layers I-EH are the most 
severely affected. At later times general tissue necrosis is observed especially in the 
piriform cortex. A consistent pattern of selective neuronal damage has been observed in 
the hippocampal formation and a definite order of hippocampal cell sensitivity to both 
local and intraventricular injection of KA has been identified by Nadler et al. (1978): 
CA3a pyramidal cells> CA3b pyramidal cells> CA3c pyramidal cells> CA4 pyramidal 
cells= subicular pyramidal cells> CA1 pyramidal cells> CA2 pyramidal cells> dentate 
granule cells. Areas functionally related to the hippocampus, for example the lateral 
septal nucleus usually show damage. Severe damage is also consistently observed in 
the bulbus and tuberculum olfactorius. Within the thalamus the mediodorsal and the 
medioventral nuclei are mostly affected. Degeneration also occurs within the lateral 
dorsal and the posterior group of thalamic nuclei, especially the geniculate nucleus 
(Ben-Ari et al. 1980a; Schwob et al. 1980; Sperk et al. 1983). The process of neuronal 
degeneration continues and eventually leads to massive shrinkage of the hippocampus, 
amygdala and piriform and entorhinal cortices after a number of months (Baran et al. 
1988; Sperk et al. 1992).
1.1.8 Mechanisms of kainic acid-induced seizures and brain damage
Several mechanisms have been proposed to contribute to the brain damage induced by 
KA. After its systemic or intracerebral injection, KA may reach vulnerable brain areas
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by diffusion and induce direct axon-sparing lesions. Secondly, KA may exert strong 
excitatory actions upon certain neuronal pathways which in turn may cause seizures and 
distant brain damage. Thirdly, brain damage may be related to secondary seizure- 
related neuropathological events such as hypoxia, hypoglycaemia or oedema.
1.1.8.1 Focal axon-sparing lesions
It has been hypothesised that KA, when applied systemically or intracerbroventriculary, 
may reach particularly vulnerable brain areas, such as the hippocampus, in small 
amounts by diffusion and induce excitotoxic lesions (McGeer et al. 1978). The most 
susceptible area is the CA3 pyramidal neurones while CA1 pyramidal cells are more 
resistant to the neurodegenerative effect of KA (Nadler et al. 1980). One reason for this 
might be the high concentration of KA high-affinity binding sites in the stratum lucidum 
of CA3, which is a region innervated by the mossy fibre axons originating from the 
fascia dentata granule cell. This contrasts with the lower affinity KA binding sites 
which characterise the CA1 hippocampal subregion (Monaghan & Cotman, 1982). 
Furthermore, it has been suggested that KA receptors located presynapdcally on mossy 
fibres may induce glutamate release and thus contribute indirectly to the neurotoxic 
action of KA (Repressa et al. 1987).
When a sufficient dose of KA is injected into any number of brain regions, 
degeneration of neurones takes place not only at the site of injection, but also at distant 
loci (Ben-Ari et al. 1979). Regions most likely to sustain distant damage are 
hippocampus, piriform cortex, amygdala, claustrum-insula and anterior, midline and 
dorsal thalamic nuclei. The hippocampal CA3 area is particularly vulnerable. Diffusion 
has also been considered as one possible mechanism causing distant lesions in the
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hippocampus following injection of KA into regions such as the striatum or amygdala 
(Zaczek et al. 1980). Several lines of evidence, however, suggest separate mechanisms 
of KA distant toxicity. The pattern of distant brain damage induced by KA does not 
correlate with diffusion and can be prevented by certain lesions and prior administration 
of anticonvulsants (Ben-Ari et al. 1980b). Furthermore, the regional distribution of KA 
after injection bears no relation to the pattern of neuronal destruction (Nadler et al. 
1980). In addition, intrahippocampal injection of low doses of KA produces a similar 
pattern of degeneration as systemic application (See Olney, 1983). N-methyl-D- 
aspartate (NMDA), although exerting convulsant activity, is only moderately toxic in 
the hippocampal formation (Zaczek & Coyle, 1981). Ibotenic acid, on the other hand, 
can cause lesions without concomitant electroencephalographic seizures (Aldinio et al.
1983). Finally, anticonvulsants, most notably diazepam, simultaneously reduces the 
behavioural electrographic and neurotoxic actions of KA when injected systemically or 
directly into the brain (Ben-Ari et al. 1980b), whereas the local excitotoxic action of KA 
can only be partially blocked by high doses of anaesthetics or barbiturates (Di Chiara et 
al. 1981). This evidence suggests that distant lesions produced by KA are caused by 
prolonged and intense seizure activity that KA initiates and not by the toxin directiy.
1.1.8.2 Distant lesions induced by kainic acid mediated through 
activation of excitatory pathways
Direct evidence for brain damage caused by stimulation of excitatory pathways in the 
brain comes from the work of Sloviter (1983) showing that sustained stimulation of the 
perforant pathway in the rat results in similar damage of CA3 and CA4 neurones of the 
hippocampal neurones as observed in KA seizures. Similar observations were made 
after continuous electrical stimulation of the amygdala after kindling (McIntyre et al.
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1982). Neuronal stimulation during epileptic events may be largely mediated by 
excitatory amino acid mechanisms. The major lines of supporting evidence are that 
lesion studies have shown that the hippocampus can be protected from KA 
neurotoxicity by removal of glutamatergic and cholinergic afferents (McGeer et al. 
1978; Nadler, 1981). Also, loss of CA3 pyramidal cells after intracerebroventricular 
KA administration can be completely blocked by prior lesioning of mossy fibres 
(Nadler & Cuthbertson, 1980). In addition, there is a close correlation between the 
incidence and severity of convulsive symptoms with brain damage (Ben-Ari et al. 
1980b) which tend to be most predominant in the hippocampal formation (Lothman & 
Collins, 1980). Within this region the susceptibility of neurones to KA correlates well 
with their excitatory action (De Montigny & Tardif, 1981) and with their seizure 
threshold (Schwartzkroin & Prince, 1978). Finally, distant neuronal damage after 
locally applied KA is blocked by anticonvulsant treatment with barbiturates or 
diazepam, leaving unprotected only the tissue around the injection site (Ben-Ari et al. 
1979).
1.1.8.3 Neuropathological events causing brain damage following 
kainic acid-induced seizures
In addition to selective neuronal lesions induced by KA, considerable brain damage 
which is unrelated to specific pathways or brain areas and is not restricted to neurones 
is observed. It consists of massive oedema, hemorrhages and necrosis of neurones and 
non-neuronal elements. After prolonged status epilepticus induced by KA the most 
severely necrosed regions are the amygdaloid nuclei, the piriform and entorhinal 
cortices and the olfactory areas of the forebrain. 24 hrs to 3 days after systemic 
injection of KA oedema and perivascular hemorrhages become prominent. These are
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accompanied by capillary sprouting, the occurrence of small cystic lesions especially in 
the amygdala and piriform cortex, caused by reactive gliosis and by loss of 
oligodendrocytes and demyelination (Sperk et al. 1983; Zucker et al. 1983). This 
unspecific necrosis is progressive. Large parts of the piriform cortex and almost the 
entire amygdala are lost after a few months (Sperk et al. 1992).
This widespread and progressive necrosis may involve various mechanisms including 
incomplete parenchymal necrosis, observed initially, which is a typical sign of anoxic- 
ischaemic damage (Levine, 1960). Damage of CA1 pyramidal neurones is typical for 
brain lesions produced by anoxic-ischaemic episodes (Karnushina et al. 1983). 
However, the general topographic pattern of lesions is different from that observed in 
hypoxia or ischaemia (Sperk et al. 1983).
Local oedema may play an important role in the pathogenesis of non-selective brain 
damage induced by KA seizures (Lassmann et al. 1984; Sperk et al. 1983). Oedema at 
the fissura rhinalis, the fissura amygdaloidea and the sulcus entorhinalis occurs early 
during acute seizures and gives rise to massive swelling of adjacent brain regions. 
Thus, early oedema may result in compression of drainage vessels and disrupted blood 
supply of affected brain areas (Lassmann et al. 1984; Sperk et al. 1983). Indeed, 
decreased accumulation of 2 -desoxyglucose has been observed in these areas 2-3 days 
after KA treatment (Ben-Ari, 1981). Early intervention by diuretic treatment for 
preventing formation of cytotoxic oedema is effective and reduces seizure activity and 
non-selective brain damage (Baran et al. 1987; Lassmann et al. 1984).
There is evidence that damage of CA3 pyramidal neurones, for example, is caused by 
hypoglycaemia rather than neuropathological mechanisms such as hypoxia. It has been 
demonstrated that in the CA3 sector a decrease in oxygen partial pressure by 35% 
occurs during seizures which is compensated by a three times increased local blood
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flow in the Ammon's horn (Pinard et al. 1984). Tanaka et al. (1992) also found an 
uncoupling of local blood flow and local glucose utilisation in CA3 and some other 
brain areas.
1.1.8.4 Neurogenerative mechanisms of kainic acid-induced cell death
The precise mechanism for the neurodegenerative effect of KA is unclear. Calcium 
entry is believed to be involved in cell death (Olney et al. 1987; See Choi, 1988). Many 
laboratories have reported that KA receptor agonists enhance intracellular calcium 
concentration by opening sodium channels, depolarising the cell membrane and causing 
calcium influx in a voltage-dependent manner (Meldrum & Garthwaite, 1990). Calcium 
accumulation in neurones can initiate cytopathological changes including loss of 
mitochondrial and nuclear function and activation of proteases and other calcium- 
dependent enzymes (See Choi, 1988); this action is called excitotoxicity. Additionally, 
KA can also stimulate glutamate release (Sun et al. 1992). Released gluamate may exert 
a positive feedback mechanism to potentiate the action of KA by acting at the NMDA 
receptor, which would lead to further increases in the entry of extracellular calcium ions 
through the receptor-operated ion channel. This would explain the observation that a 
combination of endogenous and exogenous glutamate was required to produced the 
maximum effect of the KA action (McGeer et al. 1978). Apart from calcium 
overloading, osmolysis has been proposed to account for KA-induced excitotoxicity. 
KA has been shown to generate large ion fluxes, particularly of sodium ions through 
receptor-gated ion channels, accompanied by the passive movement of chloride ions 
and water molecules into the neurones. This osmotic overloading may induce neuronal 
damage as suggested by some workers (Rothman, 1985; Olney et al. 1986) although
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osmolytically induced cell damage may not explain some delayed forms of injuries 
leading to cell necrosis observed by others (Choi, 1985).
The unchecked calcium entry leading to cell death via intracellular events remains poorly 
understood. It has been suggested that free radicals are involved in the cell death and 
tissue damage (Murphy et al. 1989; Rose et al. 1990). Overexcitation may led to the 
activation of phospholipase A2, attacking cellular membranes and liberating free fatty 
acids, which can subsequently be a source of free radicals. Sun et al. (1992) have 
detected, using in vivo spin trapping, free radical formation in the gerbil brain 
accompanied by lipid peroxidation 1 hr after KA administration. Furthermore, 
membrane-bound synaptosomal (Na+-K+)ATPase activity, which is dependent upon 
membrane integrity because its activity is greatly reduced after KA treatment (Sun et al. 
1992). Alternatively, activation of xanthine oxidase may lead to the formation of 
cytotoxic superoxide radicals as proposed by Dykens and co-workers (1987).
Nitric oxide as a neuronal messenger was first described by Garthwaite et al. (1988). 
At high concentrations nitric oxide can initiate neurotoxicity (Dawson et al. 1991) 
however its pathophysiological role is complicated by its interaction with other 
mediators and second messengers. Nitric oxide can induce the release of glutamate 
(O'Dell et al. 1991) and glutamate-stimulated calcium signals elicit nitric oxide 
production by a calcium- and calmodulin-sensitive nitric oxide synthase which can 
mediate, at least in part, glutamate toxicity in rat cortical cultures (Dawson et al. 1991). 
Likewise, KA can induce the release of nitric oxide (Balcioglu & Maher, 1993) 
although nitric oxide has both convulsant (Mulsch et al. 1994) and anticonvulsant 
effects on seizures induced in rats by KA (Maggio et al. 1995; Penix et al. 1994; 
Przegalinski et al. 1994). This is suggestive of a potential role for nitric oxide in 
mechanisms involving seizures in rats induced by KA.
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1.1.9 Kainic acid-induced receptor changes
Most receptor binding studies have used KA as a selective lesioning agent of central 
nervous pathways to localise receptors of interest following axon-sparing lesions 
induced by KA. There have been a few studies investigating the receptor changes of 
KA itself preceding induced brain damage. Kish et al. (1983) have investigated both 
the early and late changes in y-aminobutyric acid receptor binding induced by KA. 
This group showed that after subcutaneous administration of 15mg/kg KA two phases 
of y-aminobutyric acid receptor change occur. After 2 hrs no change in frontal cortex, 
hippocampus or amygdala-piriform cortex is observed (Kish et al. 1983). However, 1- 
80 days later an increase in y-aminobutyric acid receptors of between 80-200% in 
amygdala-piriform cortex occurs (Kish et al. 1983). Other studies have determined 
receptor effects subsequent to the lesioning properties of KA. For example. Perry and 
Grimes (1989) have shown that hippocampal p- but not K-opioid receptors increase in 
number (145-247%) 48 hrs after subcutaneous administration of KA whereas in the 
striatum ji- and 5-opioid receptors decrease in number (by a maximum of 90%) and 
decrease in affinity one week after microinjection of KA (Antkiewicz-Michaluk et al.
1984). Dopamine D2 receptors, measured by [3H]-spiperone, appear more resistant to 
KA-induced changes because smaller increases in binding (68%) are observed after one 
week in nucleus accumbens but not caudate putamen (Bardgett et al. 1995). 
Furthermore, benzodiazepine receptors also appear less vulnerable to KA-induced 
changes because similar percentage changes in binding in the frontal cortex are 
observed after three weeks but not 3 or 10 days (Kish et al. 1983). Also, the number 
of glucocorticoid receptors in hippocampus, frontal cortex, striatum and hypothalamus 
and hippocampal mineralocorticoid receptors are decreased 24 hrs after systemic 
administration 10mg/kg KA (Lowy et al. 1992). A similar dose of KA produces down- 
regulation of muscarinic receptors in forebrain after 3 and 10 days (Churchill et al.
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1990) whereas microinjection of KA produces an increase in maximal binding capacity 
in frontal and parietal cortices (Katayama et al. 1990). The receptor changes induced by 
KA are summarised in Table 2.
1.1.10 Kainic acid: a neurochemical lesioning tool and model of 
temporal lobe epilepsy in the rat ?
KA has become an important tool for studying functions related to excitatory amino acid 
transmission in invertebrates and mammalians during the last 20 years. Two different 
properties of KA have had a great impact for neuroscience research: KA injected locally 
into any brain region produces axon-sparing lesions (Coyle et al. 1978) and KA exerts 
a potent convulsive activity when applied systemically into limbic structures (Nadler et 
al. 1980). Not all neurones are equally vulnerable and some may be completely 
resistant, although the literature is variable. Nadler et al. (1981) found a distinction 
between the selective hippocampal pathology which characterised KA lesions and the 
non-selective hippocampal lesions made by other acidic amino acids.
Temporal lobe epilepsy is the most devastating form of epilepsy commonly encountered 
in the adult population (Janz, 1969). The attacks involve loss of consciousness thus 
exposing the individual to bodily injury. Moreover, pharmacologically intractable 
temporal lobe epilepsy is associated with the loss of neurones from the hippocampus 
and other brain regions. These cases are unfortunately common owing to the relatively 
low efficacy of available anticonvulsants against this condition. Progress in the 
understanding and treatment of temporal lobe epilepsy would be greatly facilitated by 
the availability of an animal model which reproduces the histopathological, behavioural 
and electrographic features of this condition. The outstanding feature of KA for
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epilepsy research are its potency to induce a syndrome characterised by an acute status 
epilepticus and subsequent behavioural and histopathological changes resembling the 
clinical symptoms and brain damage observed in human temporal lobe epilepsy. A 
major drawback of the use of KA is its propensity to produce selective local axon- 
sparing lesions in regions such as hippocampus, piriform cortex and amygdala (Ben- 
Ari et al. 1979; Schwob et al. 1980). However, these distant lesions can be prevented 
by pretreating animals with anticonvulsant drugs (Ben-Ari et al. 1979). The above 
characteristics suggest that the KA-treated rat possesses many of features required of a 
model of human temporal lobe epilepsy.
1.2 Excitatory amino acid receptors
The major forms of the glutamate receptors are ligand-gated ion channels and have been 
subdivided into a-amino-3-hydroxy-5-methyl-isoxazole, KA and NMDA receptors 
according to their sequence similarity and selective agonists (See Monaghan et al.
1989). Recent advances achieved using molecular cloning and functional analysis have 
revealed a high degree of molecular and functional complexity and diversity (See 
Seeburg, 1993) and these receptors are now believed to be composed of homomeric or 
heteromeric assemblies of integral membrane protein subunits which have been 
classified according to their binding and activation of channel activity: a-amino-3- 
hydroxy-5-methyl-isoxazole (AMPA) receptor subunits correspond to GluRl to 
GluR4, the KA receptor subunits are GluR5 to GluR7, and the NMDA receptor 
subunits are NMDA1 and NMDAR2A to NMDAR2D. The individual subunits of all of 
these receptors are approximately lOOkDa and each is proposed to contain a large 
extracellular ligand-binding N-terminal domain, four hydrophobic transmembrane 
domains, and an extracellular C-terminal domain. In addition to these functional
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ionotropic glutamate receptors, lower molecular mass KA subunits (40-50kDa; also 
referred to as KA binding proteins) have been cloned from non-mammalian vertebrate 
brain and are termed KBPs . The sequence homology of these low molecular
weight forms is highest (-35-40%) with the C-terminal portions of KA subunits (See 
Seeburg, 1993). The mRNAs encoding the GluR5 and GluR6 subunits can exist in 
two alternative forms specified by RNA editing either encoding for an arginine (R) or 
glutamine (Q) residue in a functionally critical region of a putative channel-forming 
segment rendering them permeable to calcium ions (Sommer et al. 1991; Sommer & 
Seeburg, 1992). Conversely, GluR7, KA-1 and KA-2 only exist in the unedited Q 
form (See Seeburg, 1993).
1.2.1 High-affinity and low-affinity kainic acid binding sites and 
subunit composition
Based on differential agonist affinities and dissociation kinetics, both high-affinity 
(Ko=5nM) and low-affinity (Kd~22-72iiM) KA binding sites have been described in 
the brain (Monaghan & Cotman, 1982; Unnerstall & Wamsley, 1983; Hampson et al 
1987). In transfected cells GluR5-GluR7 display [3H]-KA binding activity with 
disocciation constants of 36-95nM (Bettler et al. 1992; Sommer et al. 1992) which 
suggests that they are related to the low-affinity KA binding sites found in mammalian 
brain (Hampson et al. 1987). [3H]-KA binds KA-1 and KA-2 subunits with 
dissociation constants of 3.9 and 15nM respectively (Werner et al. 1991; Herb et al.
1992) and thus these may correspond to the high-affinity binding sites in mammalian 
brain (Hampson et al. 1987).
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Each KA receptor type is comprised of several distinct subunits which can assemble in 
different combinations to produce a functional receptor complex (Wenthold et al. 1994). 
Although some subunits can form functional homomeric receptors when expressed in 
oocytes or cultured cells, current evidence indicates that most functional receptor 
complexes found in the brain comprise two or more distinct subunits. However, there 
is as yet no simple and concise model for the construction of KA receptors in native 
brain membranes. The GluR5 (Q) and GluR6 subunits can form functional 
desensitising KA-gated channels in the homomeric configuration and heteromeric 
channels with the edited forms of the GluR5 and GluR6 subunits. However, the KA-1 
and KA-2 subunits cannot form detectable homomeric ligand-gated ion channels but 
when these subunits are co-expressed with GluR5 or GluR6 subunits, channels with 
new susceptibility to desensitisation to KA are generated (Herb et al. 1992). For 
example, GluR5/KA-2 subunit combinations yield rapid desensitization and different 
current-voltage relations compared with GluR5 subunit homomers. Furthermore, 
AMPA can elicit a nondesensitizing current component on GluR6/KA-2 combinations 
although the homomeric GluR6 receptors are not sensitive to AMPA (Herb et al. 1992). 
The functional responses of the KA receptor subunit complexes are summarised in 
Figure 4.
1.2.2 Arrangement of kainic acid receptor transmembrane domains
Ionotropic glutamate receptors are assumed to belong to the superfamily of ligand-gated 
ion channels, with the nicotinic acetylcholine receptor as the prototype (Hollmann & 
Heinemann, 1994). The proposed structural features of this family are four putative 
domains, with both the N and C-termini located extracellularly and with a large 
cytoplasmic loop between the third and fourth tansmembrane domains (Changeux et al.
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Figure 4. Transmembrane model of the ionotropic receptors and functional 
responses of the kainic acid subunit complexes
COOH
COOH
Extracellular
IVIV
Intracellular
Kainic acid subunit complex
GluR5(Q)/GluR5(Q)
GluR5(R)/GluR5(R)
GluR6 (Q)/GluR6 (Q)
GluR6 (R)/GluR6 (R)
KA-2/KA-2
GluR5(Q)/KA-2
GluR5(R)/KA-2
GluR6(Q/R)/KA-2
Response of cotransfected cells to kainic acid
Functional kainic acid-gated channels1
Does not form functional kainic acid-gated 
channels1
Functional kainic acid-gated channels1 
Functional kainic acid-gated channels1
Does not form functional kainic acid-gated 
channels2
Kainic acid-activated whole-cell currents with a 
more rapid current component than GluR5(Q)/
G1uR5(Q)3
Kainic acid-activated whole-cell currents2 
Kainic acid-activated whole-cell currents3
Conventional transmembrane model of the ionotropic receptors (Nakanishi, 1992) where 
I-IV refer to the four domains and below is a table of the functional responses of 
homomeric and heteromeric assemblies of kainic acid subunits where Q is the unedited
form and R is the edited form of the subunit References are from iEgebjerg et al. 1991;
2Sommer et al. 1992; 3Herb et al. 1992.
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1992). Refer to Figure 4. for a schematic representation of the ionotropic receptors. 
Recent evidence suggests that this four transmembrane model is correct and hence it is 
now universally accepted that glutamate receptors comprise four domains (Hollmann & 
Heinemann, 1994). The N-terminus of glutamate receptors is likely to be located 
extracellularly since the presence of the cleavable N-terminal region across the 
membrane of the endoplasmic reticulum is at the first step of the biosynthetic pathway 
(Von Heijne & Gavel, 1988). This is supported by the fact that in some GluR 
subtypes, potential N-glycosylation sites are present in the N-terminal half of the 
protein and that this domain is implicated in the binding of agonists, polyamine, redox 
agents and zinc (Kohr et al. 1994). Conversely, the C-terminal tail of NMDAR1 was 
shown using protein kinase C phosphorylation to be located extracellularly (Tingley et 
al. 1993). The extracellular N-terminus and cytoplasmic C-terminus imply that an odd 
number of transmembrane domains must be present and models with both three (Wo & 
Oswald, 1995) and five transmembrane domains (Roche et al. 1994) have been 
proposed (Figure 5).
1.2.3 Distribution of kainic acid receptors
Autoradiographic analyses have shown a widespread distribution of [3H]-KA binding 
in the mammalian central nervous system (Monaghan & Cotman, 1982; Unnerstall & 
Wamsley, 1983). In situ hybridization histochemistry of GluR5 to GluR? and KA-1 
and KA-2 shows distinct but overlapping patterns of expression of these subunits. 
KA-1 appears to be the most restricted with expression primarily limited to the CA3 
pyramidal neurones of the hippocampus (Werner et al. 1991), while the expression of 
KA-2 is ubiquitous (Herb et al. 1992). In the cerebellum, KA-2 and GluR6 are both 
abundant in the granule cell area (Herb et al. 1992), GluR? is expressed in
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Figure 5. Proposed models of kainic acid receptor structure
Extracellular
Asn-720
Ser-684
COOHIntracellular
M3 aM2 M4M3Ml
NH2
Extracellular
COOH
Intracellular
Proposed models of kainic acid receptor structures represent (a) schematic representation 
of the proposed topology of the GluR6 subunit showing a five transmembrane structure 
(Roche et al. 1994). The new transmembrane domain, TM3a, is located between Ser-684 
and Asn-720 and (b) schematic depiction of the proposed transmembrane topology (3-TM 
model) of the cloned cDNAs GFKARa and GFKAR(3, encoding two homologous kainate 
receptors from goldfish brain (Wo & Oswald, 1995).
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stellate/basket cells (Bettler et al. 1992) and GluR5 is expressed in the Purkinje cell 
layer (Bettler et al. 1990).
1.3 Classification of dopamine receptors
In the late seventies, before the advent of receptor cloning techniques, the effects of 
dopamine were attributed to the activation of just two receptor subtypes, termed Di and 
D2, which produce opposing effects on adenylate cyclase (Spano et al. 1978; Kebabian 
& Caine, 1979). However the application of homologous screening of the seven 
transmembrane catecholamine receptors, particularly that of the D2 sequence has led to 
the identification of previously uncharacterised dopamine receptors with functional 
diversity which offer new therapeutic potential. A dopamine D2 receptor gene was first 
cloned from a rat genomic library (Bunzow et al. 1988). The rat cDNA coded for a 415 
amino acid monomeric protein, which contained seven transmembrane domains and, 
when expressed in mouse fibroblasts, revealed radioligand binding properties similar to 
those of rat striatal dopamine D2 receptors. The dopamine D2 receptor showed the 
structural features of guanine nucleotide-binding regulatory protein (G-protein)-coupled 
receptors. Soon thereafter a human dopamine D2 receptor cDNA was cloned from a 
pituitary cDNA library; two splice variants were found, encoding a 414 and a 443 
amino acid long protein monomer, termed the short (£>25) and long (D2l )  forms of D2 
receptors respectively (Grandy et al. 1989). The additional 29 amino acid residues, 
spliced out in the short form (Giros et al. 1989; Monsma et al. 1989; Dal Toso et al.
1989), were found in the third intracellular domain, a loop which is thought to be 
involved in the coupling of the receptor to the G-protein. Similar cDNA splice variants 
encoding 415 and 444 amino acid proteins were isolated from rat brain cDNA libraries 
(Chio et al. 1990; O'Malley et al. 1990). After the cloning of the dopamine D2 splice
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variants this was followed by cloning of products of different genes, the D3 (Sokoloff 
et al. 1990), D4 (Van Toi et al. 1991), and D5 receptors. While the cloned D5 receptor 
displays structural and pharmacological similarities to the Di receptor, the D3 and D4 
receptors are similar to the D2 receptor, leading to a classification of dopamine receptors 
into the Di-like and D2-like subfamilies. Despite evidence for the existence for 
additional dopamine receptors, cloning techniques have since so far failed to identify 
any additional subtypes. Currently Di-like and D2-like receptors are therefore classified 
according to selective agonists and antagonists, receptor distribution and signal 
transduction mechanisms.
1.3.1 Pharmacology of dopamine receptors
The sensitivities of the cloned Di and D5 receptors to antagonists are similar and are 
generally the same as those of Di receptors in native tissues. For example, R-sulpiride 
is more potent than S-sulpiride whereas the opposite is the case for the D2-like receptors 
(Bergman et al. 1991). It has been difficult to obtain accurate comparisons of the 
agonist sensitivities of cloned receptors with those in native tissues using dopamine 
receptor agonists because dopamine receptors in native tissues can adopt either a high- 
affinity state or a low-affinity state for an agonist, while cultured cell lines vary in their 
ability to reveal the high-affinity state. However a consistent difference between the Di 
and D5 receptors is that dopamine is approximately 10-times more potent at the D5 
receptor. Among agonist potencies the most important selectivity difference is that 
bromocriptine is about two orders of magnitude more potent at the D2 and D3 receptors 
than at the D4 receptors while 7-OH-DPAT is approximately tenfold more potent at D3 
receptors than at D2 receptors (Baldessarinietal et al. 1993; Damsma et al. 1993). So 
far it has been impossible to differentiate pharmacologically between the short and long
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D% forms, in spite of indications that some antipsychotics, for example sulpiride and 
raclopride have marginally different pharmacology at these variants (Castro & Strange,
1993). In the case of antagonists, clozapine is approximately one order of magnitude 
more potent at D4 receptors than at D2 or D3 (the opposite is true for raclopride) 
whereas chlorpromazine is about one order less potent at D4 receptors. There is no 
drug that is highly selective for D4 receptors, however they can be measured indirectly 
in the brain using [3H] -nemonapride which labels D2, D3 and D4 receptors and [3H]- 
raclopride which labels D2 and D3 receptors (Seeman et al. 1993), the difference in 
binding densities of these two ligands, therefore, may be attributed to D4 receptors. 
The affinities of ligands at dopamine receptors is summarised in Table 3.
1.3.2 Signal transduction pathways
Dopamine Di and D2 receptors were initially distinguished in terms of signalling, that is 
positive and negative coupling to adenylate cyclase respectively mediated by G-proteins 
(Kebabian & Caine, 1979). This appears to broadly apply to the novel members of the 
Di-like and D2-like subfamilies of dopamine receptors, however in fibroblasts or 
secretory cells expressing the novel recombinant receptors, dopamine elicits both 
similar but distinct responses as compared to Di and D5 receptors. For example, within 
the Di-like subfamily, both Di and D5 receptor activation enhances cAMP formation 
whereas dopamine and other agonists have a higher affinity and potency at the D5 
subtype, and systems expressing D5 receptors have a higher basal adenylate activity 
compared to Di receptors (Tiberi & Caron, 1994).
Within the D2-like receptor subfamily, both the D2L and D2S splice variants inhibit 
cAMP formation in all cell lines tested (Filtz et al. 1993; Liu et al. 1992; Liu et al. 1994;
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Zhang et al. 1994), whereas the D3 (Chio et al. 1994) and D4 receptor (Tang et al. 
1994) do so only in a few cell lines and with a smaller inhibition. Regarding other 
cellular responses, the D2L receptor increases inositol phosphate in a fibroblast, but not 
in a dopaminergic cell line while the D3 and D4 receptors are inactive in both (Tang et 
al. 1994). Also, the D3 receptor has been shown to be either inactive or a weaker 
mitogen in a Chinese hamster ovary line compared to the D2 receptor (Chio et al. 1994), 
but potent in a neuroblastoma-glioma cell line (Pilon et al. 1994).
Each dopamine receptor subtype, at least in the D2-like subfamily, may activate multiple 
signal pathways and this is consistent with the occurrence of the highest sequence 
diversity at intracellular domains known to interact with the a-subunit of G-proteins. 
For example, the D2 (Piomelli et al. 1991) and D4 (Chio et al. 1994) receptors enhance 
arachidonate release, but the response mediated by the D2 receptor is potentiated by 
cAMP via protein kinase A activation, whereas that of the D4 receptor is not and 
requires protein kinase C (Chio et al. 1994). Also, sodium-dependent extracellular 
acidification in Chinese hamster ovary cells is observed with all D2-like receptors but 
only the D3 and D4 receptor-mediated responses are attenuated by cAMP (Chio et al.
1994).
1.3.3 Distribution of dopamine receptors
Gene transcripts of D3, D4 and D5 receptors are much less abundant and display more 
discrete expression in the brain than those of Di and D2 receptors (See Sokoloff & 
Schwartz, 1995). Gene transcripts of D3, D4 and D5 in contrast to those of Di and D2 
are virtually absent from the dorsal striatum, being exclusively expressed in certain 
limbic regions (See Sokoloff & Schwartz, 1995). The D3 receptor, for which the most
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detailed information is available, is selectively expressed in the ventral complex in the 
rat (Sokoloff et al. 1990) specifically in the granule cells of the islands of Calleja and in 
medium sized neurones in the shell of the nucleus accumbens, particularly neurotensin 
neurones projecting to ventral pallidum (Diaz et al. 1995). D3 receptor mRNA has also 
been detected in low levels within the human hippocampus and various cortical layers 
and subregions of the medial temporal lobe (Meador-Woodruff et al. 1994), areas 
known to receive scarce dopaminergic innervation, while very low or undetectable 
levels of D3 mRNA are present in the caudate putamen (Landwehrmeyer et al. 1993). 
The D4 receptor mRNA has been detected in rat (Valerio et al. 1994) and human 
(Meador-Woodruff et al. 1994) frontal cortex, amygdala and hippocampus; the D5 
receptor mRNA has been detected in rat (Meador-Woodruff, 1992) and human (Murray 
et al. 1994) thalamic and hypothalamic nuclei and layers of hippocampal and other 
temporal lobe cortical areas. In areas corresponding to cells of origin and established 
projection fields of the mesostriatal, mesolimbocortical, diencephalospinal and 
periglomerular systems and density of D2 receptors generally parallel that of dopamine 
innervation. In contrast many areas without established dopamine innervation contain 
D2 receptors, often in high density as is the case in large areas of the cerebral cortex 
(layers I-IH and V-VI), outside the projection fields of the mesocortical system, the 
cerebellum (moleculare layer and dense patches within lobule 9) and the hippocampal 
formation (lacunosum moleculare layer) (Bouthenet et al. 1987). These areas might 
correspond with minor or undetected dopamine innervation or to D2 receptors not 
receiving dopamine inputs. Finally there are several well-established dopaminergic 
areas that do not reveal any D2 labelling which might correspond to regions in which 
dopamine transmission is not mediated by D2 receptors. This is particularly evident in 
the hypothalamus (areas of origin or termination of the tuberohypophyseal and 
incertohypothalamic dopamine systems) and also in the hippocampal formation (alveus, 
fimbria, hilus dentate gyrus) and amygdaloid complex (anterior, basolateral and medial
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nuclei) (Bouthenet et al. 1987). The distribution of D2 receptors in the rat brain is 
summarised in Table 4.
1.3.4 Isoform s of the dopamine D% receptor
The cDNA and gene for rat and human dopamine D2 receptor have been cloned and 
sequenced (Grandy et al. 1989). In both species, two isoforms of the receptor resulting 
from alternative RNA splicing, have been detected (Chio et al. 1990). One isoform 
contains 415 amino acids in rat and 414 amino acids in human and is termed D2S, D2B 
or D2(4 i5 or 414) while the other isoform termed D2L, D2A or 02(444 or 443)» contains an 
additional 29 amino acid sequence in the putative third cytoplasmic domain of the 
receptor. The two isoforms appear to be functionally similar under normal 
physiological conditions but the presence of the extra 29 amino acids in the third 
cytoplasmic loop of the D2L dopamine receptor may be of significance in signal 
transduction mechanisms as this region is believed to be involved in receptor G-protein 
coupling.
Both D2S and D2L receptor mRNAs are widely and similarly expressed in rat brain 
except in the corpus striatum where the long form is more abundant (Neve et al. 1991). 
Also, using specific D2 antibodies, it was demonstrated that the D2L receptor was the 
predominant D2 receptor in rat striatum (McVittie et al. 1991). Intermediate levels of 
both forms are present in midbrain and low levels are present in hippocampus, 
cerebellum and cortex (Neve et al. 1991).
There has been little characterisation of D2L and D2S receptors in terms of the binding 
affinities of dopamine agonists and antagonists in homogenate preparations however
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Table 4. Distribution of dopamine D% and p-opioid receptors in 
rat brain by autoradiography using [125I]-iodosulpiride to label 
D 2-sites and [3H]-DAGO to label p-sites
Brain area Density of D%- Density of Vi­
sites  sites
Mesostriatal and mesolimbocortical
areas of origin:
**** & ** *** & **Pars compacta and reticulata of the
substantia nigra **** **Ventral tegmental area
Mesostriatal areas of projection: ****Caudate putamen ****
Nucleus accumbens **** ****
Olfactory tubercle **** *
Islands of Calleja **** *
Subthalamic nucleus *** 0
Bed nucleus of stria terminalis *** **
Mesolimbocortical areas of projection:
0Anterior olfactory nuclei **
Lateral septal nucleus *** 0
Lateral habenular nucleus ** 0
Dicencephalospinal area of projection:
External layers of dorsal horn * - ** 0
Periglomerular area of projection: **** N.Q.Glomerular layer of olfactory bulb
Infralimbic cortex (layers V-VI) *** - **** 0
Prelimbic cortex (layers I-IH and V-VI) ** & **** 0
Circlular layers in lobule 9 of the *** N.Q.
cerebellum
Ventroposterior thalamus nucleus 0 **
Hypothalamus
0 *Medial preoptic area
Median eminence 0 0
Suprachiasmatic nuclei 0 0
Paraventricular nuclei 0 0
Supraoptic nuclei 0 0
Tuberohypophyseal system (A12 in the 0 0
acuate nucleus)
0Incertohypothalamic system (A14 in the 0
periventricular nuclei)
Amygdala
0 ***Medial
Lateral 0 ****
Basolateral 0 ****
Hippocampus **** ***Lacunosum moleculare layer
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Levels of [1251] -iodosulpiride binding represent, 0 undetected (relative optical 
density<0.05), * low density (0.05<relative optical density<0.15), ** medium density 
(0.15<relative optical density<0.25), *** dense (0.25<relative optical density<0.40) 
and **** very dense (relative optical density>0.40). Levels were taken from Bouthenet 
et al. (1988). Levels of pH]-DAGO binding represent, 0 undetected (black tones of the 
16 tone colour scale produced by the Loats image analysis system), * low density (blue 
tones), ** medium density (yellow and green tones), *** dense (red tones) and **** 
very dense (white tones). Levels were taken from Mansour et al. (1987). N.Q. 
represents regions that were not quantified.
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when the D2 isoforms are expressed in cloned systems their ligand binding properties 
are variable. In mouse fibroblast cells expressing rat Dzs and D2L receptors, both 
isoforms show similar affinities for several compounds of different chemical classes of 
D2 receptor antagonists, including pentacyclics ((+/-)-butaclamol), thioxanthenes (cis- 
flupenthixol), butyrophenones (haloperidol) and benzisoxazole derivatives 
(domperidone) whereas the short form shows approximately 3-fold higher affinities for 
several benzamide antagonists including raclopride and (-)-sulpiride (Castro & Strange,
1993). Conversely, Ley sen and co-workers (1993) have reported that sulpiride and 
spiperone can not differentiate between the two splice forms cloned from the human 
dopamine D2 receptor when expressed in 293 human kidney cells. In addition, using 
homogenate studies this group also showed that sulpiride and spiperone could not 
differentiate between the D2 receptors in rat striatum, nucleus accumbens and olfactory 
tubercle (Leysen et al. 1993).
1.3.5 Regulation of dopamine D% receptors by sodium and H+
A characteristic of D2 receptors and of Gi-coupled receptors in general is that they are 
regulated by sodium and H+ concentration. Sodium modulates inhibition of adenylate 
cyclase (Blume et al. 1979) and decreases the affinity of Gpcoupled receptors for 
agonists (Pert & Snyder, 1974). For example, sodium acts directly at an intracellular 
site on (X2-adrenergic receptors to alter ligand potency (Nunnari et al. 1987) while 
decreased pH also lowers the affinity of (X2-adrenergic receptors for agonists by direct 
action on the receptor (Nunnari et al. 1987). It has been speculated that sodium and H+ 
bind to one site on D2 receptors to regulate conformational state through an interaction 
with the conserved amino acid residue Asp-80 (Neve, 1991). This is supported by the 
finding that mutation of the corresponding residue in (X2-adrenergic receptors yields a
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receptor whose affinity for ligands is no longer sensitive to sodium (Horstman et al.
1990). Asp-80 is not only important for the regulation of receptors but is also critical 
for the coupling of receptors to several signalling pathways involving G-proteins, 
including inhibition and stimulation of adenylate cyclase and stimulation of 
polyphosphoinositide hydrolysis. However, an unusual manifestation of the effect of 
sodium on dopamine D2 receptors is that the substituted benzamide antagonists 
epidepride and sulpride bind with considerably higher affinity in the presence of sodium 
but have a reduced affinity following H+ elevation (Neve, 1991). Conversely, sodium 
and H+ have been show to have little effect on the binding of the butyrophenone, 
spiperone. The characteristics of the binding of the substituted benzamides in vitro may 
be related to their reduced behavioural specificity as shown by their inability to cause 
catalepsy in rats as compared to any other D2 receptor antagonist (Ogren et al. 1986).
In the striatum, or in cultured cells D%, D2, D3 and D4 receptors exhibit both a high- 
affinity and low-affinity binding states for agonists. In the presence of guanosine 
triphosphate (GTP) the affinity for agonists is decreased without decreasing antagonist 
affinity (Van Toi et al. 1991) whereas an increase in affinity for agonists is observed in 
the presence of magnesium (Watanabe et al. 1985).
1.3.6 Multiple molecular forms of the dopamine D% receptor
The ability of postsynaptic receptors to modulate in number is important for the 
regulation of neuronal activity in response to neural afferent stimulation. The results of 
pharmacological and lesion studies of the rat mesostriatal dopamine system suggest that 
mechanisms exist to regulate D2 receptor number in order to preserve homeostasis. 
Denervation of this pathway or chronic D2 receptor blockade with antagonist drugs can
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increase D2 receptor number (Creese et al. 1977; Neve et al. 1985). Conversely, 
chronic 0 % receptor stimulation with either agonist drugs or neurotransmitter-releasing 
drugs can result in reduced D2 receptor number (Quik & Iversen, 1978; Chen et al. 
1993a). The total number of D2 receptors changes very slowly, however, in response 
to chronic alterations in ligand concentration suggesting that they are the result of altered 
biosynthesis and/or degradation of D2 receptors (Quik & Iversen, 1978; Chen et al. 
1993a). However, the number of D2 receptors at the synapse may be altered rapidly by 
redistribution of D2 receptors between the cell surface and intracellular pools (Chugani 
et al. 1988). This process of agonist-mediated receptor internalisation and recycling 
may help explain discrepancies between the binding of dopamine receptor ligands in 
vivo as compared to the binding to membrane preparations in vitro. For example the in 
vivo dissociation half-life of the dopamine D2 agonist pH]-spiperone is about 15 mins 
(Leysen et al. 1978) whereas its in vivo clearance half-life is greater than 16 hrs 
(Laduron et al. 1978). Another discrepancy between the in vivo an in vitro binding of 
pH]-spiperone is that dopamine competes with pH]-spiperone binding in vitro, 
whereas the dopamine-releasing drugs, d-amphetamine and bupropion increase the in 
vivo accumulation of pH]-spiperone (Bischoff et al. 1984). These apparently 
inconsistent findings might be explained by increased trapping of pH]-spiperone inside 
endosomes in vivo due to an increased rate of receptor internalisation resulting from 
increased dopamine release (Chugani et al. 1988). However, this process of agonist- 
mediated receptor internalisation and recycling of dopamine D2 receptors does not 
explain differences in the number of binding sites labelled by dopamine D2 
radioligands. Since the availability of the new imaging technique of positron 
tomography, a number of modelling studies for the in vivo binding of D2 antagonists in 
the human and primate brain have been published (Wong et al. 1986). However, these 
studies have also so far failed to clarify disparities between in vivo and in vitro binding 
to the D2 receptor. Recently it has been proposed that dopamine D2 receptors may exist 
as either monomers or dimers based on the observation that the density of dopamine D2
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receptors labelled by the benzamides [3H]-nemonapride or [3H]-raclopride is 1.8-2.0 
times higher than the density labelled by [3H]-spiperone in cells expressing cloned 
dopamine D2 receptors in either the short form (from rat) or the long form (from 
human), matching similar findings in anterior tissue (from rat or pig) or in post-mortem 
human caudate nucleus tissue (Seeman et al. 1992). Furthermore, it appears that 
compounds that release dopamine in vivo or preincubation of homogenised tissue with 
dopamine increases the proportion of dopamine D2 receptor monomers, as labelled by 
either [3H]-spiperone or [3H]-haloperidol (McManus et al. 1978; Vassout et al. 1993). 
It thus appears that dopamine D2 receptor proteins exhibit more binding sites (D2 
monomers) for radioactive benzamides than for [3H]-spiperone or [3H ]- 
methylspiperone (D2 dimers). Receptor dimer formation may be a post-translational 
event common to G-protein-linked receptors as has been previously shown for 
muscarinic M l and M2 receptors expressed in Spodoptera frugiperda insect cells 
(Parker et al. 1991), the human Di dopamine and 5-HTib receptors in Spodoptera 
frugiperda insect cells (Ng et al. 1994), and for the cloned metabotropic glutamate 
receptor expressed in hamster kidney cells (Pickering et al. 1993). The existence of 
dopamine D2 receptors in multiple molecular forms as a monomer-dimer equilibria has 
been substantiated recently by Gordon et al. (1994) who have reported that a D2 
receptor-specific antibody identified two major protein species corresponding to the 
monomer and dimer of the D2 receptor molecular mass in immunoblots. Amino acid 
sequence analysis of the human D2L receptor has revealed the presence of serine and 
theronine residues in the third putative intracellular cytoplasmic loop and cysteine 
residues in the short cytoplasmic tail (Bunzow et al. 1988). These are consensus 
sequences recognised by phosphorylating and palmitoylating enzymes respectively. 
Taken together, this structural information suggests that the D2L receptor could be 
subjected to post-translational modifications such as monomer or dimer receptor 
formation. It also appears that the monomer-dimer equilibria is not an inherent property 
unique to dopamine D2 or Di receptor proteins. [3H]-nemonapiide binds with a higher
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density of sites for human D4 receptor variants than [3H]-spiperone suggesting that the 
human D4 receptor may also exist in multiple molecular forms as a monomer-dimer 
equilibria (Hidaka et al. 1995).
1.3.7 Convulsive effects and involvement of dopamine in kainic acid- 
induced seizures
Central monoamines, such as noradrenaline (Mishra et al. 1993) and 5-HT (Tecott et al.
1995), are suggested to play an important role in the inhibition of several models of 
epilepsy while high levels of dopaminergic activity in the brain protects animals of 
different species against pentylenetetrazol and strychnine-induced convulsions (Farriello 
et al. 1987) and in kindling models (Loscher & Czuczwar, 1986). However, depletion 
of striatal dopamine using l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine does not 
show a protective effect against seizures induced by bicuculline and picrotoxin 
(Farriello et al. 1987) and a reduction in the concentration of dopamine in the brain has 
been reported to occur in the vicinity of an epileptic focus and in the cerebrospinal fluid 
of epileptics. Also, the effects of dopamine on electrically-induced seizure activity are 
unclear. For example, intracerebroventricular administration of dopamine increases 
seizure activity (Browning & Maynert, 1978), whereas L-dopa, a precursor of 
dopamine, decreases seizure susceptibility (Kilian & Frey, 1973). Similarly, the 
selective dopamine antagonists, SCH-23390 (Di), sulpiride (D2) and pimozide (D2) are 
ineffectual against electrically-induced convulsions in mice (Yokoyama et al. 1993). It 
therefore appears that the role of dopamine in seizures is dependent upon the type of 
experimental model of seizures tested.
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It appears that the traditional anticonvulsant response to non-selective dopamine 
agonists, such as apomorphine, protecting rats against maximal electroshock seizures 
(McKenzie & Soroko, 1972) and abolishing the tonic and clonic phases of seizures in 
audiogenic DBA/2 mice (Anlezark & Meldrum, 1975), is mediated by the D2 subclass, 
since compounds which are active at the D2 receptor, such as LY 171555 are 
anticonvulsant (Al-Tajir & Starr, 1990) and dopamine D2 antagonists facilitate 
pilocarpine-induced seizures (Barone et al. 1992). Additionally, convulsant effects in 
mice induced by (+)-3-(3-hydroxyphenyl)-N-(l-propyl)piperidine are prevented by 
intraperitoneal administration of the D2 agonists, spiperone and haloperidol (Pieretti et 
al. 1995). Conversely, it has been shown that Di agonists, like the benzazepine SKF 
38393 (Seller et al. 1978) and the newer phenanthridine derivative CY 208-243 
(Markstein et al. 1986), have the opposite effect to D2 stimulants and increase the 
susceptibility of rats and mice to the convulsant actions to pilocarpine (Al-Tajir et al.
1990).
Using intracerebral microinjection of dopaminergic drugs anticonvulsant and 
proconvulsant sites have been partially delineated. A D2~dependent anticonvulsant site 
has been identified in the anterior part of the striatum since LY 171555 affords 
protection against the action of pilocarpine when stereotaxically injected here (Turski et 
al. 1988). Similarly, Di stimulants are proconvulsant when applied to the substantia 
nigra (Barone et al. 1992), but not to the corpus striatum (Al-Tajir et al. 1990).
There is little information regarding any possible role of dopamine in KA-induced 
seizures. However, it has been demonstrated that dopamine depletion induced by 1- 
methyl-4 -phenyl-1,2 ,3 ,6-tetrahydropyridine attenuates the severity of convulsions and 
mortality of mice induced by 12, 18 and 36mg/kg KA (Bonuccelli et al. 1994). 
However these doses of KA have no effect on latency to, number of or time spent 
seizing. It has been hypothesised that effects on motor expression of seizures induced
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by KA may reflect a lack of dopamine attenuation of y-aminobutyric acid inhibition in 
the substantia nigra (Bonuccelli et al. 1994).
1.4 Endogenous opioid peptides
Hughes (1975) discovered a substance capable of inhibiting electrically-evoked 
contractions of mouse vas deferens and which was isolated from porcine brains. This 
substance exhibited susceptibility to inhibition by the opioid antagonist naloxone and 
after purification, was found to be composed of two peptides differing only in their C- 
terminal domains (Lord et al. 1977):
(i) [Met] -enkephalin (H-Tyr-Gly-Gly-Phe-Met-OH)
(ii) [Leu]-enkephalin (H-Tyr-Gly-Gly-Phe-Leu- OH)
These peptides were termed enkephalins. The [Met]-enkephalin sequence was also 
found to be incorporated in another peptide possessing opiate activity, called 13- 
endorphin (from 'endogenous morphine'). Another peptide with opiate activity was 
isolated from the porcine pituitary gland and following structural characterisation was 
found to contain [Leu]-enkaphalin sequences. This peptide was termed dynorphin 1-13 
(1-13 represents its 13 amino acid chain length) (Goldstein et al. 1979) and there 
subsequently followed the purification of three related compounds, a-neoendorphin, 13- 
neoendorphin and dynorphin 1-8 (Goldstein et al. 1979). By 1983, two further 
dynorphins had been characterised and termed dynorphin A and dynorphin B (Fischli et 
al. 1982). The endorphins, enkephalins and dynorphins were all found to result from 
the post-translational modification of one of three precursors: preproenkephalin, 
proopiomelanocortin and prodynorphin respectively, all of which originate from 
separate genes (See Bossier, 1982). A pharmacological disadvantage of these 
endogenous opioid ligands is their lack of selectivity and susceptibility to enzymic
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degradation. However, the advent of synthetic ligands has proved invaluable in the 
discovery and characterisation of opioid receptor subtypes and elucidation of possible 
functions.
1.4.1 Classification of opioid receptors
In the 1970's speculation of the possible existence of opioid receptor subtypes arose as 
a result of behavioural experiments which showed that nalorphine could antagonise the 
effects of morphine while producing its own analgesic effect. Further behavioural 
studies demonstrated that the administration of different opiates to the chronic spinalised 
dog could induce tolerance to their agonist effects which could not be substituted by 
each other to suppress the withdrawal symptoms in addicted dogs (Martin et al. 1976). 
Three distinct opioid receptors were hypothesised and designated according to their 
prototypic ligand: p -  for morphine, k -  for ketocyclazocine and a- for SKF10047 (N- 
allylnormetazocine). Classically, opiate effects are naloxone-reversible and 
stereospecific. However, actions mediated by the a-receptor were demonstrated not to 
be naloxone-reversible (Zukin & Zukin, 1984) and the D and L SKF10047 enantiomers 
shown to be equipotent (Akil et al. 1984). The a-receptor also interacts with the non­
opiate drug phencyclidine (Zukin & Zukin, 1979) and is therefore not recognised as an 
opioid receptor. The discovery of the enkephalins led to the proposal of a subtype 
which was present in the mouse vas deferens and appeared to show some selectivity for 
these compounds. The enkephalins were found to have potent inhibitory effects on the 
electrically-induced muscle twitch in the mouse vas deferens but were much less potent 
in the isolated guinea pig ileum and the relative potency of morphine in the two tissues 
was the opposite (Lord et al. 1977). This subtype was subsequently termed the 5- 
receptor (from vas deferens). In vitro binding studies in guinea pig brain homogenates
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supported the existence of these two receptor types and it was confirmed by others that 
an enkephalin binding site in the brain having characteristics different from the |i-site 
could be demonstrated (Chang & Cuatrecasas, 1979).
The initial studies of opioid binding in rat brain demonstrated linear Scatchard plots, 
indicative of a single population of sites (Pert & Snyder, 1973; Simon et al. 1973, 
Terenius, 1973; Pasternak & Snyder, 1974). Subsequent saturation studies using very 
high specific activity pH]-naloxone and [3H] -dihydromorphine produced curvilinear 
plots, revealing an additional binding component of approximately 10-fold greater 
affinity (KjyclnM) but lower binding capactity (Pasternak & Snyder, 1975). Thus, it 
was suggested that the jx-receptor existed as two isoforms and these high-affinity and 
low-affinity sites were termed \ii and Ji2 respectively (Pasternak et al. 1980). 
However, competition studies suggested that these two radioligands were not 
completely selective (Chang & Cuatrecasas, 1979) and most investigators favoured a 
two site binding model with selective sites for either morphine (ji) and enkephalins (5) 
and assumed that each radioligand bound to its own selective site most potently while 
also labelling the other, although with lower affinity. Two groups of studies 
questioned with validity of this two site model. The first studies examined the effects 
of naloxazone, an irreversible opiate antagonist on the binding of radiolabelled opiates 
and enkephalins (Pasternak et al. 1980a; Pasternak et al. 1980b). In saturation studies, 
naloxazone eliminated the higher affinity binding component of pH]-dihydromorphine 
(fi-ligand) and p H ]-[D-Ala2,D-Leu5]-enkephalin (ô-ligand). These results were 
inconsistent with the two site model which predicted that inactivation of the higher 
affinity component of pH]-dihydromorphine should correspond to a similar loss of the 
lower affinity component of pH]-[D-Ala2,D-Leu5]-enkephalin. The second group of 
studies also argued against a two site model. Competition studies demonstrated that 
morphine (<lnM) potently inhibited approximately a quarter of pH]-[D-Ala2,D-Leu5]- 
enkephalin binding (Nishimura et al. 1984). It was suggested that the morphine-
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sensitive binding corresponded to the higher affinity binding component of [3H]-[D- 
Ala2,D-Leu3]-enkephalin because in saturation studies InM morphine inhibited the 
higher binding component of [3H]-[D-Ala2,D-Leu5]-enkephalin far more effectively 
than the lower affinity component and naloxazone blocked the morphine-sensitive 
binding in competition studies (Wolozin & Pasternak, 1981; Hazum et al. 1981). Other 
studies offered direct evidence for a distinct binding site. For example, in reciprocal 
studies InM enkephalin inhibited the higher affinity component of binding most 
effectively (Nishimura et al. 1984). Similarly, subnanomolar concentrations of [3H]- 
[D-Ala2,D-Leu5]-enkephalin inhibited a portion of [3H]-dihydromorphine binding and 
naloxazone, which inhibited the higher affinity binding component of [3H ]- 
dihydromorphine, also eliminated this enkephalin-sensitive binding. Therefore the 
high-affinity site did not correspond to either the morphine-selective or enkephalin- 
selective receptors. Additionally, both morphine and an enkephalin protected [3H]- 
dihydromoiphine binding from the relatively selective action of a low concentration of 
N-ethylmaleimide on high-affinity sites which is again suggestive of a distinct high- 
affinity site. Hi-sites have also been distinguished from p^-sites in terms of their 
distribution and correlation with specific opiate actions. In mice, Hi-sites have a 
distinct distribution compared to H2-sites and are found in areas known to play major 
roles in antinociception, such as the medial thalamus and periaqueductal gray 
(Moskowitz & Goodman, 1984). A similar regional distribution of Hl-sites is found in 
rat with additional high binding in striatal patches (Goodman & Pasternak, 1985). Hl- 
sites appear to mediate a limited number of very specific opioid actions including 
supraspinal analgesia, prolactin release, acetylcholine turnover, catalepsy, hypothermia 
and feeding. The accepted nomenclature for high-affinity and low-affinity moiphine- 
selective sites is Hi and H2 respectively.
The majority of the evidence for 8-receptor subtypes originates from in vivo and in 
vitro pharmacology. Using the warm water tail flick latency model for the assessment
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of ô-mediated antinociception, naltrindole and the derivative naltriben (8 -receptor 
antagonists) were shown to shift the ED50 of supraspinally administered [D- 
Ser2,Leu5,Thr6]-enkephalin (8 -agonist) 4-fold but the ED50 for [D-Pen2,D-Pen5] - 
enkephalin (8 -agonist) was only shifted 1.4-1.8-fold. There was also no cross 
tolerance between the two peptides when administered supraspinally. These results 
indicate mediation by 8 -opioid subtypes (Sofuoglu et al. 1991a). Similarly, the 
antinociceptive actions of supraspinal [D-Ala2]-deltorphin II (8 -agonist) and [D- 
Ser2,Leu5,Thr6]-enkephalin were antagonised by 5'naltrindole isothiocyanate (8 - 
receptor antagonist) but not [D-Ala2,Leu5,Cys6]-enkephalin (8 -receptor antagonist) 
whereas [D-Pen2 ,D -Pen5]-enkephalin antinociception was sensitive to [D- 
Ala2,Leu5,Cys6]-enkephalin (8 -agonist) but not 5'naltrindole isothiocyanate (Jiang et 
al. 1991). Receptors activated by [D-Pen2,D-Pen5]-enkephalin and blocked by [D- 
Ala2,Leu5,Cys6]-enkephalin were designated 8 % and those mediating the effects of [D- 
Ser2,Leu5,Thr6]-enkephalin and [D-Ala2]-deltorphin II and blocked by 5 'naltrindole 
isothiocyanate, designated 82.
The earliest evidence of K-receptor heterogeneity came from in vivo pharmacological 
characterisation in the dog using ketocyclazocine (Gilbert & Martin, 1976; Martin et al.
1976) but early attempts to use pH]-ethylketocyclazocine to demonstrate the separate 
existence of K-receptors and putative subtypes in the rat brain proved unsuccessful. In 
the guinea pig brain, a richer source of K-sites, pH]-etorphine showed high-affinity 
binding to a single site which was completely displaced by [D-Ala2,D-Leu^] -enkephalin 
(8 -agonist) whereas pH]-ethylketocyclazocine bound at a greater density to high and 
low-affinity components. Only part of the high affinity pH] -ethylketocyclazocine 
binding was displaced by [D-Ala2,D-Leu5] -enkephalin thus distinguishing [D-Ala2,D- 
Leu5]-enkephalin-sensitive and insensitive components and was suggestive of the 
existence of K-receptor subtypes (Attali et al. 1982). With the introduction of the 
benzacetamide ligands based on the original 1150,488 a clearer distinction was made
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between the sites sensitive to [D-Ala2,D-Leu5]-enkephalin inhibition and having a high- 
affinity for dynorphini-i7 (K-agonist), subsequently designated Ki and those insensitive 
to [D-Ala2 ,D -Leu5]-enkephalin inhibition and preferentially interacting with 
benzmorphans, named K2. Further studies have proposed iq subtypes, subdivided into 
k ia  and k ib  (Clark et al. 1989; Kinouchi & Pasternak, 1991) and a Kg-subtype 
visualised in radioligand binding studies using pH]-naloxone benzoylhydroxone 
(Cheng et al. 1992; Clark et al. 1989) although the Kg-subtype is controversial and may 
in fact represent the [ig-receptor (Nock et al. 1993). Also recorded are K2 high and 
low-affinity states in guinea pig spinal cord (Tiberi & Magnan, 1990), two different Hé­
sites 2A and 2B in rat and human brain (Rothman et al. 1990; Rothman et al. 1992a) 
and a K2B and two K2A-sites in the rat brain (Ni et al. 1993).
1.4.2 Cloning of opioid receptor subtypes
The opioid receptor family, as it presently exists, has been characterised at the 
molecular level. For each receptor class, rodent and human homologues have been 
cloned. A brief summary of the current knowledge is presented here.
An expression cloning technique developed concurrently by Evans and co-workers 
(1992) and Kieffer and colleagues (1992) for the isolation of a mouse 6-opioid receptor 
led to the isolation of the same cDNA in 1992. Polymerase chain reaction probes 
corresponding to lengths of the mouse 6-opioid receptor were subsequently used to 
probe genomic libraries from other sources. This resulted in cloning of the rat 6-opioid 
receptor (Abood et al. 1994; Fukuda et al. 1993) and later the human 6-opioid receptor 
was cloned (Knapp et al. 1994).
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Following the isolation of a mouse 8-opioid receptor in 1992 another group while 
screening a mouse cDNA library for somatostatin receptors, found a receptor with a 
high homology to the mouse 8 -opioid receptor but which showed binding 
characteristics of the K-opioid receptor when expressed in Chinese hamster ovary cells 
(Yasuda et al. 1993). Later, isolation and chromosomal assignment was documented 
(Nishi et al. 1994). There followed several independent reports of the cloning of the rat 
K-opioid receptor (Chen et al. 1993a; Li et al. 1993; Meng et al. 1993; Minami et al. 
1993; Nishi et al. 1993) and subsequently a guinea pig K-opioid receptor was cloned 
(Xie et al. 1994). More recently, a 380 amino acid residue with a 91% homology with 
the rat K-opioid receptor has been identified from human placenta (Mansson et al. 1994; 
Simonin et al. 1995).
Chen and colleagues (1993b) generated a mouse |i-opioid receptor probe by 
polymerase chain reaction and using a low stringency screening procedure, isolated a 
novel cDNA which was further characterised as a rat ji-opioid receptor clone. Similar 
procedures relying on sequence homology to mouse 8 -opioid receptor led to the 
isolation and subsequent cloning of rat and guinea pig counterparts of 8 -opioid 
receptor. Additionally, a human receptor showing ji-opioid receptor [D-Ala2 ,N- 
Methyl-Phe4 ,Glyol5]-enkephalin (DAGO, a p-ligand) binding has been cloned and 
expressed (Raynor et al. 1995).
At the present time only three opioid receptors have been cloned and therefore any 
receptor subtypes are probably derived from the same opioid gene.
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1.4.3 Signal transduction pathways
Several lines of evidence suggest that opioid receptors are coupled to G-proteins. 
Firstly, guanine nucleotides, particularly GTP and its analogue 5'- 
guanylylimidodiphosphate, were able to decrease the binding of opioids in both 
neuroblastoma-glioma cells (Blume 1978a) and brain membranes (Blume, 1978b). 
Secondly, opioid agonists stimulate GTPase activity in neuroblastoma-glioma cells in a 
naloxone-reversible manner (Koski & Klee, 1981) and thirdly, in other systems 
expressing opioid binding, guanine nucleotides were able to discriminate between 
agonist and antagonist binding in the presence of sodium (Appelmans et al. 1986).
Reconstruction experiments of purified G-proteins with p-receptors in rat brain 
membranes suggests coupling of p-receptors to both both Gi and G0 (Ueda et al. 
1990a) and in guinea pig cerebellum, K-receptors may be coupled to Gi only (Ueda et 
al. 1990b). Heschelar et al. (1987) suggested that G0 couples 8 -receptors to calcium 
channels in neuroblastoma-glioma cells, however more recently, studies using 
antibodies directed at different subtypes of G-proteins suggested that in these cells 8- 
receptors are functionally coupled to one or more of three G-proteins: G# (McKenzie & 
Milligan, 1990), G02 and the isoform Gig (Ofri et al. 1992).
The principle effector systems associated with G-proteins identified at present are the 
stimulation or inhibition of adenylate cyclase, the stimulation of phosphaddylinositol 
turnover and direct G-protein coupling to a potassium channel or to a calcium channel 
(Bimbaumer et al. 1990). Opioid effects have been observed on all these effector 
systems.
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For example, negative coupling to adenylate cyclase has been shown both in cultured 
cells and in brain (Sharma et al. 1977; Yu et al. 1986; Attali et al., 1989). In 
neuroblastoma-glioma cells, evidence indicates that opioid inhibition of adenylate 
cyclase occurs for prostaglandin El-stimulated, adenosine-stimulated, cholera-toxin- 
stimulated activity or basal adenylate cyclase activity and like other second messenger 
systems GTP and sodium are required. The addition of pertussis toxin completely 
abolished the opioid inhibition of adenylate cyclase in cultured cells (Hsia et al. 1984) 
and in brain membranes (Abood et al. 1985) suggesting that the effect is G-protein 
mediated via Gi or G0.
Coupling of cloned opioid receptors to phosphatidylinositol turnover is less well 
documented. Johnson et al. (1994) have reported morphine-induced inhibition of 
phospholipase C in Chinese hamster ovary cells transiently expressing the rat Ji- 
receptor. Also, Kaneko and co-workers (1994) have shown that the rat K-opioid 
receptor clone-mediated increase in calcium mobilisation is the result of positive 
coupling to the phospholipase C pathway in Xenopus oocytes.
In addition to the inhibition of adenylate cyclase and stimulation of phosphatidylinositol 
turnover, opioid receptors are also associated with ion channels. This evidence comes 
from studies using myenteric neurones where selective Ji- and 5-agonists were shown 
to hyperpolarise cells in a concentration-dependent manner which was associated with a 
decrease in neuronal input resistance and was dependent on extracellular potassium 
concentration. Taken together, this action suggests that opioid-induced hyperolarisation 
occurs via an increase in membrane permeability to potassium (Morita & North, 1982). 
Also, Cherubini et al. (1985) demonstrated that evoked action potentials were followed 
by after-hyperpolarisations resulting from an increase in potassium conductance which 
were increased in duration but not amplitude by the addition of superfused morphine. 
Similarly, stimulation of both |X- and 5-receptors in dorsal root ganglion neurones
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cause a decrease in somatic calcium-dependent action potentials (Werz & MacDonald, 
1983) depressing calcium entry through voltage-sensitive channels, thus shortening the 
calcium action potential. Unlike |i- and 8 -receptors however, stimulation of K- 
receptors has no effect on potassium conductance but in spinal cord-dorsal root 
ganglion co-cultures (Vogel et al. 1994), guinea pig cerebellum synaptosomes (Olson & 
Welch, 1991) and rat neurohypophysis nerve terminals (Dayanithi et al. 1992) the 
selective K-agonist, U50,488 reduces the inward calcium current
1.4.4 Distribution of opioid receptors
The presence of opioid receptors in the central nervous system was originally 
established using homogenate binding techniques of whole brain and regional 
homogenates. The development of in vivo and in vitro autoradiography and the 
availability of more selective ligands enabled precise determination of the anatomical 
distribution of opiate receptors. Immunohistochemical techniques have improved 
discrimination between subtypes and following the cloning of the |X-, 8 -  and K- 
receptors, in situ hybridization has enabled the identification of receptor specific mRNA 
expression (George et al. 1994; Mansour et al. 1994a). These techniques have shown 
that |i-, 8 - and K-receptors are distributed widely throughout the rat, mouse, guinea 
pig, dog, monkey and human brains and that the distribution of sites is extremely well 
conserved across species.
p-binding sites have a widespread distribution in the rat brain and are observed 
throughout the telencephalon and mesencephalon. In the telencephalon the olfactory 
bulb, accessory olfactory bulb and accessory olfactory nucleus exhibit high levels of p- 
receptor binding. Dense but patchy p-binding is present in the olfactory tubercle.
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nucleus accumbens and particularly in the caudate putamen (Atweh & Kuhar, 1977; 
Herkenham & Pert, 1981; Mansour et al. 1987; Zastawny et al. 1994). Similarly, 
immunocytochemical localisation using a guinea pig antibody against the C-terminal 
peptide of rat |i-opioid receptors demonstrated intense immunoreactivity in 'island-like' 
areas of the caudate putamen with some immunoreactivity located on the cell bodies and 
dendrites of neurones (Kaneko et al. 1995). jx-binding is also dense in the anterior 
cingulate cortex and neocortex and exhibits regional and laminar heterogeneity 
(Mansour et al. 1987; Zastawny et al. 1994). The distribution within the hippocampal 
formation also differs regionally with the pyramidal cell layer and the striatum 
lacunosum-moleculare is particularly enriched in (i-sites labelled with pH]-DAGO 
(Mansour et al. 1987). Moderate levels of p,-binding are present in the medial septum 
and bed nucleus of the stria terminalis and certain amygdaloid nuclei, including the 
basolateral and intercalated nuclei and the medial nucleus (Mansour et al. 1987). The 
lateral septum has sparse |i-binding as does the globus pallidus (McLean et al. 1986). 
In the diencephalon, many nuclei contain a moderate to dense concentration of (I- 
receptors, although the ventroposterior, parafasicular and reticular nuclei are devoid of 
ji-binding sites (Mansour et al. 1987). The medial habenula is rich in g-receptors as 
are certain hypothalamic regions including the dorsomedial, ventromedial and the 
anterior and lateral hypothalamic areas (Mansour et al. 1987; Zastawny et al. 1994). 
The midbrain contains moderate levels of ji-binding in certain layers of the superior 
colliculus and dense binding is present in the inferior colliculus, the periaqueductal 
gray, the medial terminal nucleus and several raphe nuclei. Few ji-receptors are 
detectable in the cerebellum. Dense populations of ji-receptors are present in the 
trigeminal nuclei, nucleus of the solitary tract and dorsal nucleus of the vagus of the 
medulla (Xia & Haddad, 1991) and in the spinal cord moderate densities of g-binding 
sites are present in the superficial layer and the medial portion of lamina V (Morris & 
Herz, 1987; Fesse et al. 1990). Using northern blot analysis George et al. (1994) have 
demonstrated that the distribution of the mRNA species encoding the g-receptor
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correlates well with the known distribution of |i-binding sites and is predominantly 
localised to thalamic, brainstem, and reticular core nuclei and is highest in habenula and 
thalamic nuclei. However, differences have been reported in |i-receptor mRNA and 
receptor binding distributions including olfactory bulb, cortex, hippocampus, superior 
colliculus and spinal trigeminal nucleus and may be due to ji-receptor transport to 
presynaptic terminals or simply a reflection of the greater sensitivity of the in situ 
hybrization technique (Mansour et al. 1994a). The distribution of ji-receptors in the rat 
brain is summarised in Table 4 on page 37.
Autoradiography in the rat brain using pH] - [D-Ala2,D-Leu5] -enkephalin (a selective 8- 
agonist) located the highest density of 5-receptors in the cortical layers II, III, V and 
VI, the caudate putamen, amygdaloid nuclei and in the pons (Blackburn et al. 1988; 
Mansour et al. 1986). Sparse 8 -binding has been reported in the thalamus and 
hypothalamus but the periaqueductal gray and raphe nuclei are devoid of binding 
(Blackburn et al. 1988; Mansour et al. 1986). In a more detailed study using pH ]- 
DSTBULET, which has a comparable selectivity to pH]-[D-Ala2,D-Leu5]-enkephalin 
but 4 -fold greater affinity thus allowing receptor detection at a lower level, diffuse 5- 
binding was found in the substantia nigra, periaqueductal gray, raphe nuclei and 
thalamus. Again, dense 5-binding was observed in the cortex, neostriatum and nucleus 
accumbens (Delay-Goyet et al. 1990). Additionally, high levels of 5-binding have been 
detected in the somatosensory cortex, claustrum and caudate putamen (Drower et al.
1993). Although the correlation between 5-receptor mRNA expression and the results 
from binding studies is good some discrepancies exist, particularly in the pons and 
medulla areas where 8-receptor mRNA is visualised but little 5-binding exists (George 
et al. 1994).
From autoradiographic binding studies of rat brain there is a general agreement that 
concentrations of K-receptors are present in the hypothalamic nuclei (Mansour et al.
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1987; Mansour et al. 1988; Sharif & Hughes, 1989; Unterwald et al. 1991) nucleus 
accumbens and olfactory tubercle and moderate levels are reported in the deeper cortical 
layers V and VI, caudate putamen, thalamus and periaqueductal gray (Mansour, 1995; 
Nock et al. 1988; Unterwald et al. 1991; Zukin et al. 1988). The density and location 
of receptor mRNA has been shown to correspond well with the distributions from these 
autoradiographic studies (George et al. 1994). Moderate levels were demonstrated in 
the somatosensory cortex, periaqueductal gray, nuclei of the thalamus and 
hypothalamus and the amygdala. High levels of K-binding have also been described by 
Mansour et al. (1994b) and Unterwald et al. (1991) in the claustrum, hippocampus, 
caudate putamen, nucleus accumbens, substantia nigra and nuclei in the thalamus and 
hypothalamus.
1.4.5 Seizure effects of opioid peptides
The hippocampal formation is the most susceptible region of the brain to seizures and 
exhibits the most intense and long-lasting epileptic discharges after 
intracerebroventricular administration of opioid peptides (Haffmans et al. 1983). Also, 
immunocytochemical studies have revealed a unique distribution of opioid peptides in 
the hippocampus. Among the glutamate-containing pathways, the perforant pathway, 
which projects from the neocortex, subcortex, limbic and brain stem areas to the 
granule cells of the dentate gyrus, contains the greatest amount of enkephalin, whereas 
the granular-mossy fibre pathway, which projects from the granule cells of the dentate 
gyrus to the pyramidal neurones in the CA3 subfield and hilar polymorphic neurones, 
contains mainly dynorphin and some enkephalin (McGinty et al. 1983). 
Proenkephalin-derived peptides have a unique excitatory action mediated by 
disinhibition of y-aminobutyric acid containing interneurones when applied
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ionophoretically to hippocampal pyramidal cells, whereas in most other regions these 
peptides have inhibitory actions (Nicoll et al. 1977). Unlike enkephalin however, 
dynorphin displays inhibitory responses on CA3 neuronal excitability (Urea et al. 
1977). Also, electroencephalographic recordings have indicated that intrahippocampal 
or intracerebroventricular injections of enkephalin have either proconvulsant (Urea et al.
1977) or anticonvulsant (Tortella & Cowan, 1982) properties depending on 
experimental conditions whereas intracerebroventricular injection of dynorphin does not 
induce epileptiform activity in the rat. Further, U50,488H, a dynorphin derived 
specific K-agonist, provides protection against certain electroconvulsive shock-induced 
seizures in rats suggesting an anticonvulsant role of dynorphin (Tortella et al. 1986). 
The epileptiform discharges produced by opioid peptides are often accompanied by 
behavioural manifestation of nonconvulsive activities such as myclonic twitches and 
wet-dog shakes (Frenk, 1983).
1.4.6 Delineation of receptors involved in opiate-induced seizures
Several lines of evidence suggest that opiate-induced seizures are mediated by specific 
opioid receptors. First, these seizures occur in a dose-related manner and can be 
antagonised by opiate antagonists such as naloxone and (3-funaltrexamine (Tortella et al. 
1987) and second, tolerance to seizures produced by opioid peptides develops after 
repeated intracerebroventricular or intracerebral injections (Cain & Corcoran, 1985). 
Further, the mediation of convulsive effects by specific opioid receptor subtypes has 
been partially delineated but remains unclear since enkephalin-derived peptides display a 
variety of convulsant effects depending on experimental conditions including test used, 
dose range investigated, species and route of administration. For example, 
microinjection of the 8-agonist, ala-deltorphin, into the dorsal hippocampus produces
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dose-dependent motor and electrocorticographic activity (De Sarro et al. 1992b) while 
the nonpepddic ô-selective agonist, BW373U86, produces brief, nonlethal convulsions 
in mice (Comer et al. 1993). However, systemic or intracistemal injection of [D-Ala2- 
D-Leu5]-enkephalin (8 -agonist) decreases the incidence of seizures in seizure- 
susceptible El mice (Koide et al. 1992) and the selective 8 -agonist [D-Pen2 ^]- 
enkephalin does not produce convulsions or wet-dog shakes when injected unilaterally 
into the ventral hippocampus (Lee et al. 1989a). The injection of a high dose of the |i- 
agonist [NMe-Phe3-D-Pro4]-morphiceptin intraventricularly or into other brain regions 
such as the dorsal hippocampus, frontal cortex, striatum and amygdala does not 
produced seizures either (Lee et al. 1989a). However, [NMe-Phe3-D -Pro4]- 
morphicepdn and DAGO induce generalised convulsions and wet-dog shakes when 
injected unilaterally into the ventral hippocampus (Lee et al. 1989a) and epileptiform 
activity in the CA3 area is generated when another g-agonist, demorphin, is injected by 
the same route (Gioanni et al. 1995). Similar behavioural responses are also elicited by 
[D-Ala2,D-Leu5]-enkephalin, a mixed g- and 8-agonist, but with less potency than the 
selective g-agonists and are antagonised by the irreversible g-receptor antagonist, (3- 
funaltrexamine, but not by the selective 8-antagonist, ICI-174,864 (Lee et al. 1989a). 
Conversely, Yokoyama and co-workers (1992) have shown that DAGO decreases the 
duration of tonic and clonic convulsions in C57BL/6 mice, but not in g-opioid receptor 
deficient CXBX mice. Also, the g-antagonists naloxonazine and naltrexonazine 
promote the clonic phase of electrically induced convulsions in C57BL/6 mice, 
suggesting the blockade of g-receptors has a proconvulsant effect in this animal model 
(Yokoyama et al. 1992).
The effects mediated by K-receptors during convulsions are equally diverse. 
Intraperitoneal pretreatment of mice with the selective K-agonists, U69593 and 
PD117302 protect hippocampal neurones from pilocarpine-induced limbic seizures and 
neurotoxicity (Przewlocka et al. 1994). However, intracerebroventricular
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administration of the K-agonists, U-50,488H, U-69593 and PD117302 induce 
convulsions in a dose-related manner in mice (Bansinath et al. 1991) but in rats U- 
50,488H and other selective K-agonists such as dynorphin-A amide or dynorphin-A (1- 
8) do not produce convulsions or wet-dog shakes when injected unilaterally into the 
ventral hippocampus (Lee et al. 1989a).
In man, positron emission tomography has enabled the in vivo study of receptor 
binding accompanying seizures. Carfentanil binding, reflecting changes in ^.-receptors 
is decreased in the temporal neocortex and decreased in the amygdala on the side of the 
epileptic focus during temporal lobe seizures (Mayberg et al. 1991). Using in vitro 
autoradiography increased ^-binding is observed in anterior amygdala, caudate 
putamen, ventromedial thalamic nucleus and cingulate and frontoparietal cortices 24 hrs 
after the last stage of amygdaloid kindling (Rocha et al. 1993). A further increase in |i- 
binding is observed in cingulate and frontoparietal cortices 28 days after the last stage of 
amygdaloid kindling (Rocha et al. 1993).
1.4.7 Involvement of opioid peptides and receptors in kainic acid- 
induced seizures
KA evokes sustained seizures which activate the prodynorphin and proenkephalin 
system of the hippocampus (Lason et al. 1983) and are followed by degeneration of 
hippocampal pyramidal cells (Ben-Ari, 1985; Nadler, 1981). Opioids modify 
convulsions (Fuller & Olney, 1979) and behavioural effects (Kellstein et al. 1990) 
caused by KA. For example, naloxone reduces and morphine potentiates the incidence 
of convulsions induced by KA (Fuller & Olney, 1979; Fuller et al. 1982) whereas k -  
agonists are devoid of epileptogenic activity (Lason et al. 1989). In contrast, selective
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K-agonists alter some behavioural consequences of KA administration such that U- 
50,488H inhibits KA-induced wet-dog shakes (Lason et al., 1988) while scratching 
induced by intrathecal administration of KA is inhibited by pretreatment with the ji- 
agonists levorphanol, DAGO or morphine but not by 8- or K-agonists (Kellstein et al. 
1990). Opioid receptor agonists also modify KA-induced neurotoxicity but the 
relationship between opioid peptide release and vulnerability of hippocampal neurones 
is complicated because the proenkephalin-containing neurones can release peptides 
which are agonists for all known types of opioid receptors (Chavkin et al. 1985) and 
prodynorphin-containing neurones release dynorphins that protect hippocampal 
neurones from toxic insults. KA-induced seizures reduce the release of dynorphin B- 
like immunoreactivity from rat mossy fibre synaptosomes and hence limit the protective 
effects against neurotoxicity (Simpson et al. 1992). Activation of |J,-receptors by 
morphine, a non-selecdve |i-agonist, enhances KA-induced seizures and neurotoxicity 
in a naloxone-reversible manner without the involvement of the 8-subtype (Fuller et al. 
1982). Likewise, an intensification of hippocampal neurotoxicity has been observed 
after coadministration of KA and DAGO which is completely blocked by the mixed |_i- 
and 8-antagonist naltrexone (Lason et al. 1988). In contrast to DAGO, the 8-agonist 
[D-Pen2’5]-enkephalin has no effect on the KA-induced neuronal loss suggesting that 
the activation of |i- but not 8-receptors potentiates the neurotoxic effect of KA (Lason et 
al., 1988). This is substantiated by the lack of electroencephalographic seizures after 
intracerebroventricular administration of [D-Pen2»5]-enkephalin (Tortella et al. 1988) 
and that the CA1 hippocampal region, which is particularly vulnerable to KA-induced 
cell death, has only a moderate density of 8-receptors in contrast to a high density of Ji- 
receptors (Mansour et al. 1987). More recently, electrophysiological data have shown 
that hippocampal pyramidal cell excitation by DAGO leads to the activation of NMD A 
receptors in the CA1 field (Segal, 1988) which participate in neuronal degeneration 
here. Furthermore, a reduction in KA toxicity appears to be mediated by K-receptors 
since the selective K-agonist U-50,488H, inhibits KA-induced hippocampal
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neurotoxicity, notably in the CA1 but also the CA3 fields (Lason et al. 1989; Camacho- 
Ochoa et al. 1992). The seizure effects mediated by opioid receptors are summarised in 
Table 5.
1.5 Role of transcription factors in the modulation of 
neuronal activity
Genomic factors play a significant role on the long-term modulation of neurone activity, 
often referred to as neuronal plasticity. Many studies have established that excitation of 
neurones results in the activation of a plethora of genes including the transcription 
factors activator protein-1 (AP-1), c-AMP-responsive element or c-AMP-response 
element binding proteins and octamer binding proteins. These factors appear to have 
two distinct functional activities. Firstly, an ability to bind to a specific DNA sequence 
in the regulatory elements of genes to direct other transcription factors to the vicinity of 
the promoter and secondly to stimulate gene expression, c-fos, fos B and fos-related 
antigens fra 1 and fra 2  are members of a family of transcription factors that complex 
with members of the jun transcription factor family c-jun, jun B and jun D to form the 
transcription factor AP-1 (See Morgan & Curran, 1991). This complex binds with high 
affinity to the DNA regulatory element (also termed AP-1) in the promoter and enhancer 
regions of target genes to modulate gene transcription (Chiu, 1989). A common feature 
of the Fos and Jun proteins is their leucine zipper' region which allows dimérisation 
between Jun family proteins (as either homodimers or heterodimers) and those encoded 
by the Fos family of genes (Jun-Fos heterodimers) (Ryseck & Bravo, 1991).
77
Ta
bl
e 
5. 
Se
izu
re
 
eff
ec
ts 
m
ed
iat
ed
 
by 
op
ioi
d 
re
ce
pt
or
s
}
•oi
03 S1
3O :§"cZ g3> 25 3o 4)o S
B V,3 4)O'8 3
E 1o Os
1
03gQE
ceti
's
>aoo
• f lccd
<U
cd
'3
s I
e-g
a l
I’3
o 00 o ^!
Sts " 
s  S ’S
III
1!i 
-§I
i i  
£  §
cn
05
g
3
!u
1
f
■e
s
§■
(6
CN
i
z
I
03
e vo||
« 1
II
cd o
s
cd
(U OE E
cd03>-O
Q
I
03 Æ % <4-4 &
K °  |
4$5*5 o
ao
C/D
§
31o
01
034) CS
1  1 
s  .s
t
•oi
•5.^
o'*03 O
i l
T)
gS
cc
2.211 
S  8 §
i
scd m
i i3 5
ii
i i
« 103 ft) 4) O
3l!
? §
I Io o
O 3si(j 3
 ^"5'-
.14) e
• |i5
4) Os-s
I
ii03
303 O
I!
<L> o
S
1
!.
3 1H
i iII
© « 
p i
iCZ) 3 03
s
!
§ Ig
M
tiOQ
go
•5
©
>
g 2
ii
S I
g1
t
Î!
ii
ii
78
^F
ull
er 
et 
al.
 1
98
2;
 2
La
so
n 
et 
al.
 1
98
8;
 3
Pr
ze
w
lo
ck
i 
et 
al.
 1
99
4; 
4D
e 
Sa
rro
 
et 
al.
 1
99
3; 
5Y
ok
oy
am
a 
et 
al.
 1
99
2;
 6
Ko
ide
 
et 
al.
 1
99
2; 
7J
ac
ks
on
 
&
 
Nu
tt,
 1
99
1; 
8T
or
tel
la 
et 
al.
 1
98
6; 
9L
ee 
et 
al.
 1
98
9a
; 
10
De
 
Sa
rro
 
et 
al.
 1
99
2; 
^G
io
an
ni
 e
t 
al.
 1
99
5;
 1
2C
ain
 
et 
al.
 1
99
0; 
13
Ba
ns
in
ath
 
et 
al.
 1
99
1.
1.5.1 The effect of kainic acid on transcription factors
The components of AP-1 are induced in nervous tissue by a variety of stimuli including 
seizures (Gass et al. 1992) and excitotoxic insults (Popovici et al. 1991) and are 
therefore included in a category of immediate-early genes whose role is believed to be 
related to the regulation of genes that give longer-lasting responses to stimulation 
(Schilling et al. 1991). Convulsant doses of intraperitoneally administered KA induce 
the expression of c-fos, fos B, fra 2 and jun B in the adult rat hippocampus and 
entorhinal cortex after 2 hrs and 6 hrs and further induce the expression of jun B after 
48-72 hrs (Kaminska et al. 1994a). This first phase of elevated AP-1 binding activity 
correlates with the period of KA-induced seizures while the second correlates with 
neurone damage. Pennypacker et al. (1993) have reported similar increases in the DNA 
binding activity of AP-1 constituent proteins 1.5 hrs after subcutaneous administration 
of 8mg/kg KA with maximal elevation observed after 4.5 hrs. Contrary to AP-1, the 
binding activities of other transcription factors, like cAMP-responsive element or cAMP 
response element binding proteins and octamer binding proteins do not change after 
KA-induced seizures (Kaminska et al. 1994b).
1.5.2 The effect of kainic acid on opioid peptide genes
The neurones of the dentate gyrus express both preproenkephalin and preprodynorphin 
mRNA and the corresponding processed peptides (McGinty et al. 1983) and opioid 
peptide and gene expression has been shown to be altered by seizure-inducing 
paradigms (Douglass et al. 1991). For example, after KA administration, expression of 
preprodynorphin and preproenkephalin occurs, correlated with seizure activity but with
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different time courses: preprodynorphin mRNA peaks after 3 hrs, whereas 
preproenkephalin mRNA begins to increase at 3 hrs and peaks after 24 hrs (Douglass et 
al. 1991). Further, opioid gene expression, fos-related antigen, jun immunoreactivity 
and AP-1 DNA binding are all similarly reduced after the anticonvulsants, pentobarbital 
and diazepam (Pennypacker et al. 1993). Both opioid gene promoters contain a site 
termed ENKCRE 2 (Douglass et al. 1989) and the preproenkephalin sequence binds 
AP-1 proteins from human cervical cancer-derived cell extracts (Comb et al. 1988). 
Additionally, in vitro expression of c-fos and c-jun proteins have been shown to 
activate transcription from the preproenkephalin gene promoter (Sonnenberg et al.
1989) suggesting that AP-1 transcription factors could play a role in the activation of 
opioid genes in rat hippocampus after KA treatment. Additional factors may be 
involved since the preproenkephalin promoter has been shown to bind numerous 
transcription factors such as AP-2, AP-4 and nuclear factor-1 that serve to regulate 
transcription (Hyman et al. 1989) and because in DNA binding assays protein factors 
that bind the ENKCRE 2 sequence are not affected by the presence of fra or jun 
antibodies (Pennypacker et al. 1993).
1.5.3 Other effects of kainic acid on receptor mRNA
KA also affects the transcription of mRNA for neurotransmitter receptors without the 
involvement of transcription factors. For example, injection of KA into the 
hippocampal formation of rats has been studied for its effects on striatal dopamine Di 
and Ü2 receptor mRNA levels (Brene et al. 1994). Quantitative in situ hybridization 
using 35s-labelled oligonucleotide probes specific for Di and D2 receptor mRNAs 
demonstrated that KA had no effect on mRNA levels in striatum 4 hrs after injection 
(Brene et al. 1994). However, seizures induced by KA cause marked and long lasting
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elevations in the expression of neurokinin B mRNA in the hippocampus, frontal cortex 
and amygdala (Sperk et al. 1990) and a 20-fold increase in the closely related gene 
precursor for neurokinin A, preprotachykinin-A mRNA, in the dentate gyrus and CA3 
hippocampal subfield (Brene et al. 1992). Corresponding studies investigating the 
levels of mRNA encoding the receptor for neurokinin B, the neurokinin-3 receptor, 
following KA-induced limbic seizures in rats have shown transient changes in the levels 
of neurokinin-3 mRNA in the hippocampus and frontal cortex after 1 and 2 days 
respectively, elevated mRNA levels in the cerebellum after 7 and 30 days and reduced 
mRNA levels in the amygdala at all time points (Roder et al. 1994). During KA- 
induced seizures a massive depletion of neurokinin B stores has been observed which 
lasts for about 2 days (Sperk et al. 1990). The up-regulation of neurokinin-3 receptor 
mRNA could partially compensate for impaired neurokinin B neurotransmission while 
the increase in neurokinin B levels in the hippocampus and cortex coincides with a drop 
and subsequent normalisation of neurokinin-3 receptor mRNA levels. The long lasting 
decrease in neurokinin-3 receptor mRNA concentrations in the amygdala is consistent 
with brain damage observed in this region (Sperk, 1994) while increases in the 
neurokinin-3  receptor in the cerebellum suggest the development of receptor 
supersensitivity following seizures induced by KA (Roder et al. 1994).
In rats, intraperitoneal administration of KA causes an increase in AMPA receptor 
GluR2 and GluR3 mRNA levels in seizure-resistant regions of the hippocampus (CA1 
area and dentate gyrus) and a decrease in the vulnerable CA3 area after 12 and 24 hrs 
(Friedman et al. 1994). Using the same experimental conditions Condorelli et al. 
(1994) have reproduced the late increases (12-24 hrs) in GluR3 mRNA in the dentate 
gyrus with an additional increase in the CA4 subfield, but found no change in GluRl 
expression.
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Injection of a convulsant dose of KA has been shown by in situ hybridization to 
increase fibroblast growth receptor-2 and -5 mRNAs after 3 hrs, whereas fibroblast 
growth receptor-1 was only increased in the dentate gyrus (Gomez-Pinilla et al. 1995). 
Fibroblast growth receptor-2 and -5 mRNA levels peaked by 12 hrs in most brain 
regions and returned to normal levels by 24 hrs but did not correlate with the complex 
fibroblast growth receptor 1 mRNA response (Gomez-Pinilla et al. 1995).
Subcutaneous administration of 12mg/kg KA decreases somatostatin-3 and -4 receptor 
mRNAs by approximately 30% in the hippocampal CA1 subfield after 21 days (Perez et 
al. 1995).
Seizure activity in the hippocampus induced by KA leads to marked and transient 
increases in nerve growth factor and brain derived neurotrophic growth factor mRNA in 
the dentate gyrus, neocortex and piriform cortex. Using exon specific probes from the 
rat brain derived neurotrophic growth factor gene, Metsis et al. (1993) have reported 
that 3 hrs after the intraperitoneal administration of 12mg/kg KA increases in exon I, II, 
m  and IV brain derived neurotrophic growth factor mRNA in the hippocampus and 
cerebral cortex occur. Also, the addition of KA to cultured rat granule neurones 
expressing brain derived neurotrophic growth factor mRNA for 4 hrs produces 5-fold 
increased levels of mRNA in these cells (Lindholm et al. 1993).
1.5.4 O ther seizure-induced changes in receptor mRNA
Seizures induced by kindling, a model of epilepsy in which periodic subconvulsive 
electrical stimulation induce a permanently hyperexcitable state, also affect transcription 
of mRNA for neurotransmitter receptors. Gelbard & Applegate (1994) have
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demonstrated that amygdala kindling increases the expression of dopamine D2 receptor 
mRNA by approximately 30% in the nucleus accumbens and striatum 30 days after the 
last kindling stimulation. The same group has also shown that overkindling (additional 
piriform cortical kindling) further increases D2 receptor mRNA expression in both the 
accumbens (150% increase) and striatum (120% increase) (Gelbard & Applegate,
1994). Rapidly kindled seizures in which 12 stimulus trains of 50Hz/10s were 
delivered every 30 mins on alternate days for 4 days decreased AMPA/KA activated 
glutamate receptor mRNAs (GluRl, -2, -3 mRNAs) by as much as 60% in 
hippocampus, amygdala, entorhinal and frontoparietal cortices after 24 hrs but not at 30 
days (Lee et al. 1994). Conversely, Hikiji et al. (1993), have shown an increase in KA 
receptor mRNA (maximum of 25%) in similarly kindled rats after 28 days, but only in 
the hippocampal CA3 region. Further, changes in y-aminobutyric acid receptor a i- , 
« 2-, tt4- and pi-adrenoreceptor mRNA levels were not observed in any brain region 
after 24 hrs following rapidly kindled seizures or 30 days after seizures produced by a 
paradigm in which 50Hz/10s stimulus trains were given to the hippocampus three times 
daily for 16 days (Lee et al. 1994).
1.6 Relationship between kainic acid and neurodegenerative 
and psychotic conditions
The absence in lower animal species of naturally occurring neurodegenerative and 
psychotic conditions has hindered the ability to study the neuronal changes which 
manifest during these disease processes. There are also no known experimental agents 
or procedures which cause the neuropathological changes that characterise 
neurodegenerative diseases, such as neurofibillary tangles and amyloid deposits. 
Animal models of neurodegenerative and psychotic conditions typically utilise direct
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brain injection or systemic application of excitotoxic substances to mimic behavioural 
and biochemical deficits observed in a particular neuropathological process.
Alzheimer's disease is a disease of the elderly that compromises higher cognitive 
function and causes neuronal dysfunction and death. Among the neurones most 
vulnerable to degeneration in Alzheimer's disease are those thought to utilise glutamate 
as a transmitter (Cotman & Monaghan, 1986). For example, pyramidal neurones are 
lost in the neocortex (Morrison et al. 1987) and the hippocampus undergoes significant 
morphological changes (Braak & Braak, 1991). Intraperitoneal injections of KA 
produce a widespread neurodegeneration in those areas principally affected by 
Alzheimer's disease and spares brain areas which are also spared in Alzheimer's 
disease. Specifically, an area of low KA binding in pyramidal layers of region CA1 of 
Ammon's horn has been found to be significantly depleated in brains suffering from 
Alzheimer's disease that may be representative of binding in the prosubiculum, a region 
of severe pathology in Alzheimer’s disease (Penney et al. 1990). Additionally, KA 
binding is reduced in the subiculum and parahippocampal gyrus the magnitude of 
changes correlating with neuronal loss of individuals suffering from Alzheimer's 
disease (Dewar et al. 1991). Conversely, expansion in the width of the band of [3H]- 
KA binding in the stratum lucidum of hippocampal CA3 and denate gyrus has been 
described (Geddes et al. 1985) while an increase in the number of KA receptors in the 
frontal cortices of Alzheimer brains is also observed (Chalmers et al. 1990). This 
receptor plasticity might be a sign of receptor compensatory mechanisms due to 
degenerative events.
Huntington's chorea is an autosomal dominant inherited neurodegenerative disorder that 
usually begins in midlife and is characterised by involuntary choreiform movements, 
cognitive impairment, and emotional disturbances (Van Dijk et al. 1986). The major 
site of pathology in Huntington's chorea is the striatum, where up to 90% of neurones
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may be depleted (Vonsattel et al. 1985). Within the striatum there is a differential 
vulnerability of neuronal populations. Striatal medium-sized spiny neurones containing 
the neurochemical narkers y-aminobutyric acid, substance P, dynorphin and enkephalin 
are preferentially affected (Beal et al. 1988). In contrast, dopaminergic and 
serotoninergic afferent projections are spared (Beal et al. 1990). These features of 
Huntington's chorea can be mimicked in rats which receive bilateral striatal injections of 
KA. This treatment destroys y-aminobutyric acid-containing and acetylcholine- 
containing neurones whose cell bodies are intrinsic to the striatum. These 
neurochemical changes have been reported to be similar to those accompanying seizures 
induced by KA while the afflicted areas in Huntington's chorea state are analogous to 
those that show changes in KA binding and are sensitive to intrastriatal KA. For 
example, in the cerebral cortex of individuals with Huntington's chorea it has been 
documented that neuronal loss is distributed unevenly, with most striking pathology in 
layer VI (Hedreen et al. 1991). Wagster et al. (1994) have reported a decrease in KA 
receptor binding in layer VI in individuals with Huntington's chorea suggesting that 
cortical neurones possessing KA receptors may be selectively vulnerable in this 
condition. Additionally, the choreic movements which manifest during Huntington's 
chorea can be reproduced in monkeys by KA lesion of the striatum and the 
administration of L-dopa (Kanazawa, 1992). However, KA lesions are an imperfect 
model of Huntington's chorea because they result in a significant depletion of 
somatostatin levels and a loss of somatostatin neurones (Beal et al. 1985). 
Subsequently it has been shown that the focal injection of quinolinate in the rat striatum 
more precisely reprodues the human post-mortem findings, by sparing somatostatin and 
neuropeptide Y levels (Beal et al. 1986).
Parkinson's disease is a degenerative disease of the basal ganglia causing tremour at 
rest, muscle rigidity and hypokinesia, often with dementia. There is little evidence 
suggesting that the KA-treated rodent is a model of Parkinson's disease or any possible
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involvement of KA receptors in this disorder. However microinjection of KA has 
effects on the behavioural symptoms of Parkinson's disease. For example, intrastriatal 
administration of KA causes bradykinesia, increased muscle rigidity and ptosis in rats 
which are reminiscent of the Parkinsonian syndrome (Shandra et al. 1993) and 
subthalamotomy produced by KA improves spontaneous activity, facial expression and 
manual dexterity in moderately severe parkinsononian monkeys (Guridi et al. 1994).
Schizophrenia is a psychotic illness characterised by delusions, hallucinations and 
thought disorder, together with social withdrawal and often dementia. Kovelman & 
Scheibel (1984) first noted significant changes within the hippocampus that appear to be 
highly correlated with the severity of schizophrenia. Additonally, magnetic resonance 
imaging analyses of living patients indicate that significant differences in hippocampus 
exist between schizophrenics and control (Bogerts et al. 1990). Analysis of the 
hippocampi of schizophrenics have shown decreased cell density (Kane, 1987) and 
cellular disorientation (Conrad & Scheibel, 1987) with pyramidal neurones rotated by 
35° or more. Intracerebroventricular administration of KA produces neuronal loss in 
dorsal and ventral hippocampus (Bardgett et al. 1995). Neuronal loss is particularly 
marked in the CA3 pyramidal cell field of the hippocampus (Nadler et al. 1978) after 
inracerebroventricular administration of low doses of KA with higher doses of KA 
causing loss in the CA1 cell field (Nadler et al. 1978). Similarly, using quantitative 
autoradiography of schizophrenic brains a loss of KA receptors in hippocampi mainly 
from the CA4/CA3 mossy fibre termination zone of cornu ammonis as well as losses in 
dentate gyrus and parahippocampal gyrus was observed (Kerwin et al. 1990). It also 
appears that continued seizure activity induced by KA produces disorientation of 
surviving neurones through gliosis. Furthermore, gating of the rat N40 auditory 
evoked potential is reduced by intraventricular KA microinjection much like the 
attenuation found in schizophrenics (Bickford-Wimer et al. 1990). Taken together this
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evidence suggests that selective pyramidal cell loss induced by intraventricular 
microinjection of KA is a viable model of schizophrenia.
1.7 Aims of the thesis
There is evidence that acute exposure to KA induces neurochemical changes in the brain 
(Heggli & Malthe-Sorenssen, 1982; Kleinrok & TursM, 1980; Sperk et al. 1983). 
Additionally, using in vivo microdialysis it has been shown that striatal dopamine levels 
are the most markedly increased 4 hrs after the intraperitoneal injection of 16mg/kg KA 
in rats. In previous receptor binding studies KA has either been used as a selective 
lesioning agent of central nervous system pathways (Katayama et al. 1990) or its effects 
have been studied when induced neurotoxicity has already occurred (Churchill et al.
1990). The receptor toxicity of KA preceding its neurodegenerative effects was 
investigated by focusing on dopamine D% and (i-opioid receptors since the 
pharmacological data suggests that these receptors may be involved in the convulsive 
and neurotoxic effects of KA. The aim of this thesis was to investigate the toxicity of 
KA administered to rats in vivo (16mg/kg; intraperitoneal) upon brain dopamine Da and 
ji-opioid receptors. KA was considered a representative excitotoxin upon which 
neurochemical and toxicological studies could be performed to assess possible avenues 
for the military development of medical countermeasures against centrally acting 
neurotoxic agents. Comparative autoradiography for dopamine Da and g-opioid 
receptors was carried out to determine the precise anatomical location of KA receptor 
toxicity. Distribution studies were carried out using [3H]-KA adm inistered 
intraperitoneally with 16mg/kg KA to determine the percentage of KA reaching rat brain 
areas 4 hrs after treatment KA was also studied for its effect on [3H]-dopamine release 
from striatal slices in vitro.
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CHAPTER 2 
METHODS
88
2.1. ANIMALS
The animals used in this study were male Porton-Wistar derived rats weighing 200- 
250g. The rats were housed six per cage and were allowed free access to standard rat 
chow and tap water. They were housed under controlled conditions of temperature (20- 
22°C) and humidity (50-60%) in an air-conditioned unit. Lighting was maintained on a 
twelve hour light-dark cycle (light 6.00-18.00 hr).
2.2 KAINIC ACID TREATMENT
Animals were injected intraperitoneally with 16mg/kg kainic acid (KA, 2ml/kg) or 0.9% 
saline (w/v) and returned collectively to a clean cage. This dose is approximately 75% 
of the LD50 for intraperitoneal KA as estimated by probit analysis (Fosbraey et al. 
1992). Experiments began after 4 hrs, a time point proceeding histopathological 
damage (Sperk et al. 1983), during which behavioural changes were monitored. Rats 
that did not survive this period were removed.
2.3 HOMOGENATE BINDING STUDIES
To investigate the effect of KA on dopamine D% and g-opioid receptors in the rat brain 
homogenate binding was studied in six brain regions; cerebellum, cortex, 
hippocampus, medulla and pons, midbrain and hypothalamus and striatum and in 
separate studies whole brain using the selective ligands [125I]-iodosulpiride (D2
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antagonist) and [3H]-(D-Ala2,N-Methyl-Phe4,-Glyol5-enkephalin ([3H]-DAGO) (\i- 
agonist). Additionally, [125I]-iodosulpiride binding was investigated in whole brain 
minus striatum. Also, homogenate binding in whole brain minus striatum and striatum 
alone was carried out with selective D% antagonists for the putative monomer ([3H]- 
raclopride) and dimer ([3H]-spiperone) conformation of the D2 receptor. The structures 
of [ 125I]-iodosulpiride, [3H]-raclopride, [3H]-spiperone and [3H]-DAGO are shown in 
Figures 6 and 7.
2.3.1 PREPARATION OF BRAIN HOMOGENATES FOR [125I]- 
IODOSULPIRIDE SATURATION ASSAYS
Rats were killed by cervical dislocation and decapitated. The brains were rapidly 
removed and quickly dissected on ice into the cerebellum, cortex, hippocampus, 
medulla and pons, midbrain and hypothalamus and striatum according to the procedure 
of Glowinski & Iversen (1966) and placed in 50mM Tris-HCl buffer, pH 7.4. In 
separate studies tissue homogenates were also prepared from whole brain and whole 
brain minus striatum. The tissue from four rats was pooled for each assay and gently 
blotted with filter paper before being weighed and then homogenised in 50mM Tris- 
HCl buffer, pH 7.4 using a Kinematica Polytron homogeniser (Northern Media, Philip 
Harris Scientific) for 45 secs at speed 6 . The homogenates were centrifuged at 
25,000rpm for 15 mins at 4°C using a 45 Ti rotor carrying 100ml capped Beckmann 
polyallomer tubes in a Beckman L5-65B ultracentrifuge. The resulting pellets were 
resuspended in 50mM Tris-HCl buffer, pH 7.4 using a Polytron homogeniser at speed 
6 for 15 secs. The suspensions were incubated in a Julabo SW1 shaking water bath 
(Jencons Scientific Ltd.) at a speed of 110shakes/min at 30°C for 45 mins to remove 
endogenous dopamine. The homogenates were centrifuged at 25,000rpm for 15 mins
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Figure 6. Structures of three dopamine D2 radioligand antagonists
[125I]-iodosulpiride
[methoxy- H]-raclopride
OCH3 O
Cl
OH
N   CH2
H
Cl
N
CH2CH3
[3H]-spiperone
O
NH
*
Structures of [125I]-iodosulpmde, [methoxy-3H]-raclopride and [3H]-spiperone. 
Asterixes indicate radiolabelled atoms.
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at 4°C using a 45 Ti rotor carrying 100ml capped tubes in a Beckman L5-65B 
ultracentrifuge and the resulting pellets resuspended in 50mM Tris-HCl buffer, pH 7.4 
using a Polytron homogeniser at speed 6 for 15 secs at 10mg/ml (original wet weight) 
and kept on ice before the start of binding assays. 2ml aliquots of homogenates were 
frozen at -20°C for protein determination.
2.3.2 PREPARATION OF BRAIN HOMOGENATES FOR [3H ]-  
RACLOPRIDE SATURATION ASSAYS
Homogenate preparation for dopamine D2 receptor binding measured by [3H]- 
raclopride binding assays were as described in section 2.3.1 except for the following 
modifications. Brains were rapidly removed and the striata quickly dissected out on 
ice. Whole brain minus striatum and striatum were placed separately in 50mM Tris- 
HCl buffer, pH 7.7. The tissue from four rats was pooled for each assay and gently 
blotted with filter paper before being weighed and then homogenised in 50mM Tris- 
HCl buffer, pH 7.7 using a Polytron homogeniser for 45 secs at speed 6 . The 
homogenates were centrifuged at 20,000rpm for 10 mins at 4°C and the resulting pellets 
were resuspended using a Polytron homogeniser at speed 6  for 15 secs and 
recentrifuged at 20,000rpm for 10 mins at 4°C. The homogenates were not 
preincubated since this results in a loss of D2 receptors (Seeman et al. 1984). Pellets 
were resuspended in Tris-ions buffer (50mM Tris-HCl, 120mM NaCl, 5mM KC1, 
2 mM CaCl2, 2mM MgCl2, 0.1% (wt/vol) ascorbic acid), pH 7.7 at 25°C using a 
Polytron homogeniser at speed 6 for 15 secs to give a final concentration of 10mg/ml 
(original wet weight) and kept on ice before the start of binding assays. 2ml aliquots of 
homogenates were frozen at -20°C for protein determination.
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2.3.3 PREPARATION OF BRAIN HOMOGENATES FOR [3H ]-  
SPIPERONE SATURATION ASSAYS
Homogenate preparation for dopamine D2 receptor binding measured by [3H]- 
spiperone binding assays were as described in section 2.3.1 except for the following 
modifications. Brains were rapidly removed and the striata quickly dissected out on 
ice. Whole brain minus striatum and striatum were placed separately in Tris-ions buffer 
(50mM Tris-HCl, 5mM KC1,2mM MgCh, pH 7.4 at 25°C). The tissue from four rats 
was pooled for each assay and gently blotted with filter paper before being weighed and 
then homogenised in Tris-ions buffer using a Polytron homogeniser for 45 secs at 
speed 6 . The homogenates were centrifuged at 20,000rpm for 15 mins at 4°C and the 
resulting pellets were resuspended using a Polytron homogeniser at speed 6 for 15 secs 
and recentrifuged at 20,000rpm for 15 mins at 4°C. The homogenates were not 
preincubated since this results in a loss of D2 receptors (Seeman et al. 1984). Pellets 
were resuspended in Tris-ions buffer using a Polytron homogeniser at speed 6 for 15 
secs to give a final concentration of 10mg/ml (original wet weight) and kept on ice 
before the start of binding assays. 2ml aliquots of homogenates were frozen at -20°C 
for protein determination.
2.3.4 PREPARATION OF BRAIN HOMOGENATES FOR [3H]-DAGO  
SATURATION ASSAYS
Homogenate preparation for jx-opioid receptor binding measured by [3H]-DAGO 
binding assays were as described in section 2.3.1 except for the following 
modifications. Brains were rapidly removed and quickly dissected on ice into the
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cerebellum, cortex, hippocampus, medulla and pons, midbrain and hypothalamus and 
striatum according to the procedure of Glowinski & Iversen (1966) and placed in 
50mM Tris-HCl buffer, pH 7.4. In a separate study tissue homogenates were also 
prepared from whole brain. The tissue from four rats was pooled for each assay and 
gently blotted with filter paper before being weighed and then homogenised in 50mM 
Tris-HCl buffer, pH 7.4 using a Polytron homogeniser for 45 secs at speed 6 . The 
homogenates were centrifuged at 25,000rpm for 15 mins at 4°C and the resulting pellets 
were resuspended in 50mM Tris-HCl using a Polytron homogeniser at speed 6 for 15 
secs. The suspensions were incubated in a Julabo shaking water bath (speed 
110shakes/min) at 25°C for 45 mins to remove endogenous opioids. The homogenates 
were centrifuged at 25,000rpm for 15 mins at 4°C and the resulting pellets resuspended 
in 50mM Tris-HCl buffer, pH 7.4 using a Polytron homogeniser at speed 6 for 15 secs 
at 10mg/ml (original wet weight) and kept on ice before the start of binding assays. 
2ml aliquots of homogenates were frozen at -20°C for protein determination.
2.3.5 VALIDATION OF INCUBATION TIMES FOR [125I ] -  
IODOSULPIRIDE, [3H]-RACLOPRIDE AND [3 H] -SPIPERONE  
SATURATION ASSAYS
Pilot validation experiments were carried out for [l25I]-iodosulpiride in regional 
homogenates and [3H]-raclopride and [3H]-spiperone in whole brain homogenates to 
determine the time required for equilibrium binding to be reached. The equilibrium 
binding conditions for [3H]-DAGO have been previously determined in our laboratory 
(Yeadon & Kitchen, 1988). The concentrations used were InM [l25I]-iodosulpiride 
(specific activity 2000Ci/mmol), InM [3H]-raclopride (specific activity 74Ci/mmol) and 
O.lnM [3H]-spiperone (specific activity 125Ci/mmol) which are two-thirds of the
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literature Kd of [125I]-iodosulpmde (Martres et al. 1985) and the literature Kd of [3H]- 
raclopride (Hall et al. 1990) and pH]-spiperone (Levant et al. 1992) in rat striatal 
membranes.
2.3.5.1 SATURATION ASSAYS USING [125l]-IODOSULPIRIDE
Dopamine D% receptor binding was measured by [125I]-iodosulpiride and Kd (binding 
affinity) and Bmax (maximal binding capacity) determined using 12 ligand 
concentrations (0.5-15nM in triplicate). Four saturation assays were carried out for 
each homogenate. For 0.5-1.5nM [125I]-iodosulpiride the total incubation volume was 
0.5ml, whereas for 2-15nM the total incubation volume was 0.25ml which therefore 
reduced the amount of ligand required. Additionally non-radioactive (±)-sulpiride was 
diluted with [125I]-iodosulpiride because the purchased [125I]-iodosulpiride was less 
concentrated than the highest ligand concentration required. For 0.5-1.5nM [125I]- 
iodosulpiride 0.46ml homogenate was used, the final volume of the reaction mixture 
being brought to 0 .5ml after the addition of ligand solutions, displacer solutions and 
50mM Tris-HCl buffer, pH 7.4. For 2-15nM [125I]-iodosulpiride 0.23ml homogenate 
was used, the final volume of the reaction mixture being brought to 0.25ml after the 
addition of ligand solutions, displacer solutions and 50mM Tris-HCl buffer, pH 7.4. 
Reaction mixtures were prepared in 5ml polypropylene tubes (Sarstedt product no. 
55.526). The reaction was initiated by the sequential addition of varying volumes of 
three freshly prepared stock solutions of [123I]-iodosulpiride in 50mM Tris-HCl buffer, 
pH 7.4. Binding to membrane homogenates was carried out in a Julabo shaking water 
bath (110shakes/min) at 30°C and for each [ 125I] -iodosulpiride concentration non­
specific binding was determined by treating a parallel set of tubes in triplicate with 
30|xM apomorphine (-2,000 times Kd). Non-specific binding was defined with 30(iM
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apomorphine because this concentration has been shown to displace over 90% of 
specific pH]-iodosulpiride binding to D2 receptors in rat striatal homogenates and 
between 60-70% of specific pH]-iodosulpiride binding in cortical regions and 
cerebellum (Martes et al. 1985). Binding was terminated by vacuum filtration through 
glass fibre filters (Whatman GF/B) presoaked for 2 hrs in 2% v/v polyethylenimine 
(Sigma product no. P 3143) in Tris-HCl buffer, pH 7.4 at 0°C (to reduce non-specific 
binding) using a Brandel M-24 cell harvester (Semat Technical U.K. Ltd.) and washed 
four times with 3ml of ice-cold Tris-HCl buffer, pH 7.4. Radioactivity of the filters 
bound with [ 125]]-iodosulpiride was counted on a Wallac 1260 Multigamma II counter 
over a 60 sec period with an efficiency of 80%. Samples of the ligand solutions were 
also counted on each occasion and all data was corrected for radioactive decay.
2.3.S.2 SATURATION ASSAYS USING p H ]-R A C L O P R ID E
Dopamine D2 receptor binding was measured by pH]-raclopride and Kd and Bmax 
determined using 10 ligand concentrations (0.2-15nM in triplicate). A minimum of four 
saturation assays were carried out for each homogenate. For 0.2-15nM pH]-raclopride 
0.225ml homogenate was used, the final volume of the reaction mixture being brought 
to 0.25ml after the addition of ligand solutions, displacer solutions and 50mM Tris-HCl 
buffer, pH 7.7. Reaction mixtures were prepared in Sarstedt 5ml polypropylene tubes. 
The reaction was initiated by the sequential addition of varying volumes of three freshly 
prepared stock solutions of pH]-raclopride in 50mM Tris-HCl buffer, pH 7.7. 
Binding to membrane homogenates was carried out in a Julabo shaking water bath 
(110shakes/min) at 25°C and for each pH]-raclopride concentration non-specific 
binding was determined by treating a parallel set of tubes in triplicate with IjiM (+)- 
butaclamol (-100 times Kd). Non-specific binding was defined with IjiM  (+)-
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butaclamol because the (+)-isomer has been shown to displace over 95% of specific 
[3H]-raclopride binding to D2 receptors in rat striatal homogenates (Kohler et al. 1985). 
Binding was terminated by vacuum filtration through glass fibre filters (Whatman 
GF/B) presoaked for 2 hrs in 2% v/v polyethylenimine in 50mM Tris-HCl buffer, pH
8.0 at 0°C using a Brandel M-24 cell harvester and washed three times with 5ml of ice- 
cold 50mM Tris-HCl buffer, pH 8.0. Filters bound with [3H]-raclopride were placed 
in 5ml polyethylene vials. After the addition of 4.5ml of Unisolve E scintillation fluid 
and 0.5ml of 20% Triton X-100 in toluene each vial was capped and shaken. Samples 
were left for a minimum of 17 hrs to allow solubilisation of membranes and their 
dispersion into the scintillant. The filters were counted in a Wallac LKB 1216 Rackbeta 
liquid scintillation counter over a 5 min period with its efficiency determined for each 
experiment using [3H]-hexadecane (specific activity 62Bq/pl). Samples of the ligand 
solutions were also counted on each occasion to determine the exact concentrations 
used.
2.3.S.3 SATURATION ASSAYS MEASURED BY [3H ]-SPIPE R O N E
Dopamine D2 receptor binding was measured by pH]-spiperone and K d and Bmax 
determined using 10 ligand concentrations (10-2000pM in triplicate). A minimum of 
four saturation assays were carried out for each homogenate. For 10-2000pM pH ]- 
spiperone 0.225ml homogenate was used, the final volume of the reaction mixture 
being brought to 0.25ml after the addition of ligand solutions, displacer solutions and 
Tris-ions buffer. Reaction mixtures were prepared in Sarstedt 5ml polypropylene 
tubes. The reaction was initiated by the sequential addition of varying volumes of three 
freshly prepared stock solutions of pH]-spiperone in Tris-ions buffer. Binding to 
membrane homogenates was carried out in a Julabo shaking water bath
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(1 lOshakes/min) at 25°C and for each [3H]-spiperone concentration non-specific 
binding was determined by treating a parallel set of tubes in triplicate with IpM (+)- 
butaclamol (-1,000 times Kd). (±)-sulpiride has been used in a previous study to 
exclude non-specific binding of [3H]-spipeone to 5-hydroxytryptamine receptors (5- 
HT2) in nucleus acumbens and caudate putamen homogenates (Bardgett et al. 1995). 
However, (+)-butaclamol was chosen instead because the affinity of [3H]-spiperone for 
5-HT2 receptors (KD=14nM) is much lower than that for D2 receptors (KjyO.OSnM) in 
the rat brain (Seeman et al. 1986) and at the concentrations of [3H]-spipeone used in the 
present study (10-2000pM) binding to 5 -HT2 receptors should be negligible. 
Furthermore, (+)-butaclamol is approximately 100-fold more potent at inhibiting [3H]- 
spiperone binding than (-)-sulpiride and >10,000 more potent at inhibiting [3H]- 
quinpirole binding than (+)-sulpiride in rat striatal homogenates (Levant et al. 1992). 
Binding was terminated by vacuum filtration through glass fibre filters (Whatman 
GF/B) presoaked for 2 hrs in 2% v/v polyethylenimine in 50mM Tris-HCl buffer, pH
8.0 at 0°C using a Brandel M-24 cell harvester and washed three times with 3ml of ice- 
cold 50mM Tris-HCl buffer, pH 8.0. Filters bound with [3H]-spiperone were placed 
in 5ml polyethylene vials and scintillant was added and counting was as described in 
section 2.3.5.2.
2.3.S.4 SATURATION ASSAYS USING [3H ]-D A G O
p-opioid receptor binding was measured by [3H]-DAGO, specific activity 60Ci/mmol, 
to determine Kd  and Bmax using 12 ligand concentrations (0.25-9.0nM in triplicate). A 
minimum of four saturation assays were carried out for each homogenate. For 0.25- 
9nM [3H]-DAGO 0.225ml homogenate was used, the final volume of the reaction 
mixture being brought to 0.25ml after the addition of ligand solutions, displacer
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solutions and 50mM Tris-HCl buffer, pH 7.4. Reaction mixtures were prepared in 
Sarstedt 5ml polypropylene tubes. The reaction was initiated by the sequential addition 
of varying volumes of three freshly prepared stock solutions of [3H]-DAGO in 50mM 
Tris-HCl buffer, pH 7.4. Binding to membrane homogenates was carried out in a 
Julabo shaking water bath (110shakes/min) at 25°C for 40 mins and for each [3H]- 
DAGO concentration non-specific binding was determined by treating a parallel set of 
tubes in triplicate with IjxM naloxone (-100 times Kd). Non-specific binding was 
defined with IjaM naloxone because this concentration has been shown to displace over 
90% of specific [3H]-DAGO binding to g-receptors in whole brain homogenates 
(Yeadon & Kitchen et al. 1988). Binding was terminated by vacuum filtration through 
glass fibre filters (Whatman GF/B) presoaked for 2 hrs in 2% v/v polyethylenimine in 
50mM Tris-HCl buffer, pH 7.4 at 0°C using a Brandel M-24 cell harvester and washed 
three times with 2ml of ice-cold Tris-HCl buffer, pH 7.4. The individual filters plus 
membranes were placed in 5ml polyethylene vials and scintillant was added and 
counting was as described in section 2.3.5.2.
2.3.6 D E TE R M IN A T IO N  OF PR O T EIN  C O N TEN T O F T H E  
MEMBRANE PREPARATIONS
The protein content of the membrane preparations was assayed using the method of 
Lowry et al. (1951). The protein content of the test samples was determined by the 
construction of a protein assay standard curve, against which the protein content of the 
membrane samples was extrapolated.
To tubes in duplicate, bovine serum albumin, fraction V (Sigma product no. A4503) 
and reverse osmosis water were added to give a final concentration of bovine serum
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albumin ranging from 50|ig/ml to 500|ig/mL To 0.5ml of each solution 2.5ml of 
copper tartrate reagent (98 parts 2% w/v sodium carbonate in 0.1M aqueous sodium 
hydroxide, 1 part 2% w/v aqueous cupric sulphate, 1 part 1% w/v aqueous potassium 
sodium tartrate) was added and the tubes vortexed and allowed to stand for 10 mins at 
room temperature. For a standard blank, 0.5ml of reverse osmosis water was 
substituted for the protein solution. Following this, 0.5ml of 2N Folin and Ciocalteu's 
phenol reagent (Sigma product no. F9252) was added to each tube, the contents 
vortexed and left for 30 mins at room temperature. The same procedure for the 
membrane homogenates was followed as that for the construction of the standard curve.
The absorbance of the samples was read on a Cecil Instruments spectrophotometer at a 
wavelength of 750nm. The spectrophotometer was zeroed using water and the optical 
densities of standards determined to generate a standard curve by plotting the mean 
absorbance against protein concentration in jig/ml. From this the protein content of the 
homogenate preparations was determined.
2.3.7 DATA ANALYSIS AND STATISTICAL ANALYSIS
Data from four to six saturation experiments was analysed by linear regression of 
Scatchard plots. From these, measures for Kd and Bmax (determined per mg protein 
and per mg wet weight) were calculated and statistically compared to control values by 
one way analysis of variance (1-way ANOVA) followed by post-hoc analysis with 
Duncan's multiple range test. Values are means ± S.E.M. (standard error of the mean) 
and were considered to be significant at the P<0.05 level.
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2.4 AUTORADIOGRAPHIC BINDING STUDIES
Comparative autoradiography for dopamine D2 and ji-opioid receptors in the rat brain 
was carried out using [^^I]-iodosulpiride and pH]-DAGO to determine the precise 
anatomical location of KA receptor toxicity.
2.4.1 TISSUE PREPARATION AND SECTIONING
Rats were injected as described in section 2.2 and killed by decapitation after 4 hrs. 
Brains were removed and frozen in isopentane (30 secs at -20°C to -30°C) and stored at 
-70°C for no longer than 1 month before sectioning. Brains were mounted squarely and 
vertically in plastic embedding medium (O.C.T. compound, BDH), by the cerebellum, 
onto microtome stages in a cryostat (Zeiss Microm HM 505 E) at -20°C. For 
autoradiographic mapping, 20pm frozen coronal sections were cut (500pm apart) in a 
cryostat at -20°C and thaw-mounted onto precleaned and 1% gelatin/chrome-alum 
subbed ice-cold microscope slides (Lamb, U.K., size 76 by 26mm, 3 sections/slide) 
and dried by using anhydrous CaSO^ for 2 hrs at 4°C followed by 1 week at -2O°C. 
Adjacent sections were cut from the start of the frontal cortex, identified according to 
the atlas of Paxinos & Watson (1986), for the determination of total and non-specific 
binding with [ ^ ^1] -iodosulpiride and pH]-DAGO. Additionally, for each brain, three 
adjacent sections were cut at the level of the caudate putamen, an area of high dopamine 
D 2 and p-opioid binding, for the determination of total and non-specific binding in 
sections scraped from the slides to determine the level of specific binding to verify the 
success of binding so that slides could then be apposed to autoradiographic film.
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Furthermore, in pilot studies, to establish the optimum time for film development, nine 
sequential sections were cut from fore-, mid- and hindbrain regions, thaw-mounted 
onto three gelatin coated slides to be laid against cut strips of autoradiographic film for 
early development Sections for scrapes and early development were taken from areas 
normally voided in mapping studies. Each brain was sectioned in a day and did not 
undergo freezing-thawing.
2.4.2 V A LID A TIO N  OF IN CU B A TIO N  TIM ES FO R  [125I ] -  
IODOSULPIRIDE AND [3H]-DAGO BINDING
Pilot validation experiments were carried out for [ 125i]-iodosulpiride (specific acivity 
2000Ci/mmol) and [3H]-DAGO (specific activity 58Ci/mmol) in sections cut at the level 
of caudate putamen from saline-treated rat brain to determine the time required for 
equilibrium binding to be reached. The concentrations used were 1.6nM [125I]- 
iodosulpiride and InM [3H]-DAGO which are the literature Kd of [125I]-iodosulpiride 
(Martres et al. 1985) and pH]-DAGO (Robson et al. 1985).
2.4.3 BINDING ASSAYS
For autoradio graphic visualisation of dopamine D2 and |i-opioid binding sites, 
incubations with [125I]-iodosulpiride and pH]-DAGO were carried out simultaneously 
for saline and KA-treated groups. Five binding assays were carried out with [125I]- 
iodosulpiride and pH]-DAGO. The mapping concentrations were as follows: pH ]- 
DAGO (3nM) and [125I]-iodosulpiride (3nM) and were approximately 3 times and half
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of the Kd respectively as determined in homogenate binding studies. Solutions of 
[125I]-iodosulpiride and pH]-DAGO were freshly prepared in 50mM Tris-HCl buffer, 
pH 7.4 by producing stocks of double concentration and quantity, dividing in half and 
diluting with 50mM Tris-HCl buffer, pH 7.4 (total solution) or equal volumes of 
displacer and 50mM Tris-HCl buffer, pH 7.4 (non-specific solution). Prior to binding 
experiments, slides were thawed at room temperature for at least 30 mins to prevent 
condensation. Slides for determination of binding with pH]-DAGO were preincubated 
in 250ml 50mM Tris-HCl buffer, pH 7.4 plus 0.9% NaCl for 30 mins to remove 
endogenous opioids, tapped dry on the benchtop and then binding was carried out in 
50mM Tris-HCl buffer, pH 7.4 (1ml of total solution for each slide) at room 
temperature for 60 mins. Slides for determination of binding with [125I]-iodosulpiride 
were incubated in 50mM Tris-HCl buffer, pH 7.4 (1ml of total solution for each slide) 
at room temperature for 40 mins. Non-specific binding was determined by 
simultaneously treating a parallel set of slides, under identical incubation conditions as 
total slides, with the same concentration of radioligand and IpM naloxone to displace 
[3H]-DAGO and 3 0 jiM  apomorphine to displace [ 125I]-iodosulpiride (1ml of non­
specific solution for each slide). Slides were washed and gently agitated in consecutive 
250ml 50mM Tris washes (pH 7.4, 4°C). Slides incubated with pH]-DAGO were 
given three 5 min washes, while those incubated with [ 125I]-iodosulpiride were given 
two 2 min washes. Following the Tris washes, all slides except those for scrape 
binding were tapped dry on the benchtop and rapidly dried in a stream of cool air for 1- 
2 hrs and dessicated for 1 week at room temperature using anhydrous CaSO^.
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2.4.4 SCRAPES, EARLY DEVELOPM ENT AND A PPO SITIO N  OF 
SLIDES TO FILM
After ji-opioid binding assays sections from total and non-specific scrape slides were 
scraped off with strips of glass-fibre filter paper (Whatman GF/B) and put in separate 
5ml polyethylene vials. 1ml of Soluene was added to each vial which were loosely 
capped and left overnight. 4ml of Unisolve E scintillation fluid was added, the vials 
capped and shaken and counted in a Wallac LKB 1216 Rackbeta liquid scintillation 
counter over a 5 min period with its efficiency determined for each experiment using 
[3H]-hexadecane (specific activity 62Bq/jil). After dopamine 0% assays total and non­
specific sections were scraped off with strips of glass-fibre filter paper (Whatman 
GF/B) and put in separate 3ml polystyrene vials and counted immediately in a Wallac 
1260 Multigamma II counter over a 60 sec period with an efficiency of 80%.
For slides laid down for early development strips of [3H]-Hyperfilm (Amersham) were 
sandwiched between the sections and a blank slide and held in place with bull-dog 
clips. These were placed in slide boxes, the edges sealed with tape and the boxes 
wrapped in aluminium foil and left in the dark at room temperature in the p-opioid 
binding study and at 4°C in the dopamine D2 binding study. Films were developed 
sequentially in Coplin jars under ultraviolet light (red filter) in a dark room using 50% 
Kodak D-19 developer (Sigma product no. P 5670) for 3 mins followed by rinsing in 
~2% glacial acetic acid and reverse osmosis water for 30 secs and fixing with Kodak 
rapid fix (Sigma product no. P7542) for 2 mins and washed in running reverse osmosis 
water for at least 30 mins and left to dry overnight in a dust-ffee environment. Early 
development slides were developed at 1,2 and 3 weeks at room temperature in the p- 
opioid binding study and at 1,2 and 3 days at 4°C in the dopamine D2 binding study.
105
For the exposure of sections to autoradio graphic film a week after binding experiments 
saline and KA-treated slides were arranged in parallel together with [3H]-microscale 
standards (Amersham) or [14C]-labelled brain paste standards (for 125I calibration) and 
mounted on cardboard (with the sections facing up) using transparent tape and placed in 
Hypercassettes (Amersham). Under ultraviolet light (red filter) in a dark room labelled 
sections were apposed against [3H]-Hyperfilm (24 by 30cm), emulsion-side face-down 
and the Hypercassettes shut and the edges sealed with tape. Hypercassettes were left in 
the dark for 3 weeks at room temperature in the p-opioid study and in the dark for 3 
days at 4°C in the dopamine D2 study (to reduce non-specific binding). Under 
ultraviolet light (red filter) in a dark room Hypercassettes were opened and the films 
developed, emulsion-side up, in photographic trays containing 50% Kodak D-19 
developer for 3 mins followed by rinsing in ~2% glacial acetic acid and reverse osmosis 
water for 30 secs and fixing with Kodak rapid fix for 2 mins and washed in running 
reverse osmosis water for at least 30 mins and left to dry overnight in a dust-free 
environment and analysed in parallel.
2.4.5 PREPARATIO N OF [14C] AND [125i].L A B E L L E D  B R A IN  
PASTE STANDARDS
For quantitative autoradiographic studies, radioactive standards must be exposed to film 
together with the samples so that a computer calibration procedure can determine the 
relationship between the optical density image on the film and levels of radioactivity. 
Due to the short half-life of y-emitting isotopes it was impractical to use [125I]-labelled 
standards to calibrate [ 125l] -iodosulpiride autoradiograms. Radioisotopes with longer 
half-lives such as tritium have been employed to calibrate [123I]-labelled samples, but 
the response of autoradiographic film to tritium and ^2^I varies with the time of
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exposure (Crain et al. 1986). Other problems with tritium are that (3-particles will not 
penetrate beyond a thickness greater than 5Jim and are differentially absorbed by white 
and gray matter in the central nervous system. However, when 14C, a very long-lived 
isotope, is exposed with 125I to autoradiographic film for the same length of time, the 
film response is identical (Miller & Zahniser, 1987), thus making it appropriate to use 
[14C]-labelled standards to calibrate autoradiograms from samples containing 125I. 
[14C] and [125I]-labelled brain paste standards were therefore prepared.
Brains of seven rats were placed in a 100ml centrifuge tube and homogenised using a 
Kinematica Polytron homogeniser (setting 5 for 20-30 secs) until a uniform paste was 
obtained. The paste was transferred to a glass petri dish on ice and mixed with 
approximately one-fifth of the volume of plastic embedding medium (O.C.T. 
compound) using a fire-polished glass pasteur pipette. Fifteen 250mg aliquots of brain 
paste were weighed in small plastic weigh boats and placed on ice. To individual 
aliquots of brain paste were added undiluted 0.9, 0.75, 0.6, 0.45, 0.3, 0.2, 0.125, 
0.075, 0.055, 0.035, 0.02, 0.015, 0.01, 0.005 and 0.0025|iCi of DL-[1-14C]- 
omithine (specific activity 57mCi/mmol) or [125I]-iodosulpiride (specific activity 
2000Ci/mmol). The total volume added was 20JJ.1 by the separate addition of 20% 
sucrose and was small to minimise dilutional errors. Sucrose was added because it acts 
as a cryoprotectant, preventing ice crystal artifacts in frozen sections. The brain paste 
was mixed thoroughly with a fire-polished glass pasteur pipette and was transferred 
into individual 500jil polypropylene microfuge tubes using fire-polished glass pasteur 
pipettes. Tubes were vortexed hard for 2 mins and then centrifuged for 2 mins at 
14,000ipm at 4°C in a microcentrifuge to remove air bubbles. Tubes were taken out 
quickly and frozen in crushed dry ice. To loosen the standards from the microfuge 
tubes, the lid was cut off each tube and the outside of the tubes warmed for a few 
seconds by rolling between the fingers. Each tube was placed inverted inside 1.5ml 
microfuge tubes kept on crushed dry ice and centrifuged at 14,000rpm at 4°C in a
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microcentrifuge for approximately 10 secs until the standard 'popped' out of the tube. 
Standards were stored at -20°C before sectioning. Standards were mounted squarely 
and vertically in plastic embedding medium (O.C.T. compound), by the cone, onto 
microtome stages in a cryostat (Zeiss Microm HM 505 E) at -20°C. 20pm frozen 
coronal sections were cut in triplicate in a ciyostat at -20°C, at approximately the same 
depth, and thaw-mounted onto precleaned and 1% gelatin/chrome-alum subbed ice-cold 
microscope slides. Slide mounted standards were stored at room temperature. In pilot 
studies, brain paste standards and saline and KA-treated slides were apposed in parallel 
against [3H]-Hyperfilm and developed using 50% Kodak D-19 developer as described 
in section 2.4.4 after 3 days at 4°C. Determination of the optical densities of brain paste 
standards was carried out by video-based computerised densitometry using an MCID 
image analyser (Imaging Research, Ontario, Canada) to unsure that they were 
sufficently concentrated to cover the range of optical densities in [125I]-iodosulpiride 
autoradiographic studies. High and low D L-[l-l4C]-omithine hydrochloride and 
[125]]-iodosulpiride brain paste standards were apposed to [3H]-Hyperfilm at 4°C for 4- 
5 days and developed using 50% Kodak D-19 developer as described in section 2.4.4. 
Calibration curves were constructed of optical density (determined using an MCID 
image analyser) versus known radioactivity of [l25I]-iodosulpiride and DL-[1-14C]- 
omithine hydrochloride brain paste standards. From the [125I]-iodosulpiride calibration 
curve the optical density of DL-[l-14C]-omithine hydrochloride brain paste standard 
equivalents were extrapolated. The difference between extrapolated 14C values and 14C 
optical densities (determined using an MCID image analyser) was determined for each 
radioactive concentration and 125I tissue equivalents (femtamoles per milligram of 
tissue) correspondingly corrected for the generation of an l23! calibration curve 
(corrected 125I tissue equivalents versus optical density) to calibrate the imaging 
system. D L-[l-14C]-omithine hydrochloride brain paste standard slides were laid 
down with each film to provide tissue equivalents for [ l25I]-iodosu lp iride  
autoradiographic studies.
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2.4 .6  Q U A N T IF IC A T IO N  ANALYSIS USING V ID EO -B A SED  
COMPUTERISED DENSITOMETRY
Quantitative analysis of receptor binding was carried out by video-based computerised 
densitometry using an MCID image analyser. Tissue equivalents (femtamoles per 
milligram of tissue) for g-binding were derived from [3H]-microscale standard 
(Amersham) based calibrations (high and low, total activity 2.96KBq/high and 
296Bq/low) laid down with each film after subtraction of non-specific binding images 
which were at the level of background. [125I]-iodosulpiride density was calculated 
against a calibration curve constructed using [l4C]-labelled brain paste standards 
calibrated as described in section 2.4.5. and laid down with each film. Non-specific 
image alignment and superimposition with total images was carried out to determine D2 
specific binding beacause non-specific binding images were higher than background. 
Specific binding was determined after digital subtraction of non-specific binding. 
Autoradiograms were analysed as pseudo-colour images except for cortical regions 
which were analysed in reverse monchrome because this setting gave a clearer 
definition of cortical layers. For each region quantified measures were taken from both 
left and right sides of brain tissue and across two sections, 500gm apart. Quantification 
of discrete layers was carried out by sampling with box tools of adjustable size whereas 
structures with uniform distribution of binding were sampled by drawing around their 
outline. For bregma co-ordinates where measures were taken and box tool sizes used 
in this study refer to Tables 7, 8 and 9. Structures were identified and anatomical 
nomenclature is that of the atlas of Paxinos & Watson (1986) except in the following 
regions: hypothalamus and thalamus were the collective names for all their respective 
nuclei, frontal parietal cortex was frontal and parietal cortex quantified at the same level 
and cortical layers with D% or p-binding were identified and numbered according to 
Bouthenet et al. (1987) and Mansour et al. (1987) respectively.
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2.4.7 STATISTICAL ANALYSIS
Comparison of quantitative measures of autoradiographic binding (determined per mg 
tissue) for each ligand in saline and KA-treated groups was carried out using 1-way 
ANOVA followed by post-hoc analysis with Duncan's new multiple range test in 
regions quantified in homogenate binding studies. Cortical layers and structures 
comprising the cerebellum, medulla and pons and midbrain and hypothalamus were 
grouped and comparisons made between these regions from saline and KA-treated 
groups. Additionally, the individual means from hippocampus and striatum (caudate 
putamen) from saline and KA-treated groups were also compared. Values are means ± 
S.E.M. and were considered to be significant at the P<0.05 level.
2.5 pHJ-KAINIC ACID DISTRIBUTION STUDY
Distribution studies were carried out using [3H]-KA administered intraperitoneally with 
16mg/kg KA to determine the percentage of KA reaching rat brain areas 4 hrs after 
treatment
2.5.1 TREATMENT
On the day of experimentation ten rats weighing exactly 250g were placed in separate 
clean cages. 5.5ml of 16mg/kg KA containing 77gl [Vinylidene-3H]-KA ([3H]-KA, 
specific activity 58Ci/mmol) was freshly prepared and was sufficient for ten 0.5ml
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injections. Rats were injected intraperitoneally with a single dose of 16mg/kg KA 
containing 7|iCi [3H]-KA (2ml/kg) and returned to the cages. This quantity of [3H]- 
KA was used because in a previous study in this laboratory 7|iCi of radiolabelled 
opioids were injected to measure their entry into mouse brain (Green & Kitchen, 1985).
An estimate of the excess of a saturating concentration of KA binding sites in the rat 
brain that 16mg/kg KA represents was made. Firstly, the number of milligrams of KA 
in 16mg/kg KA administered to a 250g rat was calculated and converted to moles of 
KA. Secondly, the volume of KA administered to a 250g rat was calculated if 2ml of 
solution is injected per kg of body weight. Thirdly, the number of moles of KA 
administered in a 0.5ml dose of 16mg/kg KA was converted into a molar concentration 
of KA. Finally, assuming that all 16mg/kg KA penetrates the blood-brain barrier and 
assuming that this dose in the blood of the brain will reach the receptor site and will 
bind equally to high-affinity KA sites (Kd of 11.6nM) and low-affinity KA sites (Kd 
of 43.6nM) in rat brain (Unnerstall & Wamsley, 1983) at a saturating concentration of 
approximately 10-times Kd , then 16mg/kg KA represents approximately a 135,000- 
fold excess of the concentration necessary to saturate KA binding sites in the rat brain.
2.5.2 TISSUE PREPARATION
After 4 hrs, seven surviving rats were killed by cervical dislocation and decapitated. 
The brains were rapidly removed and dissected on ice into the cerebellum, cortex, 
hippocampus, medulla and pons, midbrain and hypothalamus and striatum according to 
the procedure of Glowinski & Iversen (1966). Each brain region was placed into pre­
weighed 5ml polyethylene vials. These were re-weighed and 3ml of Soluene was 
added to each vial and capped. Solubilisation was promoted by agitating and warming
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the vials to 50°C in a waterbath for 30 mins and allowing to cool at room temperature. 
Following solubilisation of brain tissue 1.8ml of Unisolve E scintillation fluid and 
0.2ml of 20% Triton X-100 in toluene were added to avoid chemiluminesence and the 
vials capped and shaken. Vials were left for a minimum of 17 hrs before counting in a 
Wallac LKB 1216 Rackbeta liquid scintillation counter over a 5 min period. The 
efficiency of counting was determined by counting lOjil of [3H]-hexadecane (specific 
activity 62Bq/gl) in triplicate. 7jiCi of [3H]-KA in triplicate was also counted and 
converted to a value in disintegrations per minute (d.p.m.) to calculate the percentage of 
7jiCi [3H]-KA in the brain regions after 4 hrs. A value for this in the whole brain was 
also determined by summing the individual d.p.m.s of each region. The binding of 
[3H]-KA in the cerebellum, cortex, hippocampus, medulla and pons, midbrain and 
hypothalamus and striatum was determined after 4 hrs and expressed as d.p.m./gram of 
brain tissue to compensate for differences in the size of each brain region.
2.5.3 EFFE C T OF KAINIC ACID ON IN  VITRO  p H ] - D A G O  
RECEPTO R BINDING
Experiments were carried out to determine if 7gCi [3H]-KA and 16mg/kg KA, 4 hrs 
after administration, was detectable in homogenates following the centrifugation stages 
of ji-opioid homogenate preparation. Rats were injected intraperitoneally as described 
in section 2.5.1 and were killed by cervical dislocation and decapitated after 4 hrs. The 
procedure of homogenate preparation for g-opioid binding assays was identical as 
described in section 2.3.4. Following the second centrifugation stage the resulting 
pellets were placed into pre-weighed 5ml polyethylene vials and solubilised and counted 
as described in section 2.5.2. IOjjI  aliquots of 7|iCi of [3H]-KA were counted in 
triplicate to determine molar concentrations of [3H]-KA from d.p.m. counts.
112
Experiments were carried out to determine if in rats injected intraperitoneally with 
16mg/kg KA containing 70jiCi [3H]-KA, residual amounts of [3H]-KA and unlabelled 
KA remaining after the cenrifugation stages of (i-opioid homogenate preparation 
affected in vitro [3H]-DAGO receptor binding. On the day of experimentation twenty 
rats weighing exactly 250g were placed in separate clean cages. 5.5ml of 16mg/kg KA 
containing 700gl [3H]-KA was freshly prepared and was sufficient for ten 0.5ml 
injections. Ten rats were injected intraperitoneally with 16mg/kg KA (2ml/kg) and ten 
with 16mg/kg KA containing 70jiCi [3H]-KA (2ml/kg) and returned collectively to the 
cages. After 4 hrs, six surviving rats injected with 16mg/kg KA and seven surviving 
rats injected with 16mg/kg KA containing 70|iCi [3H]-KA were killed by cervical 
dislocation, decapitated and whole brains removed. The preparation of homogenates 
for ji-opioid binding assays was identical to that described in section 2.3.4 and the 
method of ji-opioid binding assays and stock of [3H]-DAGO used were identical to that 
described in section 2.3.5A Protein determination was identical to that described in 
section 2.3.6.
2.5.4 COMPENSATION FOR QUENCHING
The presence of solubilised brain tissue has a quenching effect on the detection of 
scintillations. As varying amounts of brain tissue or pellets from homogenate 
preparation were present in each vial, it is important to compensate for variable 
quenching. Quench correction curves were therefore constructed. A range of ten 
weights up to 1.5g of whole brain tissue and whole brain pellets (prepared as described 
in part 2.3.4 for homogenate preparation in p-opioid receptor binding) were placed in 
5ml polyethene vials and solubilised in 3ml of Soluene. To each vial, lOpl of [3H]- 
hexadecane was added followed by 1.8ml of Unisolve E scintillation fluid and 0.2ml of
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20% Triton X-100 in toluene. Values for [3H] efficiency and ratio (a measure of how 
well [3H]-KA is eluted from brain tissue) were determined using the cLp.m. package on 
a Wallac LKB 1216 Rackbeta scintillation counter. This program plotted quench curves 
of efficiency versus ratio from which the radioactivity of samples were extrapolated and 
given in d.p.m.
2.5.5 DATA ANALYSIS AND STATISTICAL ANALYSIS
Data from six to seven saturation experiments were analysed by linear regression of 
Scatchard plots. Data analysis and statistical analysis was identical to that described in 
section 2.3.7.
2.6 EFFECTS OF KAINIC ACID ON [3 H ] -D O P A M IN E  
RELEASE FROM RAT STRIATAL SLICES
In this study dopamine release from rat striatal slices induced by KA was measured by 
pre-loading tissue with [3H]-dopamine and exposing slices to KA. The dopamine-rich 
area of the brain, the striatum, was chosen because striatal slices provide a simplified 
preparation containing only dopaminergic nerve terminals which are able to take up and 
consequently release [3H]-dopamine (Mantz et al. 1994). The effects of KA on basal 
and potassium-stimulated [3H]-dopamine release from rat striatal slices and actions of 
the selective a-am ino-3-hydroxy-5-m ethyl-isoxazole/K A  antagonist, 6,7- 
dinitroquinoxaline-2,3-dione (DNQX) were investigated. The structure of (7,8-[3H])- 
dopamine hydrochloride ([3H]-dopamine) is shown in Figure 7 on page 92.
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2.6.1 TISSUE PREPARATION
Rats were killed by cervical dislocation and decapitated. The brains were rapidly 
removed and the striata dissected out on ice, placed onto filter paper and chopped into 
slices (0.4 by 0.4mm in cross-section) with a Mcllwain tissue chopper. The slices 
were placed in a perspex test tube containing 2ml of pre-warmed (37°C) Krebs solution 
(113mM NaCl, 25mM NaHCOg, 11.5mM glucose, 1.2mM CaClz, 1.2mM MgS0 4 , 
1.2mM KH2PO4) and washed three times with 2ml of pre-warmed (37°C) Krebs 
solution (composition as before) by aspiration using a glass pasteur pipette and 
incubated in a waterbath at 37°C for 45 mins in 2ml of Krebs solution (composition as 
before) aerated with 95% O2 and 5% CO2, containing a final concentration of 200nM 
(7,8-[3H])-dopamine hydrochloride (specific activity 5ICi/mmol). Excess incubation 
medium was removed by aspiration and the slices were washed three times with 2ml of 
pre-warmed (37°C) Krebs solution (composition as before) by aspiration using a glass 
pasteur pipette to remove free label. Aliquots (~3O|fi) of slices, measured using cut-off 
pipette tips, were pipetted into reaction chambers of a Brandel Superfusion SE-12 
system (Semat Technical U.K. Ltd.) and held between filter paper discs. Reagent 
probes that delivered solutions to reaction chambers were placed into a reservoir at the 
rear of the superfusion system containing pre-warmed (37°C) and pre-aerated (95% O2 
and 5% CO2) Krebs solution (composition as before) and the slices were continuously 
superfused for 45 mins at 0.5ml/min in a system maintained at 37°C.
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2.6.2 EFFEC T OF KAINIC ACID ON BASAL [3H ] - D O P A M I N E  
RELEASE FROM  RAT STRIATAL SLICES
Following 45 mins of superfusion four 4 min fractions of basal release of [3H]- 
dopamine were collected. Reagent probes were transferred into test tubes containing 
pre-warmed (37°C) KA solutions (lOpM-lOmM) which were in contact with striatal 
slices for three 4 min fractions. Reagent probes were placed back into the reservoir 
containing pre-warmed (37°C) and pre-aerated (95% 0% and 5% CO2) Krebs solution 
and three further 4 min fractions of basal release of [3H]-dopamine were collected. 
During fraction 11 the reagent probes were removed from the reservoir and the solution 
remaining in the reaction chambers and tubing was pumped out and timed to determine 
the volume collected. The effect of calcium deficiency was investigated by superfusing 
striatal slices from the onset of experiments with a calcium free buffer by exactly the 
same procedure. Six experiments were carried out for the determination of effects of 
KA on basal stimulated release of [3H]-dopamine from rat striatal slices in the presence 
and absence of calcium. This infomation is summarised in Figure 41a.
The AMPA/KA antagonist DNQX (500pM) was tested for its effect on [3H]-dopamine 
release by two concentrations of KA. SOOpM DNQX was used because Bowyer et al. 
(1992) have shown that it completely blocks lOOgM and ImM glutamate-induced 
release of dopamine from rat striatal slices in vitro. The KA concentrations chosen 
were the concentrations that caused maximum pH]-dopamine release and one between 
this and the threshold for stimulation. Following 45 mins of superfusion four 4 min 
fractions of basal release of pH]-dopamine were collected. Reagent probes were 
transferred into test tubes containing equal volumes of pre-warmed KA and DNQX 
solutions and striatal slices were superfused for three 4 min fractions. Reagent probes 
were placed back into the reservoir containing pre-warmed (37°C) and pre-aerated (95%
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Figure 41. Representative graphs showing the effect of kainic acid on basal and 
potassium-stimulated [3H]-dopamine release from rat striatal slices
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C>2 and 5% CO2) Krebs solution and three further 4 min fractions of basal release of 
[3H]-dopamine were collected. During fraction 11 the reagent probes were removed 
from the reservoir and the solution remaining in the reaction chambers and tubing was 
pumped out and timed to determine the volume collected. Six experiments were carried 
out for the determination of effect of DNQX on KA-induced basal release of [3H]- 
dopamine from rat striatal slices. This infomation is summarised in Figure 41a.
2.6.3 EFFEC T OF KAINIC ACID ON POTASSIUM -STIM ULATED 
PH ]-D 0PA M IN E RELEASE FROM RAT STRIATAL SLICES
Two identical periods of potassium stimulation were applied to each chamber, 40 mins 
apart. Each was initiated by placing reagent probes into test tubes containg a 
superfusion medium with an elevated level of potassium chloride (30mM) for 2 mins, 
while the concentration of sodium chloride was correspondingly reduced. The rationale 
for choosing 30mM potassium chloride was that it must produce a large release of 
dopamine which was not markedly depressed upon repeated stimulation. In a previous 
study by Howells & Thomas (1993) 25,35 and 50mM potassium chloride were shown 
to produce a dose-dependent release of dopamine from rat striatal slices in vitro, 50mM 
potassium chloride was shown to be 5-times more potent at stimulating dopamine 
release (Howells & Thomas, 1993) therefore a concentration between 25mM and 
35mM potassium chloride was chosen. The first stimulation period (SI) after 20 mins 
was used as an internal control to compensate for variation among the slices. The 
effects of KA or DNQX at concentrations identical with those used in basal stimulation 
were assessed on the second stimulation (S2) period. After fraction 11 reagent probes 
were placed into test tubes containing pre-warmed (37°C) KA for 4 mins. 2 mins after 
fraction 14 reagent probes were transferred in test tubes containing equal volumes of
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pre-warmed (37°C) potassium chloride and KA for 2 mins and immediately placed back 
into test tubes containing pre-warmed (37°C) KA for 2 mins. Reagent probes were 
placed back into the reservoir containing pre-warmed (37°C) and pre-aerated (95% O2 
and 5% CO2) Krebs solution and three further 4 min fractions were collected. During 
fraction 20  the reagent probes were removed from the reservoir and the solution 
remaining in the reaction chambers and tubing was pumped out and timed to determine 
the volume collected. Six experiments were carried out for the determination of effects 
of KA on potassium stimulated release of [3H]-dopamine from rat striatal slices.
DNQX (500gM) was tested for its effect on KA inhibition of potassium-stimulated 
release of dopamine release. After fraction 11 reagent probes were placed into test 
tubes containing equal volumes of pre-warmed (37°C) KA and DNQX for 4 mins. 2 
mins after fraction 14 reagent probes were transferred in test tubes containing equal 
volumes of pre-warmed (37°C) potassium chloride and KA for 2 mins and immediately 
placed back into test tubes containing equal volumes of pre-warmed (37°C) KA and 
DNQX for 2 mins. Reagent probes were placed back into the reservoir containing pre- 
warmed (37°C) and pre-aerated (95% O2 and 5% CO2) Krebs solution and three further 
4 min fractions were collected. During fraction 20 the reagent probes were removed 
from the reservoir and the solution remaining in the reaction chambers and tubing was 
pumped out and timed to determine the volume collected. Six experiments were carried 
out for the determination of effect of DNQX on KA-inhibition of potassium-stimulated 
[3H]-dopamine release from rat striatal slices. This infomation is summarised in Figure 
41b on page 117 and as follows:
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First stimulation period (SI): 5 (first 2 mins)
Second stimulation period (S2): 13 (four mins)
15 (first 2 mins) 
15 (last 2  mins)
Fraction number Drug
High K+
Kainic acid+/- DNQX 
High K+ + Kainic acid 
Kainic acid +/- DNQX
2.6.4 ESTIM ATION OF TRITIUM
The radioactivity of 400|il aliquots from each fraction was counted in a Wallac LKB 
1216 Rackbeta liquid scintillation counter over a 5 min period. After every experiment, 
each set of striatal slices and filter papers were solubilised overnight in 2 ml of 2 % 
sodium dodecyl sulphate solution. The solutions were diluted with 3ml of distilled 
water and lOOfil aliquots in duplicate plus 5ml of Unisolve E scintillation fluid were 
counted to enable the estimation of the pH] content of the residues.
2.6.5 DATA ANALYSIS AND STATISTICAL ANALYSIS
Dopamine release was expressed as fractional release per minute and given as a 
percentage of the mean pH]-dopamine available. The basal release of pH]-dopamine 
was calculated by subtracting the mean fractional release before KA action (fractions 1- 
4) from those contributing to KA-stimulated release (fractions 5-7).
The effect of KA and DNQX on [3H]-dopamine release evoked by the second
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stimulation was evaluated by calculating the mean of the ratios of S2:S1 (termed S2/S1) 
where SI is the release during the first stimulation and S2 the release during the second 
stimulation period. Dopamine release evoked by SI was calculated by subtracting the 
mean fractional release before potassium chloride action (fractions 1-4) from the 
fraction contributing to potassium chloride stimulated release (fraction 5). Dopamine 
release evoked by S2 was calculated by subtracting the mean fractional release evoked 
by KA (with or without DNQX) (fractions 13-14 and 17-18) from the fraction 
contributing to potassium chloride and KA-stimulated release (fraction 15). The ratio 
was then expressed as a percentage of the mean of the control S2/S1 ratios. Statistical 
significance was determined using 1-way ANOVA followed by post-hoc analysis with 
Dunn's multiple comparisons test or Friedman test. Values are means ± S.E.M. and 
were considered to be significant at the P<0.05 level.
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2.6 DRUGS
D rug Mr
Apomorphine hydrochloride 303.8
(+)-butaclamol hydrochloride 398.01
pH]-DAGO (98%) 250|iCi
DNQX 252.14
[3H]-dopamine (98%) 250|iCi
[3H]-hexadecane (>95%) 8 |iCi
[1251]-iodosulpiride (>90%) lOOgCi
Kainic acid 213.2
pH]-kainic acid (98%) 250pCi
Naloxone hydrochloride 363.8
DL- [ 1 - 14C]-ornithine hydrochloride 50gCi 
(99%)
pH]-raclopride (99%) 250^iCi
[3H]-spiperone (96%) 250|iCi
(±)-sulpiride 341.4
Supplier
Sigma Chemical Co. (U.K.)
ICN Biomedicals Inc. (U.K.) 
Amersham Life Science (U.K.)
Tocris Cookson Ltd. (U.K.) 
Amersham Life Science (U.K.) 
Amersham Life Science (U.K.) 
Amersham Life Science (U.K.)
Sigma Chemical Co. (U.K.)
Sigma Chemical Co. (U.K.)
Sigma Chemical Co. (U.K.) 
Amersham Life Science (U.K.)
Du Pont Medical Products Ltd. (U.K.) 
Amersham Life Science (U.K.)
Sigma Chemical Co. (U.K.)
Radiochemical purity is in parenthesis. KA was made up in 0.9% saline and adjusted 
to pH 7.0 with 2M sodium hydroxide, fresh solutions were prepared daily prior to use. 
Apomorphine hydrochloride was dissolved in 50mM Tris-HCl buffer, pH 7.4 at 37°C 
to which ascorbic acid was added to act as an antioxidant, fresh solutions were prepared 
daily prior to use. (±)-sulpiride was dissolved in 50mM Tris-HCl buffer, pH 7.4 at 
37°C, fresh solutions were prepared daily prior to use. Naloxone was dissolved in 
50mM Tris-HCl buffer, pH 7.4 at 25°C, fresh solutions were prepared daily prior to
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use. DNQX was dissolved in 2% dimethyl sulphoxide before each experiment. All 
other drugs were dissolved in reverse osmosis water.
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CHAPTER 3 
RESULTS
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3.1. BEHAVIOURAL EFFECTS AND MORTALITY INDUCED BY 
KAINIC ACID
Marked behavioural changes were observed in all rats following the intraperitoneal 
injection of 16mg/kg KA. Within minutes of injection of 16mg/kg KA rats exhibited 
abnormal staring. The behavioural changes progressed to wet-dog shakes, paddling, 
rearing and circling and in the most severe cases catatonia and death were observed. 
Following a single intraperitoneal dose of 16mg/kg KA the mean mortality rate in the 
dopamine D2 receptor study was 40% (n>50) and in the p-opioid receptor study it was 
10% (n>40). There was no obvious correlation between severity of behavioural signs 
and observed changes in dopamine D2 or p-opioid receptor binding (Figure 8).
3.2 HOMOGENATE BINDING STUDIES
3.2.1 VALIDATION OF INCUBATION TIMES FOR [125I ] -  
IODOSULPIRIDE, [3H]-RACLOPRIDE AND [3H ].S P IP E R O N E  
SATURATION ASSAYS
A time-dependent increase in specific binding of [125I]-iodosulpiride was observed in 
all brain regions and equilibrium binding was reached after 30 mins and this time was 
used in all [125I]-iodosulpiride binding studies (Figure 9). A time-dependent increase 
in specific binding of [3H]-raclopride and [3H]-spiperone was observed in whole brain 
and equilibrium binding was reached after 90 mins and 120 mins respectively and these 
times were used in all [3H]-raclopride and [3H]-spiperone binding studies (Figure 20).
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Figure 8. Dot chart showing the relationship between 
behaviour induced by kainic acid and maximal binding
capacities of [3H]-DAGO and [125I]-iodosulpiride
250-
200 —
150
Behavioural Score
Dot chart showing the relationship between behaviour induced in 
rats by kainic acid and maximal binding capacities of [3H]-DAGO
(□) and [125I]-iodosulpiride (■) in whole brain. 16mg/kg kainic 
acid was administered intraperitoneally and rats were observed for 4 
hrs before killing. The rating scores represent: 1. abnormal staring, 
2. wet dog shakes, paddling, rearing and circling and 3. catatonia.
I Each point represents maximal binding capacities of [3H]-DAGO or 
[125i]-iodosulpiride from individual rats and data are taken from 
whole brain homogenate binding studies.
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Figure 9. Determination of the time required for equilibrium binding 
of [125I]-iodosulpiride to be reached in ra t brain regional homogenates
600-1
500-
400-
300-
200 -
100 -
Time (mins)
Pilot validation experiments were carried out to determine the time 
required for equilibrium binding to be reached in rat brain regional
homogenates. The concentration of [125I]-iodosulpiride used was InM. 
Each point represents the mean of four determinations ± S.E.M. The 
symbols represent (■) cerebellum, (# ) cortex, (À) hippocampus, (□) 
medulla and pons, (O) midbrain and hypothalamus and (A) striatum.
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Figure 20. Determination of the time required for equilibrium binding of [3H]
raclopride and [3H]-spiperone to be reached in rat whole brain homogenates
(a) 2000-1
.§ 1500-
1 1000-
500-
9060300
Time (mins)
1200-,
1000-
Z 800- 
&
1 600-
400-
Â 200-
18060 1200
Time (mins)
Pilot validation experiments were carried out to determine the time required for
equilibrium binding of (a) [3H]-raclopride and (b) [3H]-spiperone to be reached in rat 
whole brain homogenates. Homogenates were prepared from four whole rat brains and
the concentrations used were InM [3H]-raclopride and O.lnM [3H]-spiperone.
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[3H]-(D-Ala2,N-Methyl-Phe4,-Glyol5-enkephalin ([3H]-DAGO) equilibrium binding 
conditions of 30 mins have been previously determined in our laboratory (Yeadon & 
Kitchen, 1988).
3.2.2 EFFECT OF KAINIC ACID ON [125l]-IODOSULPIRIDE AND 
PHI-DAGO BINDING
The specific binding of [123I]-iodosulpiride and [3H]-DAGO to homogenates from all
regions and from whole brain of saline and KA-treated rats were saturable and
Scatchard plots were linear (Figures 10,11,15 and 16). The specific binding of [12^I]-
s at the Kd concentration 
iodosulpiride in striatum was >85% and was approximately 70% in all other regions
except for the cerebellum where it was ~50% (Table 6). The specific binding of pH ]-
at the Kd concentration
DAGO in midbrain and hypothalamus and striatum was >90% and was >80% in all 
other regions except cerebellum where it was ~50% (Table 6). The coefficients of 
linear regression (r) of Scatchard plots for [125I]-iodosulpiride in all brain regions were 
>0.8 and for pH]-DAGO were >0.9. In saline-treated rats the lowest level of 
dopamine D% binding was observed in medulla and pons whereas equivalent levels of 
dopamine D2 binding were found in cerebellum, cortex and midbrain and 
hypothalamus. Greater levels of dopamine D2 binding were observed in the 
hippocampus with approximately 8-fold higher levels of binding being found in 
striatum (Figure 12). ji-opioid binding was also highest in striatum but there was also 
appreciable binding in cortex, hippocampus, mid and hindbrain regions. Very low 
levels of g-binding were observed in cerebellum (Figure 17). Regional values of Kd 
for [125I]-iodosulpiride varied between 6nM and 9nM (Figure 13) and the binding 
affinity of pH]-DAGO was l-2nM in all regions (Figure 18).
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Figure 10. Representative saturation binding characteristics showing the binding of
[125I]-iodosulpiride in cerebellum from saline and kainic acid-treated rats
.a 250-
150-
•o 1 0 0 -
5 0 - (c)
1 0 -
% 8 -  
î 6 -
PQ 4 -
2 -
180120600
Specific bound
b) 300-1
.a 2 5 0 -
bp 2 0 0 -
©  150-
^  100 -
5 0 -
0 10 155
[l25i]_iodosulpiride concentration (nM)
Main graphs show the total binding (A), non-specific binding (#) and specific binding 
(■) in (a) saline and (b) kainic acid treated rats. Graph (c) shows Scatchard plots of the 
specific binding for (D) saline and (■) kainic acid-treated rats and were derived from 
saturation analysis. 16mg/kg kainic acid was administered intraperitoneally 4 hrs before 
killing.
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Figure 11. Scatchard plots showing the binding of [ 125I]-iodosuIpiride in saline and
kainic acid-treated rat brain
VO
Cerebellum
8 -
100 150CO
Cortex
1 0 -
100 150
Hippocampus
1 0 -
0 50 100 150
VO
Medulla and 
Pons
100 150
Midbrain and 
Hypothalamus
Striatum
3 0 -
2 0 -
1 0 -
150 300 450
Whole Brain
1 1 1 1 1
50 100 150 200 250
Specific binding (fmol/mg protein)
Whole brain 
minus striatum
5 -
100 150
Binding of [125I]-iodosulpiride in rat cerebellum, cortex, hippocampus, medulla and pons, 
midbrain and hypothalamus, striatum, whole brain and whole brain minus striatum. Values for 
specific binding in (□) saline and (■) kainic acid-treated rats were derived from saturation 
analysis and represent means of four determinations. 16mg/kg kainic acid was administered 4 
hrs before killing.
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Figure 12. The effect of kainic acid on maximal binding capacity of [125I]-
iodosulpiride in rat brain
500-1
Cere. Cort Hipp. Med. Mid. Str. Whole WB-Str.
& & Brain
Pons Hyp.
The effect of kainic acid on maximal binding capacities of [125I]-iodosulpiride in 
rat cerebellum (Cere.), cortex (Cort.), hippocampus (Hipp.), medulla and pons
(Med. & Pons), midbrain and hypothalamus (Mid. & Hyp.), striatum (Str.),
whole brain and whole brain minus striatum (WB-Str.). Values for B weremax
derived from saturation experiments analysed by linear regression of Scatchard 
plots and represent means of four determinations ± S.E.M. Open columns (D) 
represent saline-treated groups and filled columns (■) represent kainic acid- 
treated groups. 16mg/kg kainic acid was administered intraperitoneally 4 hrs 
before killing. Multi-way comparisons (1-way ANOVA and Duncan's multiple 
range test) for saline-treated groups versus kainic acid-treated groups (*P<0.05 
and **P<0.01).
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Figure 13. The effect of kainic acid on affinity of [125I]-iodosuIpiride in rat
brain
20-, **
15-
10 -
Cere. Cort. Hipp. Med. Mid. Str. Whole WB-Str.
& & Brain
Pons Hyp.
Affinity of [125I]-iodosulpiride for dopamine D2 receptors in rat cerebellum 
(Cere.), cortex (Cort.), hippocampus (Hipp.), medulla and pons (Med. & Pons), 
midbrain and hypothalamus (Mid. & Hyp.), striatum (Str.), whole brain and 
whole brain minus striatum (WB-Str.). Values for KD were derived from 
saturation experiments analysed by linear regression of Scatchard plots and 
represent means of four determinations ± S.E.M. Open columns (□) represent 
saline-treated groups and filled columns (■) represent kainic acid-treated 
groups. 16mg/kg kainic acid was administered intraperitoneally 4 hrs before 
killing. Multi-way comparisons (1-way ANOVA and Duncan's multiple range 
test) for saline-treated groups versus kainic acid-treated groups (*P<0.05 and 
**P<0.01).
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Figure 15. Representative saturation binding characteristics showing the binding of
[3H]-DAGO in striatum from saline and kainic acid-treated rats
) 1200-1
•I  1000
bp 800
&  600
(c) 0 .5-
£  0 .3 -
.5 1000 O
g> 800 200 300
Specific bound
b) 1200-
[3H]-DAGO concentration (nM)
Main graphs show the total binding (À), non-specific binding (#) and specific binding 
(■) in (a) saline and (b) kainic acid treated rats. Graph (c) shows Scatchard plots of the 
specific binding for (D) saline and (■) kainic acid-treated rats and were derived from 
saturation analysis. 16mg/kg kainic acid was administered intraperitoneally 4 hrs before 
killing.
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Figure 16. Scatchard plots showing the binding of [3H]-DAGO in saline and kainic acid- 
treated rat brain
Cerebellum
0.02-
0.01
0.3 Cortex
0.2-
0.1
100 200 300
0.3-,
Hippocampus
0.2-
0.1-
100 200 300
0.2-,
Medulla and 
Pons
0. 1-
100 200 300
Midbrain and 
Hypothalamus
100 200
0.5-, Striatum
0.4-
0.3-
0.2-
0.1-
100 200 300
0.4-,
Whole Brain
0.3-
0.2 -
0.1-
100 200 300
Specific binding (fmol/mg protein)
Binding of [3H]-DAGO in rat cerebellum, cortex, hippocampus, medulla and pons, midbrain 
and hypothalamus, striatum and whole brain. Values for specific binding in (□) saline and (■) 
kainic acid-treated rats were derived from saturation analysis and represent means of four 
determinations. 16mg/kg kainic acid was administered 4 hrs before killing.
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Figure 17. The effect of kainic acid on maximal binding capacity of [%]-
DAGO in rat brain
400-1
300-
200 -
PQ
100-
0
*
c #
Cere. Cort. Hipp. Med.
&
Pons
Mid.
&
Hyp.
Str. Whole
Brain
The effect of kainic acid on maximal binding capacities of [3H]-DAGO in rat 
cerebellum (Cere.), cortex (Cort), hippocampus (Hipp.), medulla and pons (Med.
& Pons), midbrain and hypothalamus (Mid. & Hyp.), striatum (Str.) and whole
brain. Values for Bmax were derived from saturation experiments analysed by
linear regression of Scatchard plots and represent means of four to six
determinations ± S.E.M. Open columns (□) represent saline-treated groups and
filled columns (■) represent kainic acid-treated groups. 16mg/kg kainic acid was
administered intraperitoneally 4 hrs before killing. Multi-way comparisons (1-
way ANOVA and Duncan's multiple range test) for saline-treated groups versus
kainic acid-treated groups (*P<0.05).
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Figure 18. The effect of kainic acid on affinity of [3H]-DAGO in rat brain
5-1
Cere. Cort. Hipp. Med. Mid. Str. Whole
& & Brain
Pons Hyp.
Affinity of [3H]-DAGO for g-opioid receptors in rat cerebellum (Cere.), cortex 
(Cort), hippocampus (Hipp.), medulla and pons (Med. & Pons), midbrain and
hypothalamus (Mid. & Hyp.), striatum (Str.) and whole brain. Values for
Kpwere derived from saturation experiments analysed by linear regression of
Scatchard plots and represent means of four to six determinations ±  S.E.M.
Open columns (□) represent saline-treated groups and filled columns (■)
represent kainic acid-treated groups. 16mg/kg kainic acid was administered
intraperitoneally 4 hrs before killing. Multi-way comparisons (1-way ANOVA
and Duncan's multiple range test) for saline-treated groups versus kainic acid-
treated groups (*P<0.05).
KA produced a 2-fold decrease in receptor affinity for [125I]-iodosulpiride (Figure 13) 
and a 2-fold increase in receptor density in all regions except striatum (Figure 12). KA 
produced a 2-fold increase in receptor affinity for pH]-DAGO in all regions except 
cerebellum (Figure 18) and an increase in receptor number (by a maximum of 50%) 
which was significant in cortex, medulla and pons and striatum only (Figure 17). KA 
had no effect on the non-specific binding of [12^I]-iodosulpiride or pH]-DAGO in any 
region (Table 6).
3.2.3 EFFECT OF KAINIC ACID ON pH ]-RA CLO PRID E AND [3H]- 
SPIPERO N E BINDING
The specific binding of [3H]-raclopride and pH]-spiperone to homogenates from 
striatum and whole brain minus striatum of saline and KA-treated rats were saturable 
and Scatchard plots were linear (Figure 21 and 22). The specific binding of pH ]- 
raclopride and pH]-spiperone were >75% in whole brain minus striatum and >85% in 
striatum (Table 6). Scatchard plots for pH]-raclopride and pH]-spiperone had r values 
>0.95. [3H]-raclopride binding in striatum was twice [3H]-spiperone binding in saline- 
treated rats (Figure 23, 24 and 25) whereas in the rest of the brain Bmax values for 
dopamine D2 binding were approximately equivalent (Figures 23, 24 and 25). Values 
of Kd for [3H]-raclopride and pH]-spiperone were approximately InM in both whole 
brain minus striatum and striatum (Figure 24 and Figure 25).
KA produced a significant increase in receptor number for pH]-raclopride in striatum 
and whole brain minus striatum (Figure 24) but no change in [3H]-spiperone binding 
(Figure 25). Furthermore, KA produced a 2-fold increase in receptor affinity for pH]- 
raclopride in striatum and a small but significant increase in the whole brain minus
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Figure 21. Representative saturation binding characteristics showing the binding of
[3H]-raclopride to brain homogenates from saline and kainic acid-treated rats
[3H]-raclopride (nM)
2 4 6 8 10
[3H]-raclopride specifically bound (fmol/mg tissue)
1.0 n
"Ç 0.4
1.5 n
T------1----- 1---- 1------ 1---1-----1----- 1
2 4 6 8 10 12 14 16
[3H]-raclopride (nM)
0.5 1 1.5
[3H]-raclopride specifically bound (fmol/mg tissue)
Saturation curves and Scatchard plots show the specific binding for (□) saline and (■) 
kainic acid-treated rats in (a) striatum and (b) whole brain minus striatum. 16mg/kg 
kainic acid was administered intraperitoneally 4 hrs before killing.
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Figure 22. Representative saturation binding characteristics showing the binding of
[3H]-spiperone to brain homogenates from saline and kainic acid-treated rats
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1 2 - i
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[3H]-spiperone specifically bound (fmol/mg tissue)
Saturation curves and Scatchard plots show the specific binding for (□) saline and (■) 
kainic acid-treated rats in (a) striatum and (b) whole brain minus striatum. 16mg/kg 
kainic acid was administered intraperitoneally 4 hrs before killing.
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Figure 23. Representative Scatchard plots comparing the binding characteristics of
[3H]-raclopride and [3H]-spiperone to brain homogenates from saline-treated rats
(a) 10
4
0
Specific bound (fmol/mg tissue)
(b) 10
6
4
0
1.50.5 1
Specific bound (fmol/mg tissue)
Scatchard plots show the specific binding of (□) [3H]-raclopride and (■) [3H]-spiperone 
in (a) striatum and (b) whole brain minus striatum from saline-treated rats.
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Figure 24. The effect of kainic acid on maximal binding capacity and affinity of [3H]
raclopride in rat brain
Whole brain minus striatumStriatum
1.5 —î
Striatum Whole brain minus striatum
Maximal binding capacity and affinity of [3H]-raclopride in rat striatum and whole 
brain minus striatum. Values for Bmax and KD were derived from saturation
experiments analysed by linear regression of Scatchard plots and represent means of
four to five determinations ± S.E.M. Open columns (D) represent saline-treated
groups and filled columns (■) represent kainic acid-treated groups. 16mg/kg kainic
acid was administered intraperitoneally 4 hrs before killing. Multi-way comparisons
(1-way ANOVA and Duncan's multiple range test) for saline-treated groups versus
kainic acid-treated groups (*P<0.05 and **P<0.01).
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Figure 25. The effect of kainic acid on maximal binding capacity and affinity of [3H]-
spiperone in rat brain
Whole brain minus striatumStriatum
Whole brain minus striatumStriatum
Maximal binding capacities and affinity of [3H]-spiperone in rat striatum and whole 
brain minus striatum. Values for Bmax and KD were derived from saturation
experiments analysed by linear regression of Scatchard plots and represent means of
four to five determinations ± S.E.M. Open columns (□) represent saline-treated
groups and filled columns (■) represent kainic acid-treated groups. 16mg/kg kainic
acid was administered intraperitoneally 4 hrs before killing. Multi-way comparisons
(1-way ANOVA and Duncan's multiple range test) for saline-treated groups versus
kainic acid-treated groups showed no sigificant difference.
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striatum (Figure 24) but had no effect on Kd for [3H]-spiperone (Figure 25). KA had 
no effect on the non-specific binding of [3H]-raclopride or [3H]-spiperone in whole 
brain minus striatum and striatum (Table 6).
3.2.4 PROTEIN CONTENT OF THE MEMBRANE PREPARATIONS
The protein concentration of homogenates from KA-treated rats in the dopamine D2 and 
p-opioid studies were not statistically different when compared to homogenates from 
saline-treated rats (Figures 14,19 and 26).
3.3 AUTORADIOGRAPHIC BINDING STUDIES
3.3 .1  V A LID A TIO N  OF IN CU BA TIO N  TIM ES FO R  [1 2 5 I ] -  
IODOSULPIRIDE AND [3H]-DAGO
A time-dependent increase in specific binding of [125I]-iodosulpiride and [3H]-DAGO 
(determined using scraped brain sections at the level of the caudate putamen from 
saline-treated rats) was observed and equilibrium binding was reached after 40 mins 
and 60 mins respectively (Figure 27). These times were used in all binding studies.
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Figure 14. The effect of kainic acid on protein concentration of rat brain
homogenates in the dopamine D2 receptor study measured by [125I]- 
iodosulpiride
4-i
Cere. Cort. Hipp. Med. Mid. Str. Whole WB-Str.
& & Brain
Pons Hyp.
The protein concentration of homogenates from rat cerebellum (Cere.), cortex 
(Cort.), hippocampus (Hipp.), medulla and pons (Med. & Pons), midbrain and 
hypothalamus (Mid. & Hyp.), striatum (Str.), whole brain and whole brain minus 
striatm (WB-Str.) was determined by the method of Lowry et al. (1951) against a 
bovine serum albumin standard. 16mg/kg kainic acid was administered 
intraperitoneally 4 hrs before killing. Open columns (D) represent saline-treated 
groups and filled columns (■) represent kainic acid-treated groups and are the 
mean of 4 determinations ± S.E.M. Multi-way comparisons (1-way ANOVA and 
Duncan's multiple range test) for saline-treated groups versus kainic acid-treated 
groups showed no significant difference.
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Figure 19. The effect of kainic acid on protein concentration of rat brain 
homogenates in the p-opioid receptor study measured by [3H]-DAGO
20-,
Cere. Cort. Hipp. Med. Mid. Str. Whole
& & Brain
Pons Hyp.
The protein concentration of homogenates from rat cerebellum (Cere.), cortex 
(Cort.), hippocampus (Hipp.), medulla and pons (Med. & Pons), midbrain and 
hypothalamus (Mid. & Hyp.), striatum (Str.) and whole brain was determined by 
the method of Lowry et al. (1951) against a bovine serum albumin standard. 
16mg/kg kainic acid was administered intraperitoneally 4 hrs before killing. 
Open columns (□) represent saline-treated groups and filled columns (■) 
represent kainic acid-treated groups and are the mean of 4 determinations ± 
S.E.M. Multi-way comparisons (1-way ANOVA and Duncan's multiple range 
test) for saline-treated groups versus kainic acid-treated groups showed no 
significant difference.
148
Figure 26. The effect of kainic acid on protein concentration of rat brain 
homogenates in the dopamine D2 receptor study measured by [3H]-raclopride 
and [3H]-spiperone
(a) 20-1
Striatum Whole brain minus striatum
(b) 2 0 -i
Striatum Whole brain minus straitum
The protein concentration of homogenates from rat striatum and whole brain minus 
striatum was determined by the method of Lowry et al. (1951) against a bovine serum 
albumin standard. Open columns (□) represent saline-treated groups and filled
columns (■) represent kainic acid-treated groups in (a) [3H]-raclopride and (b) [3H]- 
spiperone binding studies and are the means of four to five determinations ± S.E.M.
16mg/kg kainic acid was administered intraperitoneally 4 hrs before killing. Multi­
way comparisons (1-way ANOVA and Duncan's multiple range test) for saline-treated 
groups versus kainic acid-treated groups showed no significant difference.
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Figure 27. Determination of the time required for equilibrium binding of [125I]-
iodosulpiride and [3H]-DAGO to be reached in rat brain sections
(a) 500-1
§  400-
200 -
403020100
Time (mins)
(b)
4000-1
3000-
<5S looo-«3
9060300
Time (mins)
Pilot validation experiments were carried out to determine the time required for
equilibrium binding of (a) [125I]-iodosulpiride and (b) [3H]-DAGO to be reached 
in scraped sections cut at the level of the caudate putamen from a saline-treated rat
brain. The concentrations used were 1.6nM [125I]-iodosulpiride and InM [3H]- 
DAGO.
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3.3.2 DETERMINATION OF OPTIMUM DEVELOPMENT TIMES
Sequential development of early development films revealed that the optimum 
development times were 3 weeks at room temperature for [3H]-DAGO binding and 3 
days at 4°C for [125I]-iodosulpiride binding. These times were determined when 
images were sufficiently dark so structures could be distinguished but film saturation 
had not been reached as shown by calibration curves, generated using an MCID image 
analyser.
3.3.3 DETERMINATION OF BRAIN PASTE STANDARD  
CONCENTRATIONS AND CONSTRUCTION OF A 125 l  
CALIBRATION CURVE
In pilot studies highest dopamine D2 labelling was observed in caudate putamen which 
had an optical density of approximately 0.7 after 3 days exposure at 4°C. The most 
concentrated brain paste standard (0.9pCi) had a mean optical density of 0.8 and the 
lowest (0.0025p,Ci) was above background. Thirteen further concentrations were 
chosen between these limits.
The calibration curves of optical densities of [^C ] and [125l]-labelled standards, 
generated using an MCID image analyser, were superimposable below concentrations 
of 5000nCi/g (Figure 28). From the [125I]-iodosulpiride calibration curve the optical 
densities of [14C]-labelled standards were extrapolated. The difference between 
extrapolated and computer generated 14C optical densities was determined for each 
radioactive concentration and 125I tissue equivalents (femtamoles per milligram of
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F igure 28. [125I]-iodosulpiride and DL-[l-14C]-ornithine hydrochloride brain 
paste calibration curves
0.8-1
0.7-
0.6 -
0.5-
0.4-
0.3-
0.2 -
0.1
1000080006000400020000
Radioactivity (nCi/g)
Calibration curves of optical density of (□) [125I]-idosulpiride brain paste standards 
determined by computerised desitometry using an MCID image analyser, versus known
radioactivity. From this the optical density of (■) DL-[l-14C]-omithine hydrochloride 
brain paste standard equivalents were extrapolated and compared to (O) computer 
generated values. Points were fitted with third degree polynomial fit.
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tissue) correspondingly corrected, by up to 18%, for the generation of an 125I 
calibration curve (corrected 125I tissue equivalents versus optical density) to calibrate 
the imaging system.
3.3.4 EFFECT OF KAINIC ACID ON [125l]-IODOSULPIRIDE AND 
PH]-DAG0 BINDING
High labelling of dopamine D2 receptors was observed in major structures of midbrain 
such as caudate putamen, nucleus accumbens and olfactory tubercle. Moderate D2 
labelling was found in substantia nigra (Table 7). Dopamine D2 receptors labelled with 
[125I]-iodosulpiride in rat brain sections are shown in Figure 30. High labelling of \i- 
receptors was observed in habenula, interpeduncular nucleus, posterior cortical 
amygdaloid nucleus, endopiriform nucleus and cingulate cortex (Tables 8 and 9). High 
^-labelling was also evident in nucleus accumbens, amygdaloid nuclei, medial 
geniculate nucleus and superior colliculus (Table 8). g-receptors labelled with pH]- 
DAGO in rat brain sections are shown in Figure 34.
Regional variation in D2 labelling was observed between equivalent sections from saline 
and KA-treated groups compared at the same anatomical level. The variation in 
S.E.M.S from saline and KA-treated groups were similar in each region and varied 
between 15-45%. A 2-fold increased D2 labelling was observed in hypothalamus and 
the colliculus region of the midbrain from KA-treated rats but Post-hoc analysis showed 
no significance in KA-treated groups. Analysis of cortical regions (cingulate, frontal 
parietal, parietal, piriform and entorhinal) showed increased D2 labelling (up to 80%) 
but the difference was not significant. Furthermore, increased D2 labelling in islands of 
Calleja and in midbrain regions such as ventral pallidum and lateral preoptic area in KA-
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Table 7. Quantitative autoradiography of dopamine D% receptors in saline and 
kainic acid-treated rats in brain sections labelled with [125I]-iodosulpiride
Region [ 125j] -i0do sulpiride specific
binding
Saline Kainic acid
(fmol/mg tissue)
Cingulate cortex 21.1 ±4.9 29.9 ± 8.6
Frontal parietal cortex 21.4 + 4.7 29.3 ± 6.1
Infralimbic cortex 19.5 ± 6.6 22.6  ± 10.1
Olfactory tubercle 53.7 ±10.7 55.1 ± 9.7
Caudate putamen 113.2 ±16.4 109.2 ±17.3
Islands of Calleja 32.1 ±8.1 52.2 ± 14.2
Nucleus accumbens shell & core 61.4 ±13.1 62.1 ± 12.9
Lateral preoptic area 30.2 ±10.5 38.9 ± 8.3
Globus pallidus 24.5 ±7.6 33.3 ± 7.7
Parietal cortex 27.8 ±7.4 29.2 ± 8.1
Thalamus 20.7 ±4.5 28.5 ± 8.4
Hypothalamus 14.6 ±3.9 28.7 ± 10.1
Hippocampus (fields CA1-3 of Ammon's horn) 28.7 ±7.3 31.5 ± 10.6
Dorsal hypothalamic area 24.0 ±6.1 44.9 ± 14.0
Posterior hypothalamic area 25.6 ±7.7 30.9 ± 6.6
Piriform cortex 28.0 ±6.7 51.0 ± 14.4
Substantia nigra 41.4 ±12.1 49.8 ± 11.3
Entorhinal cortex 16.9 ±3.8 32.2 ± 11.7
Superficial gray layer of the superior colliculus 14.9 ±4.1 27.9 ± 6.1
Dorsal cortex of the inferior colliculus 17.1 ±2.7 27.1 ± 5.2
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Quantitative autoradiography of dopamine D2 receptors in saline and kainic acid- 
treated rats in brain sections labelled with [l^^I]-iodosulpiride. Quantitative 
autoradiography of dopamine D2 receptors in saline and kainic acid-treated rats 
showing the mean specific binding of five determinations in femtamoles per 
milligram of tissue ± S.E.M., with regional determinations made from both left and 
right sides of sections and across two sections 500)1 m apart, fmol/mg tissue 
equivalents were derived from [ l4C]-labelled brain paste standard based calibrations. 
Labelling with [ l25I]-iodosulpiride was carried out on adjacent sections and in a 
completely paired protocol. 16mg/kg kainic acid was administered intraperitoneally 4 
hrs before killing. Bregma co-ordinates of structures, which were identified and 
named according to the atlas of Paxinos & Watson (1986), and pixel size of box tools 
(in parentheses) used for quantification are as follows (in regions where no pixel size 
is given anatomical structures were determined with a drawing tool): cingulate cortex 
2 .20mm (12x 12); frontal parietal cortex 2 .20mm (12x 12); infralimbic cortex 2 .20mm 
(12x12); olfactory tubercle 2.20mm (8x 8); caudate putamen 1.7mm; islands of 
Calleja 1.7 mm; nucleus accumbens 1.7mm; lateral preoptic area -0.3mm; globus 
pallidus -0.92mm; parietal cortex -2 .12mm (2 0 x 2 0 ); thalamus -2 .12mm; 
hypothalamus -2.12mm; hippocampus (fields CA1-3 of Ammon's horn) -3.14mm, 
(8 x 8); dorsal hypothalamic area -3.14mm; posterior hypothalamic area -3.14mm; 
piriform cortex -3.14mm, (6 x 6); substantia nigra -4.80mm; entorhinal cortex 
-6.04mm (8x 8); superficial gray layer of the superior colliculus -7.64mm; dorsal 
cortex of the inferior colliculus -9.68mm. Multi-way comparisons (1-way ANOVA 
and Duncan's multiple range test) for saline-treated groups versus kainic acid-treated 
groups showed no significant difference.
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Figure 32. Relationship between density of kainic acid binding sites in rat 
brain and increase in [125I]-iodosulpiride binding
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Relationship between density of kainic acid binding sites in rat brain (Monaghan 
& Cotman, 1982; Patel et al. 1986) and increase in [125I]-iodosulpiride binding 
determined from autoradiographic binding studies expressed as (a) fmol/mg 
tissue and (b) percentage increase.
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Table 8. Quantitative autoradiography of p.-opioid receptors in saline 
and kainic acid-treated rats in brain sections labelled with [3H]-DAGO
Region pH]-DAGO specific binding
Saline Kainic acid
(fmol/mg tissue)
Olfactory bulb
External plexiform layer 22.6 ± 3.7 36.6 ± 1.2**
Internal plexiform layer 26.2 ± 3.5 48.3 ± 1.6**
Nucleus accumbens
Shell 58.3 ± 8.0 67.4 ±7 .1
Core early 30.5 ± 5.1 32.5 ± 4.4
Core late 60.6 ± 5.3 82.1 ± 5.2
Endopiriform nucleus 68.4 ± 3.6 84.6 ± 5.9
Ventral endopiriform nucleus 59.4 ± 8.6 64.0 ± 7.3
Olfactory tubercle 32.9 ± 2.7 44.2 ± 4.9
Caudate putamen 25.7 ± 2.0 31.4 ± 2.7
Stria terminalis 40.1 ± 4.9 54.8 ± 8.5
Amygdaloid nuclei
Basolateral 59.2 ± 4.4 52.1 ± 5.6
Basomedial 61.5 ± 2.8 60.6 ±  5.6
Medial 57.4 ±4 .8 73.7 ± 3.3
Thalamus 57.6 ± 4.8 73.7 ±  3.3
Hippocampus (fields CA1-3 of Ammon's horn) 34.6 ± 3.9 43.4 ± 3.5
Habenular nucleus (lateral and medial nuclei) 94.4 ± 11.5 139.8 ± 10.1**
Posteromedial cortical amygdaloid nucleus 72.0 ± 16.7 97.2 ± 14.7
Dentate gyrus
Ventral molecular layer 45.4 ± 7 .2 75.4 ±  6.3*
Presubiculum 16.1 ± 1.6 22.2  ± 0.8
Central (periaqueductal) gray 30.2 ± 3.2 34.6 ±  3.3
Medial geniculate nucleus 58.2 ± 6.0 67.6 ±  6.9
Superior colliculus 56.6 ± 5.7 73.3 ± 6.0
Interpeduncular nucleus 105.5 ± 14.8 144.9 ±  13.5**
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Quantitative autoradiography of |i-opioid receptors in saline and kainic acid-treated rats 
in brain sections labelled with pH]-DAGO. Quantitative autoradiography of ju-opioid 
receptors in saline and kainic acid-treated rats showing the mean specific binding of five 
determinations in femtamoles per milligram of tissue ± S.E.M., with regional 
determinations made from both left and right sides of sections and across two sections 
500jim apart, fmol/mg tissue equivalents were derived from [3H]-microscales based 
calibrations. Labelling with pH]-DAGO was carried out on adjacent sections and in a 
completely paired protocol. 16mg/kg kainic acid was administered intraperitoneally 4 
hrs before killing. Bregma co-ordinates of structures, which were identified and named 
according to the atlas of Paxinos & Watson (1986), and pixel size of box tools used for 
quantification are as follows (in regions where no pixel size is given anatomical 
structures were determined with a drawing tool): olfactory bulb 5 .20mm, external 
plexiform layer (4x4), internal plexiform layer (4x4); nucleus accumbens (shell, core 
late and core early) 2.70mm, shell (4x4); endopiriform nucleus 0.48mm; ventral 
endopiriform nucleus 0.48mm; olfactory tubercle 0.20mm (10x10); caudate putamen 
-0.26mm; stria terminalis -0.92mm; amygdaloid nuclei (basolateral, basomedial and 
medial) 2.03mm; thalamus -3.14mm; hippocampus (fields CA1-3 of Ammon's horn) 
-3.60mm, (4x4); habenular nucleus (lateral and medial nuclei) -3.80mm; posteromedial 
cortical amygdaloid nucleus -4.80mm; dentate gyrus ventral molecular layer -5.30mm 
(8x 8); dentate gyrus presubiculum -6.30mm (8x 8); central (periaqueductal) gray 
-5.80mm; medial geniculate nucleus -5.80mm (8x 8); superior colliculus -5.80mm; 
interpeduncular nucleus -6.72mm. Multi-way comparisons (1-way ANOVA and 
Duncan's multiple range test) for saline-treated groups versus kainic acid-treated groups 
(*P<0.05 and **P<0.01).
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Table 9. Quantitative autoradiography of cortical g-opioid receptors in
saline and kainic acid-treated rats in brain sections labelled with r3H l -  
DAGO
Region pH]-DAGO specific binding Percentage
Saline Kainic acid change in
(fmol/mg tissue) pHJ-DAGO
specific
binding
Frontal cortex
Layer 1 27.1 ± 3.8 48.5 ± 3.7** +79.0
Layer 4 32.1 ±3 .7 46.6 ± 2.4** +45.2
Cingulate cortex
Layer 1 73.8 ± 4.8 92.7 ± 3.7** +25.6
Layer 5 52.4 ± 2.4 67.5 ± 2.6** +28.8
Frontal parietal cortex
Layer 1 22.6  ± 1.8 28.6 ± 1.8** +26.5
Layer 2 14.7 ± 1.6 20.1 ± 1.5* +36.7
Layer 3 24.9 ± 2.4 29.6 ± 1.7 +18.9
Layer 4 13.4 ± 1.6 20.1 ± 1.2 ** +50.0
Parietal cortex
Layer 2 23.6 ± 2.5 28.9 ± 1.7 +22.5
LayerS 30.7 ± 3.0 38.5 ± 2.2* +25.4
Layer 4 18.2 ± 1.3 20.3 ± 1.1 +11.5
Temporal cortex
Layer 1 26.0 ± 3.8 36.8 ± 2.9 +41.5
Layer 2 24.6 ± 4.2 36.4 ±3.1 +48.0
Layer 3 22.9 ± 3.8 26.1 ±2 .7 +14.0
Perirhinal cortex
Layer 1 36.0 ± 6.4 47.6 ± 4.2** +32.2
Layer 2 34.5 ± 4.6 42.7 ± 5.0 +23.8
Layer 3 27.4 ± 3.5 26.7 ± 3.1 -2 .6
Occipital cortex
Layer 1 26.8 ± 3.5 34.6 ± 2.5 +29.1
Layer 2 24.6 ± 2.6 33.0 ± 2.2 +34.1
Layer 3 28.8 ± 3.9 42.3 ± 3.7** +46.9Layer 4 17.3 ± 0.9 21.4 ± 1.5 +7.2
Entorhinal cortex 26.5 ± 2.7 39.8 ± 3.0** +50.2
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Quantitative autoradiography of cortical g-opioid receptors in saline and kainic acid- 
treated rats in brain sections labelled with pH]-DAGO. Quantitative autoradiography of 
g-opioid receptors in saline and kainic acid-treated rats showing the mean specific 
binding of five determinations in femtamoles per milligram of tissue ±  S.E.M., with 
regional determinations made from both left and right sides of sections and across two 
sections 500gm apart, fmol/mg tissue equivalents were derived from [3Hj-microscales 
based calibrations. Labelling with pH]-DAGO was earned out on adjacent sections 
and in a completely paired protocol. 16mg/kg kainic acid was administered 
intraperitoneally 4 hrs before killing. Bregma co-ordinates of structures, which were 
identified and named according to the atlas of Paxinos & Watson (1986), and pixel size 
of box tools used for quantification are as follows: frontal cortex 5 .20mm, layer 1 
(4x4), layer 4 (8x 8); cingulate cortex 2.70mm, layer 1 (6x 6), layer 5 (6x 6); frontal 
parietal cortex 1.20mm, layer 1 (4x4), layer 2 (8x 8), layer 3 (4x4), layer 4 (4x4); 
parietal cortex -2.30mm, layer 2 (4x4), layer 3 (4x4), layer 4 (4x4); temporal cortex 
-4.80mm, layer 1 (4x4), layer 2 (4x4), layer 3 (4x4); perirhinal cortex -4.80mm, layer 
1 (4x4), layer 2 (4x4), layer 3 (4x4); occipital cortex -6.30mm, layer 1 (4x4), layer 2 
(6x 6), layer 3 (4x4), layer 4 (6x 6); enthorhinal cortex -6.30mm, (8x 8). Multi-way 
comparisons (1-way ANOVA and Duncan's multiple range test) for saline-treated 
groups versus kainic acid-treated groups (*P<0.05 and **P<0.01).
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Figure 36. Relationship between density of kainic acid binding sites in rat 
brain and increase in [3H]-DAGO binding
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Relationship between density of kainic acid binding sites in rat brain (Monaghan 
& Cotman, 1982; Patel et al. 1986) and increase in pH]-DAGO binding 
determined from autoradiographic binding studies expressed as (a) fmol/mg 
tissue and (b) percentage increase.
173
treated groups was not significant. D2 rich regions (e.g., caudate putamen, nucleus 
accumbens and olfactory tubercle) displayed equivalent numbers of sites in saline and 
KA-treated groups (Table 7). Dopamine D2 receptors labelled with [125I]-iodosulpiride 
in hemisections from saline and KA-treated rat brain are shown in Figure 31. 
Quantitative analysis showed an increase in p-labelling in KA-treated groups which 
was significant in the olfactory bulb, habenular nucleus, dentate gyrus and 
interpeduncular nucleus (Table 8). Significant increases in p-binding were also 
observed in KA-treated rats throughout the cortex except for the temporal region (Table 
9). p-receptors labelled with pH]-DAGO in hemisections from saline and KA-treated 
rat brain are shown in Figure 35. Specific pH]-DAGO binding in saline and KA- 
treated sections was >90% and specific [125I]-iodosulpiride binding in saline and KA- 
treated sections was >50% determined by liquid scintillation counting of scraped 
sections. Non-specific binding images for pH]-DAGO were extremely low in both 
saline and KA-treated groups but were higher for [125I]-iodosulpiride (Figures 33 and 
29 respectively) (mean values, femtomoles per milligram of tissue, pH]-DAGO, 
n>200: saline-treated, 5.9; KA-treated, 6.3; [125I]-iodosulpiride, n>200: saline-treated, 
12.7; KA-treated, 13.3). There was no correlation between literature values of density 
of KA binding sites in rat brain and increase in [125I]-iodosulpiride (Figure 32) or pH]- 
DAGO binding (Figure 36).
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3.4 pHJ-KAINIC ACID DISTRIBUTION STUDIES
3.4.1 QUENCHING EFFECT OF SOLBILISED BRAIN TISSUE AND 
PELLETS
Quench correction curves for brain tisssue and pellets from p,-opioid homogenate 
preparation were constructed to determine the quenching effects on the detection of 
scintillations. The quench correction curve for whole brain pellets was steeper and 
reached a higher percentage efficiency of counting than whole brain tissue suggesting 
that whole brain pellets had a smaller quenching effect on the detection of scintillations 
(Figure 37).
3.4.2 LABELLING OF [3H]-KAINIC ACID IN RAT BRAIN
After 4 hrs over 60% of [3H]-KA radioactivity was detected in the striatum and 
hippocampus and was 10-15 times greater than radioactivity/gram of tissue from 
medulla and pons, midbrain and hypothalamus and cerebellum and 50-times greater 
than radioactivity/gram of cortical tissue (Figure 38). When expressed as a percentage 
of 7gCi [3H]-KA reaching the brain 61.3% of [3H]-KA was detected in the rat brain 
after 4 hrs (Figure 38). [3H]-KA labelling was highest in striatum (-25% ) and 
hippocampus (-20%) with lower labelling in medulla and pons ( - 10%) and equivalent 
labelling in the rest of the brain (-5%) (Figure 39).
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Figure 37. Brain tissue and brain pellet quench correction curves
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The presence of solubilised brain tissue has a quenching effect on the detection 
of scintillations. As varying amounts of brain tissue or pellets were present in 
[3H]-kainic acid distribution studies, variable quenching was compensated for by 
constructing quench correction curves. A range of ten weights up to 1.5g of
whole brain (□) or whole brain pellets (■) were solubilised. Values for [3H] 
efficiency and ratio were determined using the d.p.m. package on a Wallac LKB
1216 Rackbeta scintillation counter. This program plotted quench curves of
efficiency versus ratio from which the radioactivity of samples were extrapolated
and given in d.p.m. The x-axis is expressed as Ratio and is a measure of how
well [3H]-kainic acid is eluted from brain tissue.
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Figure 38. Levels of kainic acid labelling in rat brain four hours after
intraperitoneal injection of [3H]-kainic acid
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Levels of [3H]-kainic acid in rat cerebellum (Cere.), cortex (Cort), hippocampus 
(Hipp.), medulla and pons (Med. & Pons), midbrain and hypothalamus (Mid. &
Hyp.) and striatum (Str.). Rats were injected intraperitoneally with a single dose
of 16mg/kg kainic acid (2ml/kg) which contained 7jiCi [3H]-kainic acid and 
killed after 4 hrs. Open columns (□) represent regions that were weighed and
solubilised and filled columns (■) represent brain regions that were homogenised, 
washed and incubated to remove endogenous ligand. Histograms represent the 
mean of seven observations ±  S.E.M. and have been corrected for quenching.
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Figure 39. Percentage distribution of kainic acid labelling in rat brain four
hours after intraperitoneal administration of [3H]-kainic acid
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The percentage distribution of [3H]-kainic acid in rat cerebellum (Cere.), cortex 
(Cort.), hippocampus (Hipp.), medulla and pons (Med. & Pons), midbrain and
hypothalamus (Mid. & Hyp.), and striatum (Str.). Rats were injected 
intraperitoneally with a single dose of 16mg/kg kainic acid containing 7jiCi
[3H]-kainic acid (2ml/kg) and killed after 4 hrs. The percentage of [3H]-kainic 
acid in whole brain represents the sum of the percentage distribution in each
individual brain region. Histograms represent the mean of seven observations ±
S.E.M. and have been corrected for quenching.
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Figure 40. The effect of [3H]-kainic acid on maximal binding capacity and
receptor affinity of [3H]-DAGO in rat whole brain
Maximal binding capacities and affinity of [3H]-DAGO in rat whole brain. 
Values for Bmax and were derived from saturation experiments analysed by
linear regression of Scatchard plots and represent means of six to seven 
determinations ± S.E.M. Open bars (□) represent 16mg/kg kainic acid-treated
groups and filled bars (■) represent 16mg/kg kainic acid plus 70pCi [3H]- 
kainic acid-treated groups. Rats were injected intraperitoneally with 16mg/kg
kainic acid (2ml/kg) or 16mg/kg kainic acid containing 70pCi [3H]-kainic acid 
(2ml/kg) and killed after 4 hrs. Multi-way comparisons (1-way ANOVA and
Duncan's multiple range test) for 16mg/kg kainic acid-treated groups versus
16mg/kg kainic acid and 70pCi [3H]-kainic acid-treated groups showed no 
significant difference.
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3.4.3 E FFE C T  OF KAINIC ACID ON IN  VITRO  p H ] - D A G O  
RECEPTO R BINDING
After the centrifugation stages of in vitro [3H]-DAGO receptor binding 7-fold 
reductions in [3H]-KA radioactivity were found in all regions except midbrain and 
hypothalamus where a 4-fold reduction was observed compared to levels of [3H]-KA 
from regions solubilised and counted (Figure 39). These levels of radioactivity 
represent pM amounts of [3H]-KA.
In rats injected intraperitoneally with 16mg/kg KA and 70jiCi [3H]-KA values for Bmax 
and Kd for [3H]-DAGO where not statistically different from those from 16mg/kg KA- 
treated rats (Figure 40).
3.5 EFFECTS OF KAINIC ACID ON [3 H ]-D O PAM INE  
RELEASE FROM RAT STRIATAL SLICES
3.5.1 EFFECTS OF KAINIC ACID ON BASAL AND POTASSIUM - 
STIM ULATED [3H]-DOPAM INE RELEASE FROM  RAT STRIA TA L 
SLIC ES
KA produced a dose dependent increase in the release of [3H]-dopamine (maximum 
release of 66.9±10.6% at ImM KA) which was calcium-dependent at low 
concentrations (lOpM and 50|iM, *P<0.01) and calcium-independent at concentrations 
above lOOjiM (Figure 42).
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An estimate of the excess of a saturating concentration of KA binding sites in the rat 
brain that ImM KA represents was made. Assuming that ImM KA will bind equally to 
high-affmity KA sites (Kd of 11.6nM) and low-affinity KA sites (Kd of 43.6nM) in rat 
striatal slices (Unnerstall & Wamsley, 1983) at a saturating concentration of 
approximately 10-times Kd , then ImM KA represents approximately a 3,500-fold 
excess of the concentration necessary to saturate KA binding sites in rat brain slices.
All S2/S1 ratios were <1 where SI represents the first stimulation period induced by 
potassium chloride and S2 represents the effects of KA on the second stimulation 
period induced by potassium chloride. KA produced a dose-dependent inhibition of 
potassium-stimulated release of [3H]-dopamine expressed as S2/S1 (percentage of 
control). Significant differences in inhibition of potassium-stimulated pH]-dopamine 
release were observed at KA concentrations above 500|iM and was greatest at ImM 
KA, which reduced the S2/S1 ratio (percentage of control) to 52.1 ±2.1% (Figure 43).
The AMPA/KA receptor antagonist 6,7-dinitroquinoxaline-2,3-dione (DNQX, 500jjM) 
completely antagonised the effects of IOOjiM KA on basal pH]-dopamine release from 
striatal slices, but only partially blocked the effects of ImM KA on basal release (Figure
44). DNQX (500jjM) completely antagonised the effects of both IOOjiM and ImM KA 
on inhibition of potassium-stimulated pH]-dopamine release from striatal slices (Figure
45). The vehicle 2% dimethyl sulphoxide and 500jjM  DNQX had no effect on pH]- 
dopamine release.
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Figure 42. The effect of kainic acid on basal stimulated release of [ H]-
dopamine from rat striatal slices in the presence and absence of calcium
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10
The effect of kainic acid (lOgM-lOmM) on basal stimulated release of [3H]- 
dopamine from rat striatal slices in the presence and absence of calcium. The
superfusion buffer contained 1.2mM calcium (□) or was calcium free (■).
Kainic acid was in contact with striatal slices for two 4 min fractions. Data
represent means of six determinations ± S.E.M. Multi-way comparisons (1-way
ANOVA and Dunn's multiple comparisons test) for data derived from buffer
containing 1.2mM calcium versus data derived from calcium free buffer
(*P<0.01).
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Figure 43. The effect of kainic acid on potassium-stimulated release of
[3H]-dopamine from rat striatal slices
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The effect of kainic acid (3jiM-lmM) on potassium-stimulated release of [ H]- 
dopamine from rat striatal slices. Open squares (□) represent values for S2 
calculated by subtracting KA effects in the presence and absence of 30mM 
potassium chloride. Data represent means of six determinations ±  S.E.M. 
Multi-way comparisons (1-way ANOVA and Dunn's multiple comparisons test)
for data versus potassium-stimulated [3H]-dopamine release during SI 
(*P<0.05, **P<0.01 and ***P<0.001).
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Figure 44. The effect of 6,7-dinitroquinoxaline-2,3-dione on kainic acid- 
induced basal release of [3H]-dopamine from rat striatal slices
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The AMPA/KA antagonist 6,7-dinitroquinoxaline-2,3-dione (DNQX) was
tested for its effects on [3H]-dopamine release from rat striatal slices stimulated 
by IOOjiM and ImM kainic acid. SOOpM DNQX was dissolved in 2% dimethyl 
sulphoxide (DMSO). Data represent means from six determinations ± S.E.M. 
Multi-way comparisons (1-way ANOVA and Friedman test) for data versus 
control values (*P<0.05 and **P<0.01).
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Figure 45. The effect of 6,7-dinitroquinoxaline-2,3-dione on kainic acid
inhibition of potassium-stimulated [3H]-dopamine release from rat striatal 
slices
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The AMPA/KA antagonist 6,7-dinitroquinoxaline-2,3-dione (DNQX) was tested
for its effect on [3H]-dopamine release from rat striatal slices stimulated by 
100pM and ImM kainic acid. SOOpM DNQX was dissolved in 2% dimethyl
sulphoxide (DMSO). Data represent means from six determinations ±  S.E.M.
Multi-way comparisons (1-way ANOVA and Dunn's multiple comparisons test)
for KA data versus KA + DNQX data (*P<0.05 and **P<0.01).
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CHAPTER 4 
DISCUSSION
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4.1 Behavioural effects and mortality of rats injected with kainic acid
The relationship between behaviour induced in rats by 16mg/kg KA and the maximal 
binding capacities of [125I]-iodosulpiride and [3H]-(D-Ala2,N-Methyl-Phe4,-Glyol5)- 
enkephalin (pH]-DAGO) was investigated by plotting a dot chart of behavioural score 
observed in rats versus Bmax (fmol/mg protein) (Figure 8). The behavioural rating 
scores represent: 1. abnormal staring, 2 . wet-dog shakes, paddling, rearing and circling 
and 3. catatonia. All rats showed behavioural signs of KA poisoning and 
approximately 70% exhibited wet-dog shakes, paddling, rearing and circling. It was 
expected that the more severely affected rats would show the highest maximal binding 
capacities and indeed catatonic rats do have higher D2 and |i-maximal binding capacities 
then some rats with a rating score of 2. In contrast however, three other rats with rating 
scores of 2 , one in the D2 study and two in the ji-opioid study, have higher D% and \1- 
maximal binding capacities then catatonic rats. More suprisingly, the least affected rat 
in this study, which had a rating score of 1, has the highest g-maximal binding 
capacity. Taken together, these findings suggest that there is no obvious correlation 
between severity of behavioural signs induced by KA and change in dopamine D2 or ji- 
maximal binding capacity. However, as a caveat to these findings they are derived 
from a small population of rats (D2 study, n=4; ji-opioid study, n=9) which makes 
interpretation more difficult.
Following the intraperitoneal administration of 16mg/kg KA the mean mortality rate in 
the dopamine D2 receptor study was 40% (n>50) and in the |Li-opioid receptor study it 
was 10% (n>40). The LD50 for intraperitoneally administered KA in rats weighing 
approximately 250g has been estimated as 20.9mg/kg by probit analysis (Fosbraey et 
al. 1992). As 16mg/kg KA is approximately 75% of the LD50 for intraperitoneal KA 
the mean mortality rate of rats injected with this dose of KA should be approximately
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40%. The lower rat death in the ji-receptor study coincided during the same period 
with a lower mortality rate to 16mg/kg KA among the same strain, sex and weight of 
rats used at other laboratories. This suggests that circannual changes may underlie 
these differences in mortality and indeed there is evidence that the sensitivity of mice to 
KA-induced convulsions displays a circadian rhythm with greatest susceptability in the 
evening (Roberts & Keith, 1994). Dallman (1993) has reported that this circadian 
rhythm may depend upon not only variation in tissue responsiveness but also the degree 
of central mineralocorticoid receptor occupancy since in nocturnal rodents 
corticosterone levels rise when they begin their active phase.
4.1.2 Dopamine D% binding measured by [125I]-io d o su lp irid e
Scatchard plots of [ 125I] -iodosulpiride binding in saline-treated rats were linear 
suggesting binding to a single population of dopamine D% receptors in all brain regions 
and values for Bmax, Kd and percentage specific binding obtained from the brain 
regions of saline-treated rats were similar to those previously reported (Martres et al. 
1985).
Scatchard plots of [125I] -iodosulpiride binding in KA-treated rats were linear 
suggesting binding to a single population of dopamine D2 receptors in all brain regions. 
KA had no effect on the percentage specific binding of [l25I]-iodosulpiride in brain 
homogenates suggesting that the total and non-specific components of binding are 
similarly affected in all regions. In autoradiographic studies the specific binding of 
[l25I]-iodosulpiride in scraped sections from saline and KA-treated rats was >50% and 
in homogenate binding it was ~50% in cerebellum, -90% in striatum and -75% in the 
rest of the brain. The lower percentage specific binding of [ l25I]-iodosulpiride in
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autoradiographic studies is probably because scraped sections predominantly comprise 
large, lower specific binding regions including the cerebellum and cortex, which dilutes 
the high specific binding of small regions like striatum. In KA-treated rats there was 
good quantitative agreement between the levels of D2 binding determined using 
homogenate binding and autoradiography. Indeed in the striatum, where most D2 
binding was found, KA had no effect in either study. In homogenate studies [I25i]_ 
iodosulpiride binding in cortex and midbrain and hypothalamus was increased 
significantly by 150% following KA administration. Likewise, in autoradiographic 
studies KA increased D2 labelling in all cortical, midbrain and hypothalamic regions 
(maximum of 90%) but was not significant. Hippocampal D2 binding in homogenate 
studies was increased significantly by 140% in KA-treated rats but autoradiographic 
quantitative analysis of the hippocampus (fields CA1-3 of Ammon’s horn) showed only 
a 10% increase in D2 labelling. This discrepancy may have occurred during the gross 
dissection of rat brain in homogenate binding studies. Deep layers of the cortex 
adjacent to the hippocampus which also showed increased D2 labelling, may have been 
inadvertently dissected out with the hippocampus resulting in an overall statistical 
significance in KA-treated rats. In homogenate studies KA significantly increased 
[125IKodosulpiiide binding in medulla and pons (-220%) and cerebellum (-50%) but 
comparisons could not be made with autoradiographic binding because D2 labelling of 
structures within these regions was low and therefore not quantified. Although KA 
increased D2 labelling throughout the brain in autoradiographic studies, Post-hoc 
analysis did not show any significance. This may partly be due to large regional 
variation in D2 labelling between equivalent sections from saline and KA-treated groups 
compared at the same anatomical level. It is unlikely however that this variability was a 
result of differences in D2 labelling among KA-treated groups because saline and KA- 
treated S.E.M.s were similar in all regions. Rat brains were stored for no longer than 1 
month before sectioning and were processed for binding within 1 week after sectioning. 
This tissue preparation and storage does not reduce D2 receptor activity (Bouthenet et
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al. 1987) therefore a loss in receptor viability could not account for the variability in D% 
labelling. To visualise changes in autoradiographic binding and to prevent excessively 
long exposure times, incubations are usually carried out at radioligand concentrations of 
between a multiple of its Kd and a saturating concentration (Leslie et al. 1988). 
However, because of the dilute concentration of [125I]-iodosulpiride and to minimise 
stock usage, D2 autoradiographic binding incubations were carried out using 50% of 
the Kd of [125I]-iodosulpiride as determined from homogenate binding. Homogenate 
binding showed that KA doubled Kd values for [125I]-iodosulpiride and increased D% 
binding in all regions except striatum. Consequently, in KA-treated rats the single 
concentration of [ 125I] -iodosulpiride bound to a smaller percentage of the total number 
of D2 binding sites in all regions except striatum. Therefore, the differences in D2 
binding between saline and KA-treated groups were smaller then if a higher 
concentration of [ 125I] -iodosulpiride was used, making significance harder to be 
reached. KA effects on [125I]-iodosulpiride receptor affinity may explain why D2 
labelling in autoradiographic studies was increased but did not show significance in 
KA-treated groups.
4.1.3 ti-opioid binding measured by [3H ]-D A G O
Scatchard plots of [3H]-DAGO binding in saline-treated rats were linear suggesting 
binding to a single population of ji-opioid receptors in all brain regions and values for 
Bmax, Kd and percentage specific binding obtained from the brain regions of saline- 
treated rats were similar to those previously reported (Robson et al. 1986; Yeadon & 
Kitchen. 1988).
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Scatchard plots of pH]-DAGO binding in KA-treated rats were linear suggesting 
binding to a single population of ji-opioid receptors in all brain regions. KA had no 
effect on the percentage specific binding of pH]-DAGO in brain homogenates 
suggesting that the total and non-specific components of binding are similarly affected 
in all regions. In autoradiographic studies the specific binding of pH]-DAGO in 
scraped sections from saline and KA-treated rats was >90% and in homogenate binding 
was >80% in all regions except the cerebellum where specific binding was -55%. The 
lower specific binding of pH]-DAGO in the cerebellum is probably because of the 
small number of fi-receptors in this region in saline and KA-treated rats. In KA-treated 
rats there was good quantitative agreement between the levels of ji-binding determined 
using homogenate binding and autoradiography. For example, in homogenate studies 
KA produced a significant 50% increase in pH]-DAGO binding in the cortex and 
similarly, ^-labelling showed on average a 32% increase in all cortical regions which 
was significant in certain frontal, cingulate, frontal parietal, perirhinal, occipital and 
entorhinal layers of KA-treated rats. Moreover, KA produced identical 25% increases 
in pH]-DAGO binding in the hippocampus when determined using homogenate and 
autoradiographic binding. A non-significant 10% increase in pH]-DAGO binding in 
midbrain and hypothalamus was observed in homogenate binding after KA 
administration and in midbrain regions quantified in autoradiographic studies |i- 
labelling in interpeduncular nucleus (+37%), superior colliculus (+30%) and central 
(periaqueductal) gray (+15%) was also non-significantly increased in KA-treated rats. 
Furthermore, KA increased striatal pH]-DAGO binding by approximately 25% in both 
studies although it was only statistically significant in homogenate binding. This 
discrepancy may have occurred during the gross dissection of rat brain in homogenate 
binding studies. The stria terminalis, a region adjacent to the striatum and which also 
showed increased ^-labelling, may have been inadvertently dissected out with the 
striatum resulting in an overall statistical significance in KA-treated rats. In homogenate 
studies KA had no effect on pH]-DAGO binding in cerebellum but significantly
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increased g-receptor density in medulla and pons by 50%. However, comparisons 
could not be made with autoradiographic binding because (i-labelling of structures 
within these regions was low and therefore not quantified.
4.1.4 Relationship between density of kainic acid binding sites and 
[125I]-iodosulpiride or [3H]-DAGO binding induced by kainic acid
The relationship between the density of KA binding sites and change in [125I]- 
iodosulpiride or [3H]-DAGO binding induced by KA was investigated by plotting 
literature values of density of KA binding sites in rat brain from Monaghan & Cotman 
(1982) and Patel et al. (1986) versus increase in [125I]-iodosulpiride or [3H]-DAGO 
binding. Although regression analysis was not carried out because the densities of KA 
binding sites were qualitative measurements, in certain regions correlations exist when 
fitted by eye. These include thalamus and hypothalamus where a positive correlation is 
apparent (a low density of KA binding sites and a small percentage increase in D2 
binding) and the entorhinal cortex and hippocampus where an inverse correlation exists 
(a high density of KA binding sites and a small percentage increase in D2 binding). 
Moreover, a small percentage increase in [3H]-DAGO binding was found in the 
hippocampus, a region very densely populated with KA binding sites (inverse 
correlation). However, in most regions there does not appear to be any correlation. 
For example, nucleus accumbens and caudate putamen, regions that are moderately 
populated with KA receptors, show only small percentage increases in D2 and 11- 
binding. In addition, moderate percentage increases in D2 and |i-binding where found 
in regions densely populated with KA binding sites such as the cingulate and frontal 
cortices. Overall, no one type of correlation predominates and indeed in most regions 
does not exist Furthermore, because there is not a positive correlation between regions
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densely populated with KA binding sites and a large increase in [l25I]-iodosulpiride or 
[3H]-DAGO binding, KA may act by a mechanism that does not involve its own 
receptors. However, the effects of KA may be mediated by KA receptors but as the 
result of KA-induced seizure activity or seizure-related neuropathological events at 
distant regions.
4.1.5 Effects of KA on D% receptor binding
Dopamine D2 receptors may exist as either monomers or dimers based on the 
observations that the density of D2 sites in cloned cells and in rat striatal homogenates 
as measured by the binding of either [3H]-nemonapride or [3H]-raclopride is 
approximately twice the density measured by [3H]-spiperone (Seeman et al. 1992; Hall 
et al. 1990; Levant et al. 1992). The effect of KA on dopamine D2 receptors may 
reflect an equilibrium shift to the monomer conformation of this receptor in all brain 
regions except striatum. This shift could reveal more [125I]-iodosulpiride binding sites 
and is thus reflected as an increase in Bmax.
The proportion of dopamine receptors existing as either monomers or dimers can be 
modulated by agonists in vivo. For example, compounds that release striatal dopamine 
such as bupropion increase the density of dopamine D2 receptor dimers labelled by 
[3H]-spiperone (Vassout et al. 1993). KA has also been shown to release dopamine 
from the striatum by impairing the dopamine autoreceptor-mediated feedback 
mechanism (Bonanno et al. 1989) and destroying modulatory cholinergic intemeurones 
(Versace et al. 1987). These effects of KA on striatal dopamine release may afford 
protection upon changes in [125I] -iodosulpiride receptor density and affinity in this 
region.
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The possible effects of KA on D% receptor monomer-dimer equilibria in rat brain were 
investigated by carrying out homogenate receptor binding with [3H]-raclopride and 
pH]-spiperone which are agonists for the monomer and dimer conformation 
respectively.
Scatchard plots of pH]-raclopride and pH]-spiperone binding in saline-treated rats 
were linear suggesting binding to a single population of dopamine D2 receptors in all 
brain regions and values for Bmax, Kd and percentage specific binding obtained from 
the brain regions of saline-treated rats were similar to those previously reported for both 
radioligands (Hall et al. 1990; Kohler et al. 1985; Levant et al. 1992). pH]-raclopride 
binding in the striatum was twice pH]-spiperone binding in saline-treated rats which is 
in agreement with reports of D2 binding in rat striatal homogenates (Hall et al. 1990; 
Levant et al. 1992) and in cells expressing cloned rat D2 receptors (Seeman et al. 1992). 
In whole brain minus striatum Bmax values for pH]-raclopride and pH]-spiperone 
were approximately equivalent.
Scatchard plots of pH]-raclopride and pH]-spiperone binding in KA-treated rats were 
linear suggesting binding to a single population of dopamine D2 in all brain regions. 
KA had no effect on the percentage specific binding of pH]-raclopride or p H ]- 
spiperone in brain homogenates suggesting that the total and non-specifc components of 
their binding are similarly affected in all regions. It has been suggested in this thesis 
that the effect of KA on dopamine D2 receptors measured by [l25I]-iodosulpiride may 
reflect an equilibrium shift to the monomer conformation of this receptor in all brain 
regions except striatum. This shift should reveal more pH]-raclopride and [125I]- 
iodosulpiride binding sites in in all regions except striatum and indeed KA increases the 
maximal binding capacities of pH]-raclopride and [ 125I]-iodosulpiride in whole brain 
minus striatum. With this shift should be a concomittent decrease in dimer 
conformation, labelled by pH]-spiperone, in whole brain minus striatum and because
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striatal D2 receptors may be resistant to an equilibrium shift the binding of [3H]- 
raclopride should be unaffected by KA. However, KA increased both [3H]-spiperone 
binding in whole brain minus striatum and [3H]-raclopride binding in striatum. 
Therefore, a shift in the monomer-dimer equilibria of D2 receptors could not explain the 
binding profiles of [3H]-raclopride or [3H]-spiperone in KA-treated rats.
In rat and humans, two isoforms of the D2 receptor resulting from alternative RNA 
splicing, have been detected (Chio et al. 1990). One isoform contains 415 amino acids 
in rat and 414 amino acids in human and is termed D 2S, D 2B or D2(415 or 414) (called 
D2S here) while the other isoform is termed D2L, D2A or D2(444 or 443) (called D2L 
here), contains an additional 29 amino acid sequence in the putative third cytoplasmic 
domain of the receptor. There has been little characterisation of D2L and D2S receptors 
in terms of the binding affinities of dopamine agonists and antagonists in homogenate 
preparations however when the D2 isoforms are expressed in cloned systems their 
ligand binding properties are variable. In mouse fibroblast cells expressing rat D2S and 
D2L receptors, both isoforms show similar affinities for several compounds of different 
chemical classes of D2 receptor antagonists, including pentacyclics ((+/-)-butaclamol), 
thioxanthenes (cis-flupenthixol), butyrophenones (haloperidol) and benzisoxazole 
derivatives (domperidone) whereas the short form shows approximately 3-fold higher 
affinities for several benzamide antagonists including raclopride and (-)-sulpiride 
(Castro & Strange, 1993). Conversely, Leysen and co-workers (1993) have reported 
that sulpiride and spiperone can not differentiate between the two splice forms cloned 
from the human dopamine D2 receptor when expressed in 293 human kidney cells. In 
addition, using homogenate studies this group also showed that sulpiride and spiperone 
could not differentiate between the D2 receptors in rat striatum, nucleus accumbens and 
olfactory tubercle (Leysen et al. 1993).
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A working hypothesis presented in this thesis is that certain D2 radioligands may be 
able to differentiate between the short and long forms of the D2 receptor so that [3H]- 
spiperone binds with high affinity (Kd ~0.1nM) to D2S receptors and [3H]-raclopride 
and [l25I]-iodosulpiride bind to D2L receptors with lower affinities (Kd ~lnM  and 
~6nM respectively). Both D2S and D2L receptor mRNAs are widely and similarly 
expressed in rat brain except in the corpus striatum where the long form is more 
abundant (Neve et al. 1991). Intermediate levels of both forms are present in midbrain 
and low levels are present in hippocampus, cerebellum and cortex (Neve et al. 1991). 
Equivalent numbers of D2S and D2L receptors are present in whole brain minus striatum 
therefore the maximal binding capacities of [3H]-raclopride, [ 125i]-iodosulpiride and 
[3H]-spiperone are similar in saline-treated rats. In striatum, the long form of the D2 
receptor is more abundant therefore [3H]-raclopride binding is similar to [125I]- 
iodosulpiride both of which are greater than [3H]-spiperone binding.
Although there have been a number of studies investigating the effects of KA on 
dopamine D2 receptors in the rat brain these have focused on its effects following 
neurodegeneration. Csemansky et al. (1987) have demonstrated that injection of KA 
into the left caudate nucleus of the rat produces a decrease in striatal [3H]-spiperone 
binding to D2 receptors after three weeks due to a direct effect of KA on dopaminergic 
terminals. More recently, Bardgett et al. (1995) have reported that KA may also 
produce indirect effects on D2 binding because intracerebroventricular KA increases 
[3H]-spiperone receptors in nucleus accumbens but not caudate putamen one week after 
administration. It has been suggested by these authors that the increase in [3H]- 
spiperone binding in the nucleus accumbens may be caused by cell loss in limbic- 
cortical regions which project to the accumbens (Bardgett et al. 1995) Indeed, [3H]- 
spiperone binding in the nucleus accumbens is also increased after kindling of the 
hippocampus or the amygdala (Csemansky et al. 1988). The KA-induced increase in 
[3H]-spiperone binding in the nucleus accumbens (Bardgett et al. 1995) may be due to
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inceased D2 receptor protein synthesis, although protein analysis of striatal 
homogenates was not determined by Bardgett and colleagues (1993). In this thesis the 
changes in D2 receptor density following KA administration when expressed relative to 
protein were not statistically significant when compared to saline-treated groups and 
therefore probably do not represent an increased synthesis of new D2 receptor protein. 
This finding is consistent with the short time frame of the study during which receptor 
protein synthesis is unlikely to be significant because the maximum turnover rate 
(corrected for receptor degradation) of Di receptors in striatum of the rat brain is 
9.96fmoI/mg of protein/hr (Giorgi et al. 1991) or approximately 1.5% of total striatal 
Di binding of pH]-SCH 23390 every 4 hrs (Hall et al. 1988).
KA has also been shown to increase the transcription of mRNA encoding numerous 
neurotransmitter receptors, including neurokinin B (Sperk et al. 1990), a-amino-3- 
hydroxy-5-methyl-isoxazole subunits GluR2 and GluR3 (Condorelli et al. 1994; 
Friedman et al. 1994) and fibroblast growth factor receptors-1, -2 and -5 (Gomez- 
Pinilla et al. 1995). However, there have been no reports suggesting that seizure 
inducing stimuli are capable of modifying D2 receptor mRNA transcription. Indeed, 
quantitative in situ hybridization using -labelled oligonucleotide probes specific for 
striatal dopamine D% and D2 receptor mRNAs demonstrated that intrahippocampal 
injection of KA had no effect on mRNA levels in striatum 4 hrs after injection (Brene et 
al. 1994). Although contrary to the work by Brene et al. (1994) the KA-induced 
changes in D2 binding reported in this thesis could be attributed to a number of different 
events, primarily involving either an increase in the synthesis or a decrease in the 
degradation of the D2 receptor mRNA. In the whole brain minus striatum, KA may 
either increase gene transcription of the D2 receptor gene, which can then give rise to 
either receptor isoform through alternative RNA splicing or increase mRNA stability or 
decrease mRNA destabilisation of both D2 receptor forms reflected as increased binding 
of [3H]-raclopride, [125I]-iodosulpiride and [3H]-spiperone. In the striatum, KA may
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increase mRNA stability or decrease mRNA destabilisation of the long form of the D2 
receptor only which is reflected as increased binding of [^Hj-raclopride. It has been 
demonstrated in all cell lines that pretreatment of D2S and D2L receptor-expressing cells 
with dopamine results in a 2-fold increase in the maximum receptor [3H ]- 
methylspiperone-binding activity of the D2L receptor-expressing cells and a small 
down-regulation of D2S receptors which may result from a change in the stability of D2 
receptor mRNA (Zhang et al. 1994). KA has also been shown to release dopamine 
from the striatum by impairing the dopamine autoreceptor-mediated feedback 
mechanism (Bonanno et al. 1989) and destroying modulatory cholinergic intemeurones 
(Versace et al. 1987). Therefore, KA effects on maximal binding capacity of [3H]- 
raclopride may be the result of dopamine release in the striatum.
Intracerebroventricularly administered pertussis toxin, an inhibitor of G-proteins, 
decreases the duration of absence seizures in rats induced by y-hydroxybutyrate and 
pentylenetrazole (Snead, 1992). This finding suggests that G-protein mediated 
mechanisms may be involved in the pathogenesis of generalised absence seizures. 
Also, electrophysiological evidence indicates that pertussis toxin suppresses long-term 
potentiation of hippocampal mossy fibre synapses (Ito et al. 1988) while KA-induced 
seizures are followed by long-lasting hyperexcitability of hippocampal neurones, a 
proposed model of epileptogenesis (Nakajima et al. 1991). Additionally, in situ 
hybridization studies have shown that increased GSa  G-protein mRNA and decreased 
G0a G-proteion mRNA levels occur in the dentate gyms 3 hrs after intraperitoneal 
administration of 15mg/kg KA (Lason & Przewlocki, 1994). These results are 
suggestive of a role of G-protein biosynthesis in KA-induced epileptogenesis and imply 
that KA might increase the binding affinity of radioligands that bind to Gsa G-protein 
coupled receptors and decrease the binding affinity of radioligands that bind to Goa G- 
protein coupled receptors. [l25I]-iodosulpiride, [3H]-raclopride and [3H]-spiperone are 
all antagonists which bind to dopamine D2 receptors coupled to Gi/0 G-proteins (See
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Table 3 for the affinities of these ligands at dopamine receptors on page 33). However, 
a characteristic of antagonist binding to the majority of receptor systems, including D2 
receptors, is that it cannot be altered by the G-protein coupling state of the receptor.
The ligand binding site of the two D2 isoforms is thought to be formed from the seven 
putative transmembrane spanning a-helices. The 29 amino acid insert that differentiates 
between the short and long forms is in the third intracellular loop is a region that is not 
usually considered important in directly influencing ligand binding. Since it has been 
suggested here that [125I]-iodosulpiride, [3H]-raclopride and [3H]-spiperone can 
differentiate between the two D2 isoforms, then these radioligands may bind to the D2 
receptor in a manner that is very sensitive to its conformation. KA may alter the ligand 
binding site of all D2L transcripts in whole brain minus striatum so that the receptor 
affinity for [3H]-raclopride is increased and the receptor affinity for [125I]-iodosulpiride 
is decreased. In the striatum, KA may alter the ligand binding site of new striatal D2L 
transcripts so that only the receptor affinity of [3H]-raclopride is affected. The 
structural features of dopamine D2 tricyclic antagonists like [125I]-iodosulpmde that are 
crucial for high-affinity binding, but are less important for the dicyclic antagonist [3H]- 
raclopride, include the presence of a substituent on a phenyl ring and the curvature of 
their tricyclic structure (Teeter et al. 1994). Following KA treatment [125I]- 
iodosulpiride may have reduced affinity for all D2L transcripts in whole brain minus 
striatum and may be unable to bind to new D2L transcripts in the striatum because of the 
particular curvature of its tricyclic structure and the presence of bulkier iodine and 
ethylsulphone (C2H5SO2) substituents on the phenyl ring (See Figure 6 on page 76).
An unusual feature of dopamine D2 receptors is that the substituted benzamide 
antagonists epidepride and sulpride bind with considerably higher affinity in the 
presence of sodium but have a reduced affinity following H+ elevation (Neve, 1991). 
These results suggest that substituted benzamide antagonists can bind to both the low-
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affinity and high-affinity states of the D2 receptor (Strange, 1987). KA may increase 
the affinity state of original and new D2L transcripts which is reflected as a lower Kd of 
[3H]-raclopride in whole brain minus striatum. [ 125I] -iodosulpiride may be unable to 
bind to the high-affinity state of all D2L transcripts therefore the receptor affinity for 
[125i]-iodosulpiride is decreased in whole brain minus striatum of KA-treated rats. KA 
may only increase the affinity state of new striatal D2L transcripts which is reflected as a 
lower Kd of [3H]-raclopride in all regions. [125I]-iodosulpiride may be unable to bind 
to the new higher affinity state of striatal D2L transcripts and therefore the receptor 
affinity for [l25I]-iodosulpiride is unchanged in the striatum of KA-treated rats. The 
ability of [125Ij-iodosulpiride to bind to D2 transcripts following KA treatment may be a 
reflection of its tricyclic structure and phenyl ring substituents.
4.1.6 Effects of kainic acid on g-opioid receptor binding
KA effects on p-opioid receptors in rat brain have been studied subsequent to 
neurodegeneration. Using homogenate binding Antkiewicz-Michaluk et al. (1984) have 
shown that p-opioid receptors on the cell bodies of striatal neurones decrease in number 
(by a maximum of 90%) and decrease in affinity one week after microinjection of KA 
as a consequence of the propensity of KA to induce axon-sparing lesions (Coyle et al. 
1978). Conversely, at an earlier time point Perry & Grimes (1989) demonstrated using 
autoradiography that hippocampal p-opioid receptors increase in number (145-247%) 
48 hrs after subcutaneous administration of KA due to the seizure-related release of 
opioid peptides from granule cell mossy fibres (Chavkin et al. 1983). These 
investigators where however unable to determine if this effect was due to increased 
protein synthesis of p-receptors because it is impractical to determine the protein 
content of slide-mounted brain sections. In this study the changes in p-receptor density
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following KA administration when expressed relative to protein were not statistically 
significant when compared to saline-treated groups and therefore probably do not 
represent an increased synthesis of new |i-receptor protein. This finding is consistent 
with the 4 hr duration of this study and with the slow opioid receptor turnover rate 
found by MacDermot & Nirenberg (1978) who used cycloheximide to inhibit protein 
synthesis and demostrated that in neuroblastoma-glioma cells, ji-receptors have a half- 
life of 16.5 days.
The neurones of the dentate gyrus express the highest levels of both preproenkephalin 
and preprodynorphin mRNA and the corresponding processed peptides in rodents 
(McGinty et al. 1983). Changes in hippocampal opioid peptides have been reported 
following seizures induced by electroconvulsive shock (Kanamatsu et al. 1986) and 
kindling (Lee et al. 1989b). Also, a convulsant dose of KA induces the expression of 
prodynorphin and proenkephalin in the rat hippocampus correlated with seizure activity 
but with different time courses: prodynorphin mRNA peaks after 3 hrs (13-fold 
increase), whereas proenkephalin mRNA begins to increase at 3 hrs (7-fold increase) 
and peaks after 24 hrs (24-fold increase) (Douglass et al. 1991). Changes in opioid 
peptides are not only confined to the hippocampus because in epileptic rats levels of 
proenkephalin and prodynorphin mRNA are increased in striatum and frontal cortex 
(Lason et al. 1994). After 1.5 hrs, convulsant doses of KA also induce the expression 
of AP-1 (activator protein-1) constituent proteins c-fos, fos B, fra 2 and jun B in the rat 
hippocampus and entorhinal cortex with maximal elevation observed 4.5 hrs after 
administration (Pennypacker et al. 1993). AP-1 transcription factors could play a role 
in the activation of opioid genes in the rat brain after KA treatment because c-fos and c- 
jun proteins have been shown to activate transcription in vitro from the 
preproenkephalin gene promoter termed ENKCRE 2 in its 5* promotor region 
(Douglass et al. 1989). Moreover, the preproenkephalin sequence binds AP-1 proteins 
from human cervical cancer-derived cell extracts (Comb et al. 1988). In homogenate
201
binding studies KA produced a 25% increase in receptor number of pH]-DAGO in 
hippocampus and significantly increased ^-binding (maximum of 50%) in cortex, 
striatum and medulla and pons. Also, quantitative analysis of p H ] - D A G O  
autoradiograms from KA-treated groups showed an increase in g-labelling within these 
regions which was significant throughout the cortex except for the temporal region. 
The effects of KA on pH]-DAGO binding may reflect a compensatory increase in the 
rate of jx-receptor mRNA transcription in all regions as a result of ji-receptor 
stimulation by enkephalin produced from elevated levels of mRNA of its precursor 
proenkephalin (Douglass et al. 1991). This process may be initiated by induction of 
AP-1 transcription factors by KA, whose substituents in vitro have been demonstrated 
to activate transcription by binding to a specific sequence on the preproenkephalin 
promoter (Sonnenberg et al. 1989). Additional factors may be involved since the 
preproenkephalin promoter has been shown to bind numerous transcription factors such 
as AP-2, AP-4 and nuclear factor-1 that serve to regulate its transcription (Hyman et al. 
1989).
Opioid effects at g-opioid receptors coupled to Gi/0 G-proteins have been demonstrated 
to include the stimulation or inhibition of adenylate cyclase, the stimulation of 
phosphatidylinositol turnover and direct G-protein coupling to a potassium channel or 
to a calcium channel (Bimbaumer et al. 1990). Intraperitoneal administration of 
15mg/kg KA has been shown by in situ hybridization studies to increase GSa  G- 
protein mRNA and decrease G0a G-protein mRNA levels in the dentate gyrus 3 hrs 
after administration (Lason & Przewlocki, 1994) suggesting that KA might increase the 
binding affinity of radioligands that bind to GSa G-protein coupled receptors and 
decrease the binding affinity of radioligands that bind to G0a G-protein coupled 
receptors. However, the findings of this present study are not in keeping with these 
observations since pH]-DAGO, an agonist which binds to p-opioid receptors coupled 
to Gi/o G-proteins, has a 2-fold higher affinity in all regions except cerebellum
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following KA administration. The proposed effect of KA on maximal binding capacity 
of [3H]-DAGO may provide a clue to the mechanism underlying its actions on binding 
affinity. Studies with SH-SY5Y cells chronically exposed to g-opioids have 
demonstrated an increased abundance of Gia i, ia2, sa, oa, za and p G-protein subunits 
after exposure (Ammer & Schulz, 1993). Also, concomitant treatment of the cells with 
cycloheximide, an inhibitor of mRNA translation, prevented this effect suggesting that 
G-protein up-regulation developed due to enhanced protein synthesis de novo (Ammer 
& Schulz, 1993). Thus, if KA up-regulates enkephalin mRNA transcription due to 
increased expression of proenkephalin mRNA (Douglass et al. 1991) as suggested in 
this thesis then KA may also increase the expression of Gi G-protein subunits. 
However, Ammer and Schulz (1993) also carried out reconstruction experiments using 
S49 eye- lymphoma-cell membranes which suggested that this increase is probably due 
to elevated levels of functionally intact Gs G-protein and this was confirmed in 
functional studies assessed with guanosine 5'-[p y-imido]triphosphate that showed that 
the intrinsic activity if Gi G-proteins was unchanged (Ammer & Schulz, 1993). The 
findings of Ammer & Shulz (1993) are therefore not in keeping with increased 
expression of Gf G-protein subunits after KA treatment.
G-proteins have been shown to be modulated by seizure-inducing paradigms other than 
KA-induced seizures. Iwasa et al. (1994) have reported that amygdaloid kindling 
increased adenosine diphosphate-ribosylation of Gi/0 a-subunits in cortical and 
hippocampal membranes by as much as 190% after 24 hrs. This effect has been 
suggested to be the consequence of either an increase in the functionality of the Gi/0 G- 
protein complex or an increase in the amount of Gi/0 G-protein based on the 
observation that pertussis toxin-catalysed adenosine diphosphate-ribosylation of G- 
proteins in the normal (Duman et al. 1991) and kindled brain may occur endogenously. 
KA may increase the expression G0 G-proteins since the data from kindled brains 
suggests an increase in the amount of Gj/0 G-protein following kindling and the
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findings of Ammer & Schulz (1993) argue against increased expression of Gi G- 
proteins as a consequence of increased expression of proenkephalin mRNA induced by 
KA. Functional enhancement of Gi/0 G-proteins but not G-protein expression has also 
been reported after ischaemia, a secondary KA seizure-related neuropathological event. 
This is based on the finding that in hippocampal slices from ischaemic rats, glutamate 
increases polyphosphoinositide hydrolysis and the accumulation of inositol phosphates 
and inositol 1,4,5-triphosphate (Lu et al. 1993). In addition, ischaemia did not change 
either the high-affinity binding of [3H]-glutamate or the stimulation of 
polyphosphoinositide hydrolysis by carbachol or noradrenaline and lead the authors to 
suggest that ischaemia may alter the function of Gi/0 G-proteins involved in the 
activation of phospholipase C (Lu et al. 1993). More recently work by another group 
has suggested that ischaemia may have functional effects on G-proteins coupled to 
another second messenger system. In this work, Suyama et al. (1995) demonstrated 
that in the gerbil hippocampus, cAMP production increased 1.5-fold 6 hrs after 
ischaemia. Moreover, these changes were not accompanied by alterations in Gs/0 G- 
protein subunit levels as assessed by immunoblotting using specific monoclonal 
antibodies raised against specific G-protein subunits (Suyama et al. 1995). This is 
consistent with a previous report that demonstrated that the amounts of Gaii and Goo 
G-protein in rat cortex did not change following decapitation-induced complete global 
ischaemia (Takenaka et al. 1991). Taken together, KA effects on binding affinity of 
[3H]-DAGO occurring in all regions except cerebellum may be a reflection of increased 
expression of G0 G-protein mRNA and/or increased functionality of Gi/0 G-proteins 
posdschaemia.
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4.1.7 Histopathological changes induced by kainic acid
Systemic administration of KA produces reversible dendritic swelling and shrinkage of 
the neuroplasm of axon cell bodies in rats 3 hrs after injection (Sperk et al. 1983). Both 
of these effects are widespread in the rat brain although are less prominent in cerebellum 
and medulla and pons (Sperk et al. 1983). An overall decrease in volume of cell bodies 
with or without loss in receptor binding would result in an actual or apparent increased 
maximal binding capacity. Conversely, an overall increase in volume of dendrites with 
or without loss in receptor binding would result in an actual or apparent decreased 
maximal binding capacity. Using polyclonal antibodies, dopamine D2 receptor protein 
in rat brain has been predominantly localised on the cell bodies of neurones in the 
caudate putamen, midbrain, cerebral cortex, nucleus accumbens, hippocampus and 
substantia nigra with positive-staining also evident on dendrites (Brock et al. 1992). 
Likewise, antibodies specific to portions of the amino acid sequence of ji-receptors 
have been visualised by microscopy and were found on cell bodies and plasma 
membranes of dendrites throughout the rat brain (Eide et al. 1995). From the 
histopathological changes induced by KA and the localisation of D2 or ^-receptors, 
increased or unchanged D2 or g-binding to cell bodies in KA-treated rats would be 
reflected as an increased maximal binding capacity and a small decrease in D2 or p.- 
binding reflected as either an increased or unchanged Bmax. Also, following KA 
treatment a large reduction in D2 or ji-binding to cell bodies would be reflected as a 
decrease in maximal binding capacity. Although this scenario is complicated by the 
proportion of D2 and ^-binding to dendrites, dendritic binding may only reduce total 
binding modestly since it represents a small fraction of binding to cell bodies. Since 
every conceivable combination of receptor change could be accounted for depending on 
the extent of cell body shrinkage induced by KA, these alterations may explain KA 
effects on D2 and ji-receptors.
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4.1.8 Physiological implications of kainic acid-induced effects on D% 
and p,-opioid receptors
The physiological implications of increased D2 and |i-opioid receptor number in KA- 
treated rats are difficult to predict and it should be remembered that it is an assumption 
to extrapolate the demonstrated effects in an experimental animal to effects in humans. 
Dopamine has been suggested to play a role KA-induced convulsions since dopamine 
depletion induced by l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine attenuates the 
severity of convulsions and mortality of mice induced by 12, 18 and 36mg/kg KA 
(Bonuccelli et al. 1994). Dopamine D% receptors are believed to mediate anticonvulsant 
responses to non-selective dopamine agonists, such as apomorphine (Anlezark & 
Meldrum, 1975) since compounds which are active at the D2 receptor, like LY 171555 
are anticonvulsant (Al-Tajir & Starr, 1990) and D2 antagonists facilitate pilocarpine- 
induced seizures (Barone et al., 1992). In KA-treated rats an up-regulation of D2 
receptors occurs in all rat brain regions except striatum where the density of D2 sites 
depends on the radioligand used to measure them. Using intracerebral microinjection of 
dopaminergic drugs a D2-dependent anticonvulsant site has been identified in the 
anterior part of the striatum since LY 171555 affords protection against the action of 
pilocarpine when stereotaxically injected here (Turski et al. 1988). This suggests that 
KA might not affect convulsions mediated by the striatum but could self-limit 
convulsions originating from the entorhinal cortex and propagated by other regions of 
the brain. Activation of ^-receptors by morphine, a non-selective ji-opioid receptor 
agonist, enhances KA-induced seizures and neurotoxicity in a naloxone-reversible 
manner without the involvement of the 8-subtype (Fuller et al. 1982). Likewise, an 
intensification of hippocampal neurotoxicity has been observed after coadministration of 
KA and DAGO, which is completely blocked by the mixed p.- and 8-antagonist 
naltrexone (Lason et al. 1988). In KA-treated rats an up-regulation of p-opioid
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receptors occurs in all regions of the brain suggesting that this effect, if maintained 
beyond 4 hrs, might further attenuate KA-induced neurotoxicty. Likewise, a functional 
enhancement or increase in expression of G-proteins coupled to p-receptors as 
suggested in this thesis might reflect an increase in susceptability to toxicity induced by 
KA.
4.2 [3H]-kainic acid distribution studies
Distribution studies were earned out using pH]-KA administered intraperitoneally with 
16mg/kg KA to determine the percentage of KA reaching rat brain areas 4 hrs after 
treatment Although one drawback of this method is that only total radioactivity is 
measured and the presence of radioactive metabolites possessing pharmacological 
activity is not distinguished, KA has no known degenerative pathway (Nadler et al. 
1981) so it is likely that only the parent drug enters the brain.
The dicarboxylic structure of KA suggests that it circulates in the bloodstream in a 
charged hydrophilic state and is thus hindered in penetrating the blood-brain barrier 
(Preston & Hynie, 1990). Following the intraperitoneal injection of 16mg/kg KA and 
7pCi [3H]-KA (~0.03pCi/g) over 60% of labelled KA was detected in the rat brain 4 
hrs after administration. At an earlier time point, in conscious rats, following the 
administration of [3H]-KA (IpCi/g) through the femoral vein the overall penetration 
across the blood-brain barrier after 30 mins has been shown to be very limited (Patel et 
al. 1986). The lower penetration of KA following administration through the femoral 
vein is unliMey to be due to the different routes of injection used in the two studies but 
rather the earlier detection of KA in the brain. KA does not seem to have its own 
protein carrier as its uptake is not saturable and there is no uptake in isolated
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microvessels (Lefauconnier et al. 1986). However, KA may cross the blood-brain 
barrier by the glutamate carrier, particularly in periventricular regions where it is 
abundantly found (Price et al. 1981). Additionally, the entry of KA into the brain may 
be assisted by induced seizures disrupting the blood-brain barrier (Saija et al. 1992) and 
indeed Pont et al. (1995) have shown that intraventricular administration of KA 
produces a rapid increase in hippocampal blood-brain barrier permeability which is 
closely correlated to epileptic activity in awake rats. Disruption of the blood-brain 
barrier might be mediated by the a-amino-3-hydroxy-5-methyl-isoxazole(AMPA)/KA 
receptor subtype GluRl, which is abundant on the astrocytic endings and glial fibres 
surrounding the capillaries, and it has been suggested that they might play an important 
role in the functions related to the control and establishment of the blood-brain barrier 
(Matute et al. 1994).
16mg/kg KA is theoretically an approximately 135,000-fold excess of the concentration 
necessary to saturate KA binding sites in the rat brain. After 4 hrs, over 60% of 
intraperitoneally administered 7|iCi [3H]-KA and 16mg/kg KA was detected in the 
brain and therefore KA in the blood of the brain represents an approximately 80,000- 
fold excess of the concentration necessary to saturate KA binding sites in the rat brain. 
However, the concentration of KA actually present at the KA receptor site is likely to be 
lower than this but is probably still many times the concentration necessary to saturate 
KA binding sites in the rat brain. Therefore, 7gCi [3H]-KA and 16mg/kg KA can 
potentially label all KA binding sites in the brain since KA is metabolically inert and 
therefore capable of diffusing throughout the brain (Saija et al. 1992). Highest 
radioactivity of [3H]-KA/gram of tissue was detected in the hippocampus and striatum 
and was between 10-15-times greater than radioactivity/gram of tissue from medulla 
and pons, midbrain and hypothalamus and cerebellum and 50-times greater than 
radioactivity/gram of cortical tissue. This pattern of labelling correlates with the 
distribution of high-affinity KA sites which are concentrated in the hippocampus and
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striatum (Unnerstall & Wamsley, 1983). It is unclear why [3H]-KA, comprising a 
concentration able to saturate all KA binding sites in the rat brain, should predominantly 
label areas where high-affinity KA binding sites are located. One reason may be that 
the highest number of both high-affinity and low-affinity KA binding sites is located 
primarily in the stratum lucidum and the mossy fibre area of the hippocampus 
(Monaghan & Cotman, 1982) and ventral striatum (Patel et al. 1986) and indeed, of the 
KA reaching the brain over 60% of KA was found in these regions with 2-fold lower 
levels in medulla and pons and 4-fold lower levels in the midbrain and hypothalamus, 
cortex and cerebellum. Two less likely explanations are firstly, the differential 
penetration of KA across the blood-brain barrier into the hippocampus and striatum via 
the glutamate carrier since the distribution of the glutamate carrier is ubiquitous (Price et 
al. 1981). Secondly, certain toxic insults differentially effect the blood-brain barrier 
surrounding the striatum and hippocampus, for example chronic aluminium glutamate 
intoxication leads to an accumulation in these areas (Deloncle et al. 1995) whereas 
following forebrain ischaemia transport of [3H]-sucrose is delayed (Preston et al.
1993). However, localised disruption of the blood-brain barrier following KA 
administration does probably not take place since Saija et al. (1992) demonstrated by 
measuring the blood-to-brain transfer constant for [ 14C] a-aminoisobutyric acid that 
there is not regional blood-brain barrier susceptibility to the acute seizure phase 
produced by 12mg/kg KA. Further evidence is provided by Bennett and co-workers 
(1995) who found that 3-5 hrs after intraperitoneal administration of 10mg/kg KA 
blood-brain barrier breakdown as assessed by extravasation of goat anti-rat Ig 
molecules into brain parenchyma is distributed randomly throughout the brain around 
haemorrhaging blood vessels.
Experiments were carried out to determine if 7p.Ci [3H]-KA and 16mg/kg KA, 4 hrs 
after administration, were detectable in homogenates following the centrifugation stages 
of p,-opioid homogenate preparation and if a ten-fold higher concentration of [3H]-KA
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and lômg/kg KA had any effect on in vitro [3H]-DAGO receptor binding. Residual 
pM amounts of 7gCi [3H]-KA and 16mg/kg KA were found in all homogenates 
following the centrifugation stages of [3H]-DAGO receptor binding. In rats injected 
intraperitoneally with 16mg/kg KA and 70|iCi [3H]-KA the levels of [3H]-DAGO 
binding and Kd values were not statistically different from those from 16mg/kg KA- 
treated rats. These findings suggest that the centrifugation stages of p-opioid 
homogenate preparation removes KA from the membrane preparation so that it has no 
in vitro effect.
The status of the blood-brain barrier is a critical factor in the manifestations of KA 
intoxication which result from actions within the central nervous system. Distribution 
studies have shown that after 4 hrs over 60% of intraperitoneally administered KA 
enters the brain in regions (predominantly the hippocampus and striatum) which could 
account for the initiation of seizures. Some radioactivity was also found in the cortex, 
and stimulation of KA sites in this region may contribute to limbic seizure activity by 
activating the entorhinal-hippocampal pathway.
4.3 Effects of kainic acid on [3H]-dopamine release from rat striatal 
slices
KA produced a dose dependent increase in the release of [3H]-dopamine from striatal 
slices in vitro which was calcium-dependent at low KA concentrations (10|iM and 
50pM). Reports have suggested that a dual action is responsible for striatal presynaptic 
KA-induced release of dopamine, a predominating KA receptor-mediated effect 
involving in calcium-dependent glutamate release (Young et al. 1988) and a calcium- 
independent action representing inhibition of the sodium co-transport glutamate carrier
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(Pocock et al. 1988). The results from this study and those outlined above suggest the 
following mechanism for [3H]-dopamine release in Krebs buffer containing calcium 
when striatal slices are exposed to KA. Firstly, activation of presynaptic KA receptors 
on cordcostriatal glutamatergic terminals (Tallaksen-Greene et al. 1992) combined with 
the inhibition of the sodium co-transport glutamate carrier generates an increase in 
extracellular glutamate. Glutamate is subsequently co-transported with sodium ions 
through the sodium co-transport glutamate carrier situated on dopaminergic terminals 
(Lonat & Zigmond, 1991), while calcium ions and sodium ions pass through their 
respective voltage-sensitive channela and KA receptors (Desce et al. 1991; Wong, 
1991). Consequently an elevation in intracellular sodium is produced, that releases 
calcium ions from intraneuronal pools through Na+/Ca2+ exchange (Cunningham & 
Neal, 1981; Lockerbie & Gordon-Weeks 1986; Sandoval, 1980) triggering 
spontaneous efflux (Adams et al. 1985; Bemath & Vizi, 1987) of newly synthesised 
dopamine. Moreover, dopamine release may also be a reflection of the stimulation of 
other excitatory amino acid receptors because glutamate has been found to directly 
stimulate dopamine release from striatal synaptosomes by acting on both N-methyl-D- 
asparate (NMDA) and AMPA receptors located on dopaminergic terminals (Desce et al. 
1991).
KA produced a dose dependent increase in the release of pH]-dopamine from striatal 
slices in vitro which was calcium-independent at concentrations above 100|iM. 
Neurotansmitters such as dopamine, y-aminobutyric acid, noradrenaline and 5- 
hydroxytryptamine, are removed from the synapse by sodium and chloride-dependent 
transport located in the plasma membranes of nerve terminals and glial cells (Kanner,
1994). Calcium-independent dopamine release produced by KA in this study may be a 
reflection of the sodium-dependent dopamine uptake (Carrozza et al. 1991). In this 
study, as demonstrated by McGeer and colleagues (1977), calcium-independent 
dopamine release probably results from a decreased entry competition through
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postsynaptic voltage-sensitive calcium channels and KA receptors due to the absence of 
calcium in the supervision medium. This permits sodium ion influx which modifies the 
sodium gradient of dopamine uptake, reversing it and promoting dopamine release from 
cytoplasmic stores. Furthermore, KA may directly induce sodium-dependent uptake by 
activation of a KA-type receptor since studies in primary astrocyte cultures have shown 
that although KA was a very effective stimulant of sodium uptake, astrocytes have no 
sodium-dependent uptake of [3H]-KA (Kimelberg et al. 1989). Alternatively, calcium- 
independent dopamine release produced by concentrations of KA above lOOgM may 
result from non-specific mechanisms such as destructive lysing of dopaminergic nerve 
terminals because Lehmann et al. (1983) have shown that intrahippocampal 
administration of 6mM KA results in a non-specific release of amino acids possibly due 
to increases in membrane permeability. It is also possible that dopamine release could 
be from non-neuronal sources such as striatal glial cells since calcium-free Krebs 
solution does not effectively eliminate endogenous calcium.
The maximum stimulated dopamine release of 67% by ImM KA from striatal slices in 
vitro is small when compared to in vivo increases of dopamine levels in the striatum of 
between 1250-2500% following intraperitoneal administration of 16mg/kg KA 
(Fosbraey, unpublished observations). The variation of in vivo dopamine release may 
be attributable to heterogeneity of the striatum to which the probe is exposed and indeed 
a rostrocaudal gradient of increasing dopamine release related to the density of 
dopaminergic terminals has been previously reported (Yamamoto & Pehek, 1990). 
ImM KA present in the superfusion medium in vitro represents an approximately 
3,500-fold excess of the concentration necessary to saturate KA binding sites in the rat 
brain whereas 16mg/kg KA in the blood of the brain represents an approximately 
80,000-fold excess of the concentration necessary to saturate KA binding sites in the rat 
brain since distribution studies have shown that approximately 60% of intraperitoneally 
injected 16mg/kg KA penetrates the blood-brain barrier. However, the concentration of
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lômg/kg KA actually present at the KA receptor site is likely to be lower than in the 
blood of the brain but is probably still many times the concentration necessary to 
saturate KA binding sites in the rat brain. As both in vivo and in vitro doses of KA are 
in excess of the concentration necessary to saturate KA binding sites in the rat brain the 
difference in [3H]-dopamine release may be attributable to in vivo replenishment 
enhancing dopamine release and loss of connectivity with other brain regions in vitro, 
such as the destruction of the y-aminobutyric acid containing striatonigral tract, 
reducing dopamine release. Futhermore, the effect of nitric oxide, which has been 
shown by Hanbauer et al. (1992) to stimulate dopamine release in the striatum, cannot 
be addressed using an in vitro slice preparation, because striatal dopamine terminals do 
not possess nitric oxide synthase (Augood et al. 1992).
KA produced a dose-dependent inhibition of potassium-stimulated [3H]-dopamine 
release from rat striatal slices in vitro. Inhibition of dopamine release was expressed as 
S2/S1 (percentage of control) where SI represents the first stimulation period induced 
by potassium chloride and S2 represents the effects of KA in the presence or absence of 
the AMPA/KA receptor antagonist 6,7-dinitroquinoxaline-2,3-dione (DNQX) on the 
second stimulation period induced by potassium chloride. The S2/S1 ratios in this 
study were less than 1 because of dopamine depletion following repeated potassium 
chloride stimulation (DeLangen et al. 1979). Potassium ions affect dopamine release by 
firstly producing local depolarisation of dopaminergic terminals by lowering the 
potassium ion gradient across the nerve membrane (Hillman & Mcllwain, 1961) leading 
to the activation of voltage-sensitive calcium and sodium channels. Calcium influx 
stimulates the release of newly synthesised (Glowinski, 1973; Korf et al. 1976a; Korf 
et al. 1976b), stored and carrier-mediated dopamine efflux (Liang & Rutledge, 1982; 
Okuma & Osumi, 1986). Secondly, potassium ions also inhibit or reverse the 
glutamate carrier reducing glutamate-induced dopamine release (Messripour & Ali- 
Babaie, 1994). However, if the depolarisation effect of potassium ions releasing
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dopamine is greater than the actions of potassium ions on the glutamate carrier reducing 
glutamate induced dopamine release this would explain the massive release of dopamine 
induced by potassium chloride during SI. KA activation of receptors on cordcostriatal 
fibres should evoke additional dopamine release due to KA stimulating glutamate 
release (Desce et al. 1991). However, when KA binds postsynaptically to NMDA and 
AMPA receptors on dopaminergic terminals an influx of potassium ions occurs which 
lowers the positive gradient across the nerve membrane reducing the activation of 
voltage channels and therefore reduces the local depolarization effect of potassium ions.
DNQX (500|iM) completely antagonised the effects of lOOjiM KA on basal [3H]- 
dopamine release from striatal slices in vitro , but only partially blocked the effects of 
ImM KA on basal release. DNQX (500gM) completely antagonised the effects of both 
IOOjjM and ImM KA on inhibition of potassium-stimulated pH ]-dopamine release 
from striatal slices in vitro. This suggests that blockage of KA and AMPA receptors 
occurs without the involvement of the NMDA subtype, since DNQX has low affinity 
for the NMDA receptor (Honore et al. 1988). Antagonism of KA receptors is believed 
to be due primarily to the blockage of cordcostriatal afferent KA receptors, since 
activation of KA receptors remaining after cortical deafferentation is insufficient to 
trigger events leading to dopaminergic depolarisation (Fedele et al. 1993). Although 
distinct receptors for KA and AMPA exist in the central nervous system (Dingledine,
1991), antagonists able to discriminate between these two sites remain unavailable.
It has been demonstrated previously that pargyline (IOOjiM), an inhibitor of 
monoamine oxidase that prevents metabolism of dopamine (Snape & Holman, 1985) 
and nomifensine (IOjiM ), a dopamine uptake inhibitor, when present in the 
superfusion medium have no effect on the actions of D^ receptor agonists on the 
electrically-stimulated release of pH]-dopamine from rat striatal slices (Dwoskin &
214
Zahniser, 1986). Therefore, in all experiments pargyline and nomifensine were not 
added.
The physiological relevance of KA effects on dopamine release in the striatum is unclear 
since it seems improbable that glutamate ever reaches mM concentrations extracellularly 
(Girault et al. 1986; Palmer et al. 1989; Young & Bradford, 1986). Also, due to the 
poor synaptic contact between the terminals of dopaminergic and cordcostriatal afferents 
(Freund et al. 1984) glutamate could only influence dopamine release by diffusion 
across the extracellular space. It is impossible however to exclude the involvement of a 
more complex indirect mechanism in vivo through an action on non-dopaminergic 
structures. Nevertheless, these KA-induced glutamate effects may underlie pathogenic 
conditions involving massive excitatory amino acid release such as traumatic brain 
injury and stroke (Rothman & Olney, 1986).
In conclusion, the effects of KA on dopamine release are complex; low doses inhibit the 
potassium-stimulated release of pH]-dopamine from rat striatal slices while high doses 
increase basal release displaying partial calcium-dependence. Intermediate doses affect 
basal and evoked release and are both blocked by the AMPA/KA receptor antagonist 
DNQX.
215
GENERAL DISCUSSION
The foregoing chapters show that 16mg/kg KA changes the binding profiles of [125I]- 
iodosulpiride, [3H]-raclopride and [3H]-spiperone in the rat brain 4 hrs after 
intraperitoneal administration. See Table 10 for a summary of the effects of KA on the 
maximal binding capacities of [125I]-iodosulpiride, [3H]-raclopride and [3H]-spiperone. 
It has been suggested in this thesis that [3H]-spiperone binds with high affinity to the 
short form of the receptor (Das) and [3H]-raclopride and [125I]-iodosulpiride bind to 
long form (D2l) with lower affinities. This contrasts with the findings of Leysen and 
co-workers (1993) who showed that spiperone and sulpiride could not differentiate 
between Da receptors in homogenates from rat striatum, nucleus accumbens and 
olfactory tubercle. The discrepancy between these studies may be because only the 
radiolabelled versions of Da antagonists can distinguish between the Da receptor 
isoforms in rat brain. The effects of KA on Da receptors may either be a reflection of 
an increase in gene transcription of the Da receptor gene or a change in its mRNA 
stability and this supports a previous report which demonstated that chronic 
administration of N-methyl-D-aspartate (NMDA) antagonists induce Da receptor 
synthesis in the rat striatum (Micheletti et al. 1992). In the study by Micheletti and 
colleagues (1992) the expression of both striatal DaL mRNA and total Da mRNA were 
induced by ketamine and MK-801. Contrary to the findings of Micheletti et al. (1992) 
an in situ hybridization study has demonstrated that intrahippocampal injection of KA 
has no effect on D% and Da receptor mRNA levels in the striatum 4 hrs after injection 
(Brene et al. 1994). However, the failure of Brene and colleagues (1994) to detect 
changes in the level of Da mRNA in the striatum after KA treatment may reflect the Da 
probe distinguishing between the two isoforms of the Da receptor only labelling the 
short form. The effects of KA on the binding affinity of the benzamide Da radioligands
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[125i]_iodosulpiride and [3H]-raclopride, may be due to KA altering the affinity state or 
ligand binding site of old and new D2L transcripts. This is in keeping with the 
existence of high-affinity and low-affinity sites of the D2 receptor (Strange, 1987), 
which are only recognisable by benzamides (Neve, 1991), and the finding that the 
structural characteristics of the tricyclic antagonist [125I]-iodosulpiride is crucial for 
high-affinity D2 binding but is less important for the binding of the dicyclic antagonist 
[3H]-raclopride (Teeter et al. 1994).
lômg/kg KA increased [3H]-DAGO binding in the rat brain 4 hrs after administration 
and this could reflect a compensatory increase in the rate of p,-receptor protein 
translation as a result of p-receptor stimulation by enkephalin produced from elevated 
levels of mRNA of its precursor preproenkephalin. This hypothesis is in agreement 
with work by Douglass et al. (1991) who have shown that KA produces a 7-fold 
increase in the expression of preproenkephalin mRNA 3 hrs after administration. KA 
also increased the binding affinity of [3H]-DAGO and this may be a reflection of 
increased expression of G0 G-protein mRNA and is in accordance with the effects of 
kindled seizures which produce massive increases in Gj/0 G-protein a-subunits (Iwasa 
et al. 1994). KA may increase the functionality of Gj/0 G-proteins after ischaemia, a 
secondary KA seizure-related neuropathological event. This evidence comes from 
findings in the hippocampus which have shown that an increase in functionality of Gj/0 
G-proteins involved in the activation of phospholipase C (Lu et al. 1993) and Gs/o G- 
proteins linked to cAMP production subunit levels (Suyama et al. 1995) occurs after 
ischaemia.
KA effects on D2 and p-receptor maximal binding capacities may be a reflection of KA- 
induced shrinkage of neurone cell bodies. An inverse-type relationship between change 
in neurone cell body size and change in receptor binding has not been reported before 
and indeed in an earlier study where the volume of the rat brain was monitored after
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toxic insult no correlation appears to exist. In this earlier study hypoxic-ischaemic 
injury to the neonatal rat brain did not produce a change in hemispheric volume but was 
accompanied by a decrease in dopamine D2 binding, measured by [ l25I]-iodine- 
methoxybenzamide (Zouakia et al. 1994). Moreover, in work investigating platelet 
volume and receptor responsiveness a positive coirelation has been demonstrated. The 
study by Marx and colleagues (1992) showed increased platelet binding of fibrinogen 
after platelet cell volume was increased by incubation with ouabain.
4hrs after the intraperitoneal administration of 16mg/kg KA the mean mortality rate in 
this study was 27% (n>90). In contrast, Fosbraey et al. (1992) reported no deaths with 
16mg/kg KA among the same sex, weight and strain of rat (n-9). Differences in the 
mortality of rats have also been reported with lower doses of KA. For instance, 
lOmg/kg KA killed about 15% of male Sprague-Dawley rats weighing under 300g in 
the study of Dawson & Wallace (1992) but caused over twice as many deaths in an 
earlier study (Sperk et al. 1981). Although sex (Dawson & Wallace, 1992), weight 
(Sperk et al. 1983) and strain (Golden et al. 1991) differences to the sensitivity to KA- 
induced seizures have been demonstrated in rats this does not explain the discrepancies 
reported here. It is possible that circannual variations underlie the susceptability of rats 
to KA because during the same period at other laboratories a similar mortality rate was 
reported among rats treated with 16mg/kg KA. The signs of poisoning observed in this 
study following KA treatment are comparable with those seen previously after 
intoxication with 16mg/kg KA (Fosbraey et al. 1991). Furthermore, the percentage of 
rats showing wet-dog shakes, paddling and rearing is consistent with the report of 
Lenicque et al. (1981).
4 hrs after the intraperitoneal injection of 16mg/kg KA and 7|iCi [3H]-KA over 60% of 
KA was detected in the rat brain. A similar increase in the level of [ l4C ]a - 
aminoisobutyric acid in the rat brain has been reported 1 hr after the acute seizure phase
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of intravenously injected 12mg/kg KA (Saija et al. 1992). These two studies 
demonstrate an increase in the blood-brain barrier permeability following treatment with 
a convulsant dose of KA which is consistent with the propensity of KA-induced 
seizures to disrupt the blood-brain barrier (Saija et al. 1992; Pont et al. 1995) and with 
reports that blood-brain barrier leakiness is increased by the excitotoxins NMDA (Nag,
1992) and quinolinic acid (Batshaw et al. 1993).
The results reported in this thesis show that KA produced a dose-dependent increase in 
the release of [3H]-dopamine from striatal slices in vitro which was calcium-dependent 
at low KA concentrations and calcium-independent at concentrations above lOOpM. 
Similarily, data from striatal synaptosomes (Mantz et al. 1994) and in vivo 
micodialysis (Imperato et al. 1990) also demonstrate a stimulatory effect of KA on 
dopamine release in rat striatum that is sensitive to calcium, although in the study by 
Mantz and colleagues (1994) KA was approximately 100-times less potent then 
reported here. This discepancy could be reconciled by their use of synaptosomes, 
isolated pinched-off nerve terminals, which unlike striatal slices do not preserve the 
local microcircuits within the striatum involved in dopamine release, and thus precludes 
looking at indirect mechanisms involving other neurones. KA also produced a dose- 
dependent inhibition of potassium-stimulated [3H]-dopamine release from rat striatal 
slices in vitro. These results agree with those obtained by in vivo microdialysis of the 
rat striatum (Carrozza et al. 1991) and by ex vivo release of dopamine from rat striatal 
slices following intrastriatal injection of KA (Versace et al. 1987). The a-amino-3- 
hydroxy-5-methyl-isoxazole (AMPA)/KA receptor antagonist 6,7-dinitroquinoxaline- 
2,3-dione (DNQX, 500gM) antagonised the effects of intermediate doses of KA 
suggesting that blockage of KA and AMPA occurs without the involvement of the 
NMDA subtype, since DNQX has low affinity for the NMDA receptor (Honore et al. 
1988). These results are in agreement with Imperato and colleagues (1990) who
220
demonstrated that DNQX but not CPP, a selective NMDA antagonist, reduced KA- 
stimulated dopamine release from caudate and accumbens nuclei of freely moving rats.
Convulsants are a wide and diverse group of chemical compounds including ibotentic 
acid, quinolinic acid, NMDA, AMPA, domoic acid and KA. Most anticonvulsant 
treatments have a relatively low efficacy against this condition and this is illustrated by 
the lack of full spectrum effects on KA-induced poisoning in the rat. The effects of a 
representative drug from each major class of anticonvulsants on the signs of KA- 
induced poisoning in the rat are presented in Table 11. Most studies investigating 
receptor changes produced by these convulsants have focused on their effects following 
lesions of specific neuronal pathways. For example, ibotenic acid lesion of the nucleus 
basalis magnocellularis, which comprises neurones within the basal forebrain that 
project to cortical areas, has been used extensively as a tool to measure the distribution 
of muscarinic (Bogdanovic et al. 1993a; Rossner et al. 1994), NMDA, AMPA, KA 
(Rossner et al. 1994), somatostatin (Bogdanovic et al. 1993b) and dopamine D% and D2 
receptors (Al-Tikriti et al. 1992; Mansour et al. 1992). Likewise, quinolinic acid- 
induced degradation of the striatonigral pathway has been used to measure the 
distribution of y-aminobutyric acid (Nicholson et al. 1995), dopamine Di (Hicks et al. 
1994; Levivier et al. 1994; Norman et al. 1991; Ryu et al. 1994), dopamine D2 (Hicks 
et al. 1994; Levivier et al. 1994; Ryu et al. 1994), adenosine A2 (Levivier et al. 1994), 
NMDA (Levivier et al. 1994; Norman et al. 1991), histamine H3 (Ryu et al. 1994) and 
g-opioid receptors (Masuo et al. 1992; Sahin et al. 1992). Although not used as a 
selective lesioning agent, the effects of domoic acid convulsions on receptors have also 
been limited to time points after induced neurtoxicity (Dakshinamurti et al. 1993). 
Safety evaluation studies of anticonvulsants are assessed by histopathological analysis 
of tissue and the monitoring of induced behavioural symptoms. The investigation of 
early receptor changes could be carried out to study the receptor mechanisms that 
underlie seizure precipitation and neurotoxicity of convulsants.
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More recently and in a military context, research has focused on the organophosphorus 
compounds, in particular soman (0-1,2,2-trimethylpropyl methylphosphonofluoridate) 
because it is highly toxic and therefore a potential potent chemical warfare agent. 
Although organophosphates have not been used in anger against allied troops the recent 
admission that the unsupervised spraying of military areas with organophosphate 
insecticides to control insect-boume diseases may be responsible for service people 
suffering from so-called Gulf War syndrome emphasises the importance for further 
research into this class of neurotoxins. Like KA, soman at convulsant doses produces 
limbic-type seizures (Pazdemik et al. 1985) with subsequent seizure-related 
neuropathology in similar brain areas (Ben-Ari et al. 1981; Lothman & Collins, 1981) 
as early as 1 hr after acute soman intoxication (Skopec & Bajgar, 1992) accompanied 
by an increase in monoamine neurotransmitters (Fosbraey et al. 1990). The seizures 
induced by soman may result from both central and peripheral accumulation of 
acetylcholine after rapid and prolonged inhibition of the degradative enzyme 
acetylcholinesterase (Shih, 1982). While muscarinic mechanisms appear to be involved 
in the aetiology of convulsions it is probable that other neurotransmitter systems are 
responsible for the maintenance and associated brain damage (McDonough et al. 1987). 
Credence for this assumption comes from observations that acute pretreatment with 
carbamate cholinesterase inhibitors together with anticholinergic drugs (for example 
atropine sulphate) and oxime therapy significantly increase the 24-hr survival rate in 
experimental animals exposed to multiple doses of soman but is less effective in 
protecting against well-developed soman-induced convulsions (Dimhuber et al. 1979). 
However, lower doses of carbamate cholinesterase inhibitors would need to be effective 
in preventing soman incapacitation to be considered possible treatments in man. Even 
with the combined pretreatment available today which can protect animals from several 
times the lethal dose of soman, under battle conditions if humans are not killed they 
may remain alive with permanent brain damage. Moreover, because of the fast acting 
action of soman on cholinesterase inhibition, research might be better focused on the
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early stages of soman intoxication so that incapacitation as well as brain damage can be 
prevented. Consequently, putative soman-induced receptor changes preceding 
neurodegeneration may provide insights into the mechanisms underlying toxicity of this 
agent. However, studies investigating soman-induced receptor changes have generally 
focused on its effects subsequent and therefore attributable to neurodegeneration. For 
example, Churchill and colleagues (1990) found that soman decreased muscarinic 
receptor density in the rat forebrain 3 days after convulsions. Additionally, because 
soman-induced convulsions and neuropathology are prevented by pretreatment with 
benzodiazepines (Ben-Ari et al. 1979; Fuller & Olney, 1981) this group also 
investigated binding to benzodiazepine receptors and found that pH] -flunitrazepam 
binding to central benzodiazepine receptors did not change 3 days after convulsions 
(Churchill et al. 1990) whereas peripheral-type benzodiazepine binding site densities 
significantly increased in limbic areas, thalamic nuclei, hypothalamus and frontoparietal 
cortex 2 days after soman-induced convulsions (Lallement et al. 1993). However, in 
an earlier study Lallement and co-workers (1991) investigated L-pH]-glutam ate 
competition binding to rat hippocampal AMPA, NMDA and KA receptors 10 mins and 
40 mins after the onset of soman-induced seizures. After 10 mins AMPA binding was 
only increased significantly in CA3 (31%) and after 40 mins the increase in AMPA 
binding was larger in CA3 (>50%) and appeared in CA1 (>30%) (Lallement et al. 
1991). These results are the only evidence so far for receptor changes at the earliest 
stages of soman-induced seizures and suggest that in the hippocampus, the primary 
activation of AMPA in the CA3 region could lead to the secondary recruitment of 
AMPA mechanisms in CA1. At this present time work is commencing in other 
laboratories using the guinea pig, the best non-primate-model for predicting the efficacy 
of treatments for soman poisoning (Berry & Davies, 1970; Gordon et al. 1978; 
Dimhuber et al. 1979), investigating the effect of soman on brain muscarinic and 
benzodiazepine receptors preceding neurodegeneration using receptor homogenate and 
receptor autoradiographic techniques.
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This study has shown that a convulsive dose of KA alters the binding characteristics of 
dopamine D2 and p-opioid receptors in rat brain preceding its neurodegenerative effects 
and possible mechanisms by which these changes may take place. This is of 
importance not only as an example of the receptor effects of KA itself but also to justify 
research investigating receptor changes at the early stages of seizures induced by other 
neurotoxins which may further the development of medical countermeasures against 
more potent centrally acting agents.
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FURTHER STUDIES
It has been suggested in this thesis that the effects of KA on D2 and |i-receptors in rat 
brain may be a reflection of an increase in gene transcription of D2 and p-receptor 
mRNA. To investigate if KA effects on D2 and p-receptors are due to changes in 
receptor protein synthesis, homogenate binding could be carried out in the presence of 
cycloheximide, a blocker of mRNA translation. KA may increase the binding affinity 
of [3H]-DAGO by increased expression of G0 G-protein mRNA and/or increased 
functionality of Gi/0 G-proteins. Another route of investigation may be to address the 
possible effect of KA on pH]-DAGO binding by inhibiting Gi/0 G-protein subunits. 
Pertussis toxin analogues could by added to the homogenate reaction mixtures and 
pH]-DAGO saturation assays carried out It has been postulated here that KA-induced 
dopamine release may up-regulate D2L receptors measured by pH ]-raclopride. 
Depleting exogenous dopamine by prior administration of reserpine and oc-methyl-p- 
tyrosine and then carrying out homogenate binding with pH]-raclopride could clarify 
the role of dopamine in KA effects on D2 receptors. KA effects on D2L transcripts 
receptor affinity may be due to a shift to the high-affinity state in KA-treated rats. The 
binding of D2 radioligands could be repeated in the presence of a high H+ concentration 
because Neve (1991) has demonstrated that elevated H+ lowers the affinity state of D2 
receptors. Another possible avenue for investigation could to carrying out a mapping in 
situ hybridization study to locate gene expression of D2L, D2S and p-opioid mRNA 
receptor proteins in rat brain 4 hrs after 16mg/kg KA administration. The effects of KA 
on D2L, D2S and p-opioid mRNA receptor proteins could then be correlated with 
increases in regional specific binding of [1251]-iodosulpiride and [^Hj-DAGO 
determined using receptor autoradiography.
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Additional characterisation of kainic acid effects on [3H]-dopamine release from rat 
striatal slices would further clarify its mechanism of action. One approach might be to 
measure the levels of dopamine metabolites, homovanillic acid and dihydroxyphenyl 
acetic acid, using the high-performance liquid chromatography to investigate any effects 
of KA on individual dopamine metabolites. Furthermore, the effects of KA on 
potassium induced release of [3H]-dopamine from rat striatal slices could be further 
investigated to clarify if they are real or simply a consequence of dopamine depletion. 
KA has been hypothesised to inhibit [3H]-dopamine release from striatal slices by the 
inactivation of voltage channels on dopaminergic terminals. Further experiments could 
be carried out with the addition of calcium and sodium channel openers, such as Bay K 
8644 (calcium channel opener) and cromokalim (sodium channel opener), in the 
superfusion medium to establish if KA effects are abolished and therefore real.
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